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Abstract
Volumetric muscle loss (VML) is an injury to skeletal muscle characterized by a loss of
more than 20% of a muscles volume. The combination of the bulk loss of tissue, transection and
separation of myofibers proximal and distal to the injury, loss of innervation and blood supply,
and the depletion of muscle progenitor cells results in permanent fibrosis and functional deficits
due to loss of contractile tissue. Scaffolds, cells, and engineered constructs have been explored as
potential therapeutic interventions to induce myogenesis at the site of a VML injury in animal
models, in addition to limited clinical trials. This dissertation summarizes the current state of the
field and explores possible strategies for repairing VML and understanding the mechanisms
underlying the regenerative response of VML-damaged muscle. The challenges currently facing
the skeletal muscle tissue engineering are presented along with potential approaches to further
the field and deliver effective treatment options for patients and their physicians.
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Chapter 1

Introduction
A. Overview of Skeletal Muscle Tissue

Skeletal muscle, which makes up almost half of the mass of the human body, is an
organized tissue composed of muscle cells, nerves, blood vessels and connective tissue.(Lieber
& Friden, 2000) Cells within skeletal muscle tissue include the multi-nucleated myofibers,
regenerative satellite cells, and fibroblasts. Skeletal muscle tissue also contains the neurons,
endothelial cells, and smooth muscle cells associated with the nerves and blood vessels that
respectively innervate and exchange required molecules. The primary function of skeletal muscle
is to provide contractile force to enable locomotion at the joints. The contractile cells of skeletal
muscle are multinucleated myofibers that contract in response to acetylcholine being released
into the neuromuscular junction between the muscle and a motor nerve.(Lieber & Friden, 2000)
Muscle contraction causes muscle to have very high energy demands compared to most other
tissues in the body and requires muscle to have an extensive blood supply. Muscle cells have
such high oxygen requirements that they contain an intracellular protein, myoglobin, which has a
higher affinity for oxygen than hemoglobin within red blood cells.(Wittenberg, 1970)
Skeletal muscle has a hierarchical construction in which myofibers are enclosed within a
layer of connective tissue called endomysium and multiple endomysium-wrapped myofibers are
surrounded by connective tissue, perimysium, to make up a structure called a fascicle.(Lieber &
Friden, 2000) Multiple fascicles are then surrounded by a final layer of connective tissue known
as the epimysium. The connective tissue within the muscle transmits the contractile force
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collectively to musclulotendinous junctions after which the force is then transferred from the
tendon to bone to provide movement.(Lieber & Friden, 2000) Within this paper and unless
otherwise noted, the epimysium, perimysium, and endomysium, in addition to the basement
membrane, will be collectively referred to as the extracellular matrix (ECM).
The ECM of muscle provides a scaffold for cell attachment with specific architecture, a
conduit for blood vessels and nerves within the belly of the muscle, and also protects myofibers
from excessive stretching and distributes forces to minimize damage.(Gillies & Lieber, 2011) In
addition, the ECM provides feedback from stretch and contraction to cells; mechanical stimuli
has been shown to be very important for cell survival, growth, and metabolic activity.(KJÆR,
2004) Fibroblasts within muscle tissue are responsible for maintaining ECM and responding to
injury when the structure of ECM is compromised. In cases when recovery from a traumatic
defect is incomplete, fibroblasts will deposit an excess of ECM to create a fibrotic, noncontractile region.(Mann et al., 2011; Serrano & Muñoz-Cánoves, 2010; Tomasek, Gabbiani,
Hinz, Chaponnier, & Brown, 2002)
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B. Repair and Regeneration of Skeletal Muscle

When muscle receives an injury, cells within the muscle are capable of repairing and
regenerating the contractile myofibers as well as the underlying ECM supporting
structure.(Huard, Li, & Fu, 2002; Turner & Badylak, 2012) The normal repair process can be
broken down into five stages: degradation, inflammation, regeneration, remodeling, and
maturation. These stages are demarcated by the expression of different cytokines, release of
growth factors, and the recruitment and activity of various cells. The initial degradation of
myofibers has been linked to damage to the sarcolemma, the cell membrane of the
myofiber.(Clarke & Feeback, 1996; Fredsted, Gissel, Madsen, & Clausen, 2007; Kasper, 1995)
A damaged sarcolemma, which normally maintains a calcium ion gradient across the membrane,
will allow an unregulated flood of calcium ions into the myofiber. These calcium ions activate
proteases that will breakdown cellular components which recruit neutrophils, macrophages, and
cells responsible for restoring the architecture of the muscle.(Fredsted et al., 2007) Necrotic
tissue and damaged ECM also contribute to the pro-inflammatory environment present
immediately after muscle damage.(Laumonier & Menetrey, 2016) Neutrophils are the first cells
to arrive at the site of injury by releasing cytokines (TNF-α, IL-6), chemokines (CCL17, CCL2)
and growth factors (FGF, HGF, IGF-I, VEGF; TGF-β1).(Laumonier & Menetrey, 2016; Tidball,
1995; Toumi & Best, 2003) Neutrophils can also damage healthy muscle cells. Damaging
healthy muscle cells can increase the inflammatory response by recruiting more M1
macrophages. M1 macrophages appear hours after a muscle is injured and their numbers are
gradually reduced over the days that follow in the case of mild injury where complete
regeneration is possible.(Arnold et al., 2007) M1 macrophages are pro-inflammatory cells which
lyse cells, phagocytize cellular components, and upregulate the differentiation of myoblasts from
3

satellite cells. The initial wave of M1 macrophages subsides and M2 macrophages arrive at the
injury site 2-4 days after the initial damage. M2 macrophages suppress the inflammatory
response and stimulate the fusion of myoblasts which forms the myofibers.(Tidball & Wehling‐
Henricks, 2007) The interplay of M1 and M2 macrophages can lead muscle repair toward
myogenesis or fibrosis depending on injury severity and the inflammatory environment.(MuñozCánoves & Serrano, 2015) When muscle repair is deviated toward myogenesis, macrophage
incursion into the defect site will be transient. As the inflammatory stages are taking place,
regenerative processes will begin after having been initiated by immune cells that took part in
clearing damaged tissue components.(Arnold et al., 2007)
Satellite cells are key cells of the regenerative stage. Satellite cells differentiate in
response to factors released by the ECM upon incurring damage.(Montarras, L'honoré, &
Buckingham, 2013) Factors that have been shown to activate satellite cells include:
FGF(DiMario, Buffinger, Yamada, & Strohman, 1989), HGF(Allen, Sheehan, Taylor, Kendall,
& Rice, 1995; Tatsumi, Anderson, Nevoret, Halevy, & Allen, 1998), IGF(Musarò et al., 2001)
and TNF-α(Y. P. Li, 2003). Nitric oxide has also been shown to indirectly induce satellite cell
differentiation by stimulating MMP production.(Tatsumi, 2010) Upregulating MMPs causes
further degradation of the ECM, releasing more growth factors confined within the
ECM.(Tatsumi, 2010) Satellite cell division must take place not only to provide the cells
necessary to replace damaged myofibers, but also to renew the stockpile of satellite cells needed
for future regeneration. Renewal of skeletal muscle stem cells during a myogenic event will
occur through the asymmetric division of satellite cells.(Dumont, Bentzinger, Sincennes, &
Rudnicki, 2015) One daughter cell will be an activated cell that will differentiate to a myoblast
and the other daughter cell will remain a satellite cell. The asymmetric division of satellite cells
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is characterized by the presence of Myf5 in cells committed to myogenesis and the absence of
Myf5 in cells that will remain stem cells.(Knoblich, 2008) These uncommitted satellite cells can
undergo symmetric division to replenish the pool of satellite cells in preparation for the next
regenerative event.(Shi & Garry, 2006) Alongside stem cell activation, myogenic cell migration
is also initiated by cytokines to recruit regenerative cells to the injury site. Migration of satellite
cells can occur before or after activation, but studies have shown that the rate of migration is
higher before activation takes place.(Schultz, Jaryszak, & Valliere, 1985; Siegel, Atchison,
Fisher, Davis, & Cornelison, 2009a) A transmembrane protein, CD34, appears to be important
for satellite cell migration as CD34-deficient mice have reduced satellite cell motility.(Alfaro et
al., 2011) Chemotactic cytokines are not the only type of molecule responsible for myogenic cell
migration, MMPs also aid in the process by degrading the ECM surrounding the satellite
cells.(Kaar et al., 2008) MMP1, MMP2, and MMP9 proteolyze the collagen fibers that make up
the ECM(Kaar et al., 2008), but MMP action is attenuated by an upregulation in TIMP, an MMP
inhibitor. Therefore increased expression of both MMPs and TIMPs is seen during skeletal
muscle regeneration to facilitate regenerative cell chemotaxis without compromising the integrity
of the ECM.(Karalaki, Fili, Philippou, & Koutsilieris, 2009; Nishimura et al., 2008)
Myoblast proliferation begins after progenitor cells have been activated and migrate to
the injury. A spike in pro-inflammatory cytokines, such as IL-6 and TNF-α, has been shown to
take place concurrently to myoblast proliferation.(Allen et al., 1995) There are a number of
pathways that can be activated or repressed to induce either proliferation of myoblasts or further
differentiation. The JNK(Alter, Rozentzweig, & Bengal, 2008; Perdiguero, Ruiz-Bonilla,
Serrano, & Muñoz-Cánoves, 2007) and NF-kB(Otis et al., 2014) pathways can both be activated
to promote myoblast proliferation, while the JAK1/STAT1/STAT3 pathway suppresses genes

5

responsible for differentiation and pushes cells towards mitosis.(Sun et al., 2007) Suppressing
premature complete differentiation allows for a more robust response to a skeletal muscle injury
by increasing the pool of myogenic cells. The final steps of differentiation involve the repression
of Pax7 and the increased expression of MyoD.(Olguin, Yang, Tapscott, & Olwin, 2007) Cells
expressing MyoD will initiate the production of molecules associated with the contractility of
mature myofibers.(Megeney, Kablar, Garrett, Anderson, & Rudnicki, 1996; Sabourin, GirgisGabardo, Seale, Asakura, & Rudnicki, 1999) Myosin heavy and light chains, troponin, α-actinin,
and muscle creatine kinase will all be produced after myogenin, a downstream product of MyoD,
is expressed.(Davie et al., 2007) Myotubes in turn fuse to one another to form multinucleated
myofibers. These nascent myofibers are identified by cross sectional views that show centrally
located nuclei, contrasted with mature myofibers in which the nuclei are located at the periphery
of the fiber.
In addition to myofiber regeneration, ECM regeneration also must take place to restore
the muscle to pre-injury condition. Fibroblasts within the tissue deposit new ECM when directed
by cytokines released during the inflammatory stages. Muscle that receives a critical defect due
to a massive wound or muscle compromised by disease will not regenerate and will instead
develop a fibrotic scar. Myostatin is a pro-fibrotic growth factor responsible for inhibiting
muscle regeneration and facilitating the proliferation of fibroblasts.(Z. B. Li, Kollias, & Wagner,
2008)
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C. Volumetric Muscle Loss

If muscle sustains mild to moderate injury, such as contusions and small lacerations,
satellite cells within the muscle are capable of replacing damaged myofibers and returning the
muscle to full function.(Grogan, Hsu, & Skeletal Trauma Research Consortium, 2011; Mauro,
1961; Turner & Badylak, 2012) However, in the case of volumetric muscle loss (VML), where
more than 20% of muscle volume is lost due to severe trauma, satellite cells are incapable of
replacing the damaged tissue and the muscle will suffer permanent functional deficit.(Grogan et
al., 2011; Sicari et al., 2012; Wu, Corona, Chen, & Walters, 2012a) The loss of volume from the
muscle not only removes contractile myofibers, it also removes a significant stockpile of satellite
cells. The remaining muscle undergoes fibrosis at the injury site, limiting the future contractile
potential.(Corona et al., 2013a; Meyer & Lieber, 2012) The effect VML has on a muscle is
dependent on the joint angle and muscle length, as found by Garg et al. in 2015. They reported
that strength deficits in VML-damaged muscles may be significantly worse in joint angles in
which the muscle is in a shortened position, such as dorsiflexion of the tibialis anterior
(TA).(Garg et al., 2015) They also noted that VML results in a persistent reduction of fiber
length. Their study highlights the complexity of VML injuries and considerations that must be
understood to regenerate skeletal muscle tissue. “Not only the gross loss of muscle tissue but also
architectural and histologic adaptations of the remaining tissue underlie the persistent functional
deficits. Therefore, approaching full strength recovery of VML injured muscle will require
therapies that maximize the functional capacity of the remaining muscle tissue, promote de novo
regeneration of muscle tissue, and integrate these tissues to re-establish the intrinsic properties of
the original muscle.”(Garg et al., 2015) Clinically, there are few options available to physicians
to treat VML and regenerate lost tissue.(Grogan et al., 2011) Autografts have been used although
7

they introduce an additional surgical site and cause donor site morbidity.(Fisher & Mauck, 2013;
Grogan et al., 2011)
Initial studies of skeletal muscle autografts performed over 100 years ago showed that if
muscle was implanted back into the body it would undergo fibrosis and/or necrosis. Muscle was
replaced in frogs, rodents, and canines with researchers eventually concluding that muscle could
not remain viable after being freely transferred into an autologous or homologous host. In 1906,
Hildebrandt hypothesized that muscle could be transferred as long as the tissue remained
innervated. He found that muscle rapidly deteriorated and underwent fibrosis except of portions
that were in contact with the healthy tissue that surrounded the implant site.(Thompson, 1971)
He discovered that nascent anastomosis between the healthy tissue and implanted tissue had kept
the nearest myofibers alive.(Thompson, 1971) Other early animal studies have shown that even
if an autograft retains its blood supply and vasculature, gradual atrophy and fibrosis of the
muscle will take place if it is not innervated. Thus, muscles that do not have a blood supply and
are not receiving stimuli from a motor neuron will undergo ischemia and lose contractility.
However, in 1970 Thompson showed that free muscle autografts could be successfully
transplanted in humans if the autograft was reinnervated by a motor neuron from the muscles
surrounding the implant site. Thompson transplanted either the palmaris longus or extensor
digitorum brevis to treat facial paralysis in 8 patients.(Thompson, 1971) By implanting the free
autografts in contact with functioning facial muscles, the intact motor neurons from adjacent
muscles were able to branch such that the terminal buds came into contact with the motor end
plate. All of the patients were able to demonstrate voluntary control of implanted muscles after 4
months and retained control through the end of the year and a half long study.(Thompson, 1971)
Muscle flap autografts have been a treatment option for physicians treating VML for at least the
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past 30 years.(Mase et al., 2010) Flap autografts differ from free autografts in that flap autografts
remain attached to the origin of the muscle and preserve the connection to the systemic blood
supply.(Klebuc & Menn, 2013) Many cases of flap autografts to repair the lower limb use the
anterolateral flap to replace tissue lost in the anterior crural compartment of the lower limb.(T.
Kim, Kim, Kim, & Lee, 2012; Lin, Lin, Yeh, & Chen, 2007) Functional recovery from this
procedure is not expected as this intervention is used to create a favorable environment for soft
tissue repair and for cosmetic reasons.(T. Kim et al., 2012) Free and flap muscle transfers are
also used to improve functional outcomes of bone repair with or without bone allografts by
providing a suitable environment for osteogenic repair.(N. Li, Yuan, Chen, Chen, & Jin, 2009;
Masquelet, 2003) Similarly, in the upper extremity, physicians use free or flap muscle autografts
to repair soft tissue damage.(Coulet, Boch, Boretto, Lazerges, & Chammas, 2011; Fan et al.,
2008; Fischer, Elliott, Kozin, & Levin, 2013; Lohse, Lee, & Watson, 2014; Vekris et al., 2008)
There have been isolated cases of free muscle transfers being used to restore function,
specifically in restoring elbow flexion to patients that have suffered brachial plexus
injuries.(Coulet et al., 2011; Fan et al., 2008; Lohse et al., 2014; Vekris et al., 2008)
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D. Skeletal Muscle Tissue Engineering

Advances in tissue engineering have yielded researchers and physicians a number of
treatment options for other tissues such as bone and skin.(Bi & Jin, 2013; Rossi, Pozzobon, & De
Coppi, 2010) In contrast, very few options exist for skeletal muscle repair, although a number of
scaffold-based and cell-based strategies are currently being developed.(Bursac, Juhas, & Rando,
2015; Laumonier & Menetrey, 2016; Qazi, Mooney, Pumberger, Geissler, & Duda, 2015)
Scaffolds that are designed for skeletal muscle tissue engineering are not unlike scaffolds used
for other applications in the body. They must promote the adhesion and proliferation of cells,
they must be composed of biocompatible materials and they must provide the engineered tissue
with properties similar to native tissue. However, skeletal muscle tissue has several additional
requirements of scaffolds designed to repair skeletal muscle. Skeletal muscle tissue constructs
must have parallel fibers to promote the formation of parallel myofibers, which are essential for
contractile force, and must allow for vascularization and innervation in vivo.(Turner & Badylak,
2012) Vascularization is exceedingly important because cells must have access to oxygen and
needed biomolecules from the moment the cells are seeded onto the scaffold.(Levenberg et al.,
2005a) Innervation is necessary to provide electrical stimuli for the directed contractile force.
3D scaffold integration with host vascular and nervous networks must take place for successful
regeneration of skeletal muscle.(Bursac et al., 2015) Damaged or diseased skeletal muscle can
also be repaired without the use a three dimensional scaffold. Researchers have been able to
repair a skeletal muscle defect using fibrin microthreads seeded with muscle-derived
fibroblasts.(Page et al., 2011) The fibrin microthreads allowed the host to replace skeletal muscle
tissue without forming considerable scar tissue as was seen in an untreated defect.(Page et al.,
2011) The fibrin microthread treated muscle was able to regain 80-95% of original tetanic force,
10

whereas untreated, defected muscle only had around 55% of the original tetanic force.(Page et
al., 2011)
Biologic and synthetic scaffolds have been developed to provide a stable environment for
cell proliferation and the production of contractile tissue under in vitro and in vivo conditions.
Biologic scaffolds include acellular extracellular matrix (ECM), collagen, hydrogels, and
polymeric constructs which can be seeded with cells ranging from human stem cells to
differentiated myoblasts.(Wolf, Dearth, Sonnenberg, Loboa, & Badylak, 2015) ECM scaffolds
can have many different configurations; scaffolds can be therapeutically delivered as a powder,
in sheets (either single-ply or laminate), as a hydrogel, or whole tissue 3D constructs.(Wolf et al.,
2015) ECM has been shown to be an effective scaffold in many translational applications and, in
various forms, is currently an FDA-approved biomaterial.(Chen, Xu, Wang, & Zheng, 2009)
ECM not only provides a scaffold for cell attachment, but host immune degradation of the ECM
also provides a pro-regenerative environment in many applications.(S. F. Badylak, Dziki, Sicari,
Ambrosio, & Boninger, 2016; J. L. Dziki, Sicari, Wolf, Cramer, & Badylak, 2016)

ECM Scaffold Based Repair Strategies
In recent years, many researchers have used ECM based scaffolds to repair skeletal
muscle defects in animal models. The research group out of the University of Pittsburgh led by
Dr. Stephen Badylak has been using ECM derived from the small intestine submucosa (SIS) or
urinary bladder submucosa of pigs a therapeutic scaffold to repair various tissues and structures
since 1995.
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The first studies used the SIS as a vascular graft in canines.(S. F. Badylak, Lantz, Coffey,
& Geddes, 1989; Lantz, Badylak, Coffey, Geddes, & Blevins, 1990) Through these initial
studies, they addressed the biocompatibility of the graft and found that by stripping the cells,
they reduced the rejection response of the host’s immune system, which is the principal
challenge for any study involving the transplantation of whole organs or tissues. They also
demonstrated decellularized porcine SIS is an effective scaffold, allowing for the infiltration of
host cells while maintaining structural integrity of the entire tissue in conjunction with
surrounding host tissue.(Lantz et al., 1990) The vascular grafts were gradually replaced by host
cells and ECM which indicated to the researchers that complete recovery had taken
place.(Sandusky Jr, Badylak, Morff, Johnson, & Lantz, 1992) This lead Badylak and his
colleagues to use decellularized porcine SIS and the submucosa from the urinary bladder to
repair a variety of tissues. They subsequently published papers on bladder wall, dural tissue, and
esophageal repair using porcine SIS.(S. Badylak, Meurling, Chen, Spievack, & Simmons-Byrd,
2000; Cobb, Badylak, Janas, Simmons-Byrd, & Boop, 1999; Kropp et al., 1995; Kropp et al.,
1996) They also used porcine SIS as a wound healing patch in a rodent model.(Prevel, Eppley,
Summerlin, Sidner et al., 1995)
Within the field of musculoskeletal repair, they investigated the regenerative capabilities
of an SIS bioscaffold in tendon, bone, and muscle of animal models. The tendon repair study, led
by Badylak, showed that a defect within the Achilles tendon in canines could be repaired using
decellularized porcine SIS.(S. F. Badylak et al., 1995) By measuring the uniaxial longitudinal
tensile strength, they determined that the repaired portion of the tendon had greater strength than
the proximal or distal ends of the tendon 12 weeks post-recovery. The SIS bioscaffold had been
degraded and replaced by host tissue 8 weeks after implantation according to
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immunohistological analysis.(S. F. Badylak et al., 1995) The initial bone repair study, led by
Suckow, showed that SIS rapidly repaired a long bone defect in Sprague-Dawley rats.(Suckow,
Voytik-Harbin, Terril, & Badylak, 1999) The SIS performed similarly to demineralized cortical
bone treatment by first allowing for cartilage formation which was interchanged with
mineralized bone.(Suckow et al., 1999) The first study investigating the regenerative potential of
SIS in a muscle defect model took place in 1995 using an abdominal wall defect model.(Prevel,
Eppley, Summerlin, Jackson et al., 1995) The abdominal wall defect model was developed using
rats who received a 2cm x 2cm defect within the skeletal muscle of the abdominal wall. An SIS
bioscaffold was placed into the defect. To assess skeletal muscle regeneration, Prevel and his
group did qualitative histological analysis of thin muscle sections to determine that the SIS
incorporated into the existing abdominal wall after two months with minimal inflammation and
there was no evidence of host rejection of the donor tissue.(Prevel et al., 1995)
More recently, research groups associated with Dr. Badylak and the University of
Pittsburgh have published research on using porcine SIS to repair VML in animal models. In one
study, Turner et al. made a defect in the distal third of the gastrocnemius muscle and proximal
half of the associated Achilles tendon of canines.(Turner et al., 2010) While in another study,
Sicari et al. made a defect in murine quadriceps.(Sicari et al., 2012) The techniques used in
determining the effectiveness of the SIS in repairing the skeletal muscle defect in both studies
were similar. The researchers looked at the vascularization of the wound site, the infiltration of
myoblasts and nascent myofiber formation, and they observed the progressive degradation of the
SIS scaffold in the wound site. They noticed that the repair proceeded similarly to the earlier
abdominal wall defect models, with a rapid degradation on the bioscaffold, neovascularization,
and myoblasts forming isolated myofibers within the defect.(Sicari et al., 2012; Turner et al.,
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2010) Badylak’s group relies on histological evidence of wound repair and muscle formation and
does not use in vivo functional testing as a measure of regeneration, although they have reported
on ex vivo functional testing.(Turner et al., 2010) In addition to investigating decellularized
porcine SIS as a bioscaffold to repair VML, Wolf et al. compared the regenerative performance
of SIS to ECM derived from decellularized skeletal muscle.(Wolf, Daly, Reing, & Badylak,
2012) They observed differences in the biochemical composition of the ECM scaffolds,
specifically: growth factors, glycosaminoglycans, and structural proteins of the basement
membrane. However, using the same criteria as previous studies, they found that there was little
difference between the regenerative capacities of the two bioscaffolds when used to repair an
abdominal wall defect.(Wolf et al., 2012) They concluded that “superior tissue remodeling
outcomes are not universally dependent upon homologous tissue derived ECM scaffold
materials.”(Wolf et al., 2012) Another Sicari et al. study (again within the Badylak group)
published a translational study using ECM derived from porcine urinary bladder to repair VML
in a rat model and in five human patients.(Sicari et al., 2014) The ECM derived from porcine
urinary bladder matrix (UBM) is structurally and biochemically very similar to ECM derived
from porcine SIS. The UBM elicited functional improvement in three of the five human
patients.(Sicari et al., 2014) Although the authors were careful not to call the response
“regeneration” and instead referred to the recovery as constructive remodeling. The distinction
between these terms was more clearly explained in a recent review by Badylak et al. in 2016.
The response of the host to the ECM bioscaffold is similar to innate repair mechanisms with
infiltration of macrophages and a transient pro-inflammatory environment, followed by
myogenesis and ECM remodeling, but the processes are not identical since current ECM-based
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repair modalities are accompanied by long-lasting, though isolated, fibrosis at the injury site and
no study has yet shown complete functional recovery from VML.(S. F. Badylak et al., 2016)
Badylak’s group has since performed a larger clinical study with a 13 patient cohort. The
patients had a variety of defect sites and mechanisms of injury but most experienced functional
recovery after treatment with porcine ECM bioscaffolds (SIS, UBM, and dermal ECM). The
authors reported a 37% improvement in functional strength and a 27% increase for range of
motion tasks.(J. Dziki et al., 2016) This study provides evidence to justify the further exploration
of ECM bioscaffolds as a therapy for VML, but the percent improvement from this study do not
necessarily correspond to expected clinical outcomes due to the diversity of VML injury
locations and severity. These patients also were outside the acute injury response phase and had
undergone several previous surgeries for debridement and/or tenolysis.(J. Dziki et al., 2016)
Animal models used for investigating VML repair typically deliver scaffolds and/or cells
immediately after creation of a VML injury. Therefore it is difficult to compare functional
recovery results from this human study to results seen in small or large animal models. This
study also self-identifies several limitations with respect to the lack of a control treatment (scar
debridement and prescribed physical therapy), the presence of varying comorbidities even with
similar implantation sites, and failing to control for the placebo effect.(J. Dziki et al., 2016)
However, this study, published online in July 2016, is currently the largest clinical study to date
to explore ECM bioscaffold therapies for VML in human patients.
In addition to investigations with decellularized porcine submucosa scaffolds, Dr.
Badylak and his group has advanced the characterization and use of decellularized scaffolds
more broadly.(Gilbert, Sellaro, & Badylak, 2006) Decellularization is a process which removes
the cellular components from a tissue leaving behind the intact ECM.(Gilbert et al., 2006)
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Decellularized tissue is promising as a biologic scaffold because it retains the biochemical and
morphological structure of the native ECM while having dramatically lower antigenicity than an
allograft because it lacks foreign cell antigens.(Gilbert et al., 2006) Decellularization of tissues
and whole organs can be accomplished through the use of chemical agents such as: surfactants,
detergents or osmotic solutions.(Gilbert et al., 2006; Gillies, Smith, Lieber, & Varghese, 2010)
Decellularization has been used to produce whole organ scaffolds for the heart(Ott et al., 2008),
liver(Uygun et al., 2010), lungs(Ott et al., 2010), and kidneys(Sullivan et al., 2012). Whole
organ decellularization in many cases has been achieved through the use of vascular
perfusion.(Ott et al., 2008; Ott et al., 2010; Sullivan et al., 2012; Uygun et al., 2010) The major
inlets and outlets (arteries and veins) and the capillary network of organs allow for perfusion of
the entire organ.
One of the hallmark papers of decellularized tissue was published by Ott et al. in Nature
Medicine in 2008. They sought to decellularize a mammalian heart and subsequently return cells
to the resulting scaffold in an attempt to engineer a functional “bioartificial” heart.(Ott et al.,
2008) They successfully decellularized the heart and repopulated the scaffold with neonatal
cardiomyocytes, fibrocytes, endothelial cells, and smooth muscle cells. Although the bioartifical
heart was responsive to electrical and chemical stimuli after 8 days, the contractile force only
produced 2% of adult rat heart function. They did, however, report rhythmic depolarizations and
contractions up to 5 minutes after the heart was removed from electrical pacing. The authors also
stated that recellularization of the scaffold was incomplete as only 34% of tissue cross-sections
were populated by injected cells.(Ott et al., 2008) While this study left a lot to be improved upon,
it demonstrated the potential that decellularization had as a method for fabricating scaffolds with
regenerative capacity.

16

While most skeletal muscle lacks the major arteries and veins used for perfusion
decellularization, skeletal muscle can also be decellularized to form an ECM-based scaffold.
Scaffolds composed of decellularized muscle are unique because they retain the parallel
alignment of the native muscle from which they were obtained and pores for cell attachment left
by the previous cells.(Wilson, Terlouw, Roberts, & Wolchok, 2016) Decellularization of
skeletal muscle can be accomplished through the use of chemical agents such as: surfactants,
detergents or osmotic solutions.(Gilbert et al., 2006) Decellularized skeletal muscle (DSM)
lacks the antigenicity of an allogenic transplant but requires the infiltration of host cells and
revascularization with associated integration into the host vasculature to produce functioning
myofibers.
Several research groups around the world are currently exploring the use of DSM as a
scaffold to repair VML in animal models. In 2010, Merritt et al. published a study in Tissue
Engineering in which they used DSM along with bone marrow-derived mesenchymal stem cells
to repair a VML injury in the gastrocnemius of a rat.(Merritt et al., 2010) The peak isometric
contractile force produced by the muscle repaired with ECM+cells was 84% of the uninjured
contralateral muscle after a 42 day recovery period. The authors also noted a dense population of
desmin+ cells in the defect area of ECM+cells repaired muscles as well as significantly more
vWF+ blood vessel ingrowth.(Merritt et al., 2010) Results confirming this robust regenerative
capacity of DSM in VML injuries have been reported in other research groups.
In a 2011 Biomaterials article, Perniconi et al. presented research in which most of a
murine TA was removed, leaving only the distal tendon and enough muscle at the tibial origin to
anchor a DSM scaffold.(Perniconi et al., 2011a) The authors did not perform any functional
testing but described a pro-myogenic environment with capacity to support the de novo
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formation of myofibers after implantation into a VML injury. The authors tracked the
degradation of the accelular scaffold over four weeks and noted that it remained stable during
initial macrophage invasion and was gradually degraded as host myoblasts migrated to the defect
site. Centrally located nuclei were observed in the newly formed myofibers, indicative of skeletal
muscle regeneration.(Perniconi et al., 2011a)
Repair of VML is not the only application which is being researched to investigate the
regenerative potential of DSM. DeQuach et al. developed an injectable skeletal muscle matrix
hydrogel to repair peripheral artery disease (PAD) in a rat hindlimb ischemia model.(DeQuach et
al., 2012) In order to create ischemia, the femoral artery was resected in a rat model. One week
post-hindlimb ischemia, either DSM hydrogel or collagen hydrogel was injected intramuscularly
below the site of the initial defect. Arteriole density was significantly greater in the DSM
hydrogel compared to collagen at 3, 5, and 7 days post-injection. The authors also reported a
significant increase in the number of desmin+ cells that co-expressed Ki67, an indicator for
proliferating satellite cell, present at the site of DSM hydrogel injection.(DeQuach et al., 2012)

Cell Based Repair Strategies
Many researchers in the field of skeletal muscle regenerative medicine tout the
advantages of “off the shelf” therapies such as DSM derived ECM compared to cell-based
therapies.(Swinehart & Badylak, 2016) The disadvantages of cell-based therapies include:
inadequate supply of fresh donor cells, difficulty delivering cells, and potential for implanted
cells to undergo transdifferentiation, leading to cancerous growth.(Dumont et al., 2015) The
inadequate supply of donor cells is due to several reasons. One of which is due to the host
rejection response typically associated with whole organ donation. Stem cells are usually
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autologous and harvested from many different sources within the patient’s body to include many
different cell types. However, the first stem cell transplants were performed using allogeneic
myoblasts to treat Duchenne Muscular Dystrophy (DMD). Although researchers had success
initially with preclinical animal trials, the results from the first clinical trials were
unsuccessful.(Huard et al., 1992; Huard et al., 1994; Kinoshita et al., 1994; Skuk, 2012) The
conclusions drawn from these studies were that allogeneic myoblasts were not an effective
treatment for DMD. Only 25% of the donor myoblasts remained viable after three days in two
studies which was explained in a subsequent study that insufficient immunosuppressive therapy
led to the host destroying most of the implanted myoblasts.(Guérette, Asselin, Skuk, Entman, &
Tremblay, 1997) Almost 10 years later, Skuk et al. found that the implanted myoblasts did not
migrate more than 200μm from the injection site.(Skuk et al., 2006) Another study hypothesized
that the myoblasts had undergone precocious differentiation leading to a much smaller pool of
myoblasts and by delaying cell cycle exit into asymmetric differentiation, the implanted pool of
myoblasts was able to migrate further into the tissue.(Riederer et al., 2012) Other muscle derived
cells have been indentified and studied for their impact on muscle regeneration, such as: CD133+
progenitor cells, muscle derived stem cells, multipotent perivascular progenitor cells.(Meng et
al., 2014; Sampaolesi et al., 2006; Zheng et al., 2007) Studies using these cell types have been
limited in scope and have not been used in clinical trials other than to determine the safety of
delivery methods.(Cossu et al., 2015)
Mesenchymal stem cells (MSCs) are another broad stem cell type that have been used as
a cell source for skeletal muscle tissue engineering. MSCs are precursor cells which eventually
form the tissues of the mesoderm through chondrogenic, osteogenic, adipogenic, or myogenic
differentiation.(Sicari, Dearth, & Badylak, 2014) The sources of donor MSCs used to investigate
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muscle repair range from bone marrow and adipose tissue to placenta and umbilical cord.(Erices,
Conget, & Minguell, 2000; Jiang et al., 2002; Scherjon et al., 2004; Zuk et al., 2001) Bone
marrow derived MSCs (BM-MSCs) have been shown to provide a dose dependent effect on
functional recovery from a crush injury.(Winkler et al., 2008) They have also been shown to
interact with the microenvironment at the defect site to induce paracrine signaling with the host’s
own pro-inflammatory or myogenic cells.(Cizkova et al., 2011; Gang et al., 2009) Adipose
derived stem cells (ADSCs) are an additional type of MSC that have been used in small animal
hindlimb repair models. In 2010, Kang et al. found that injections of ADSCs into the ischemic
hindlimb of a mouse improved perfusion after three days and had contributed to new myofiber
formation after four weeks post-injury.(Kang et al., 2010) Work more recently by Kesireddy, has
shown that while ADSCs do not increase myogenesis to the extent of muscle derived progenitor
cells, they induce greater angiogenesis at the wound site and thus provide similar therapeutic
outcomes within the context VML repair.(Kesireddy, 2016) Finally, umbilical cord blood (UCB)
derived MSCs have been shown to have high myogenic potential by Pesce et al. when used in an
ischemic hindlimb models.(Pesce et al., 2003) Like other MSCs, UBC derived MSCs have the
potential to not only induce myogenesis but promote angiogenesis and deliver paracrine signals
that encourage differentiation of host satellite cells and other progenitor cells.(Sicari et al., 2014)

Skeletal Muscle Repair with Minced Muscle
One novel approach for reducing the complexity of satellite cell delivery is the use of
minced muscle (MM). MM is derived by mincing a small volume of muscle into pieces smaller
than 1-2mm.(Corona et al., 2013b) MM differs from other cell-based therapies by delivering
more than just progenitor cells to the injury site; basement membrane fragments, damaged
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myofibers, and ECM captive growth factors are also present at implantation.(Corona et al.,
2013b) If taken from around the area of the defect site, MM would not require an additional
surgical site. In 2013, Corona et al. from the United States Army Institute of Surgical Research at
Fort Sam Houston, published a paper on the use of autologous minced muscle grafts. This
research further explored the regenerative capacity of minced muscle which had first been
observed by Studinsky and Carlson in 1964 and 1972, respectively.(Carlson, 1968; Studitsky,
1965) Corona et al. first determined the proliferative capacity of the MM by culturing it on
collagen coated dishes. They observed increasing nucleic acid out to 14 days and increasing
numbers of desmin-positive cells, indicating that not only were cells proliferating but that
myogenesis was occurring. Using immunohistochemical staining the authors also found that the
expression of Pax7, CD31, myogenin, embryonic myosin heavy chain (emb-MHC), and CD163
were all significantly higher in MM treated VML injuries than non-repaired VML
injuries.(Corona et al., 2013b) They then used a rat TA model for VML injuries and implanted
the defected muscle orthotopically back into the defect site after mincing in into 1mm3
fragments. The contralateral limb was untreated to serve as a control and the rats were given an
eight or sixteen week recovery period. The mass of the repaired TA was 11 and 21% heavier
than unrepaired TAs after eight and sixteen weeks, respectively. The MM-treated limbs also
produced ~14% more isometric torque at 16 weeks post-injury than unrepaired limbs. Motor
endplates were also observed in regenerated muscle fibers using α-bungarotoxin staining at 8
weeks post-injury. They also determined that the fibers were innervated by repeatedly
stimulating the muscle to deplete glycogen storage in innervated fibers. Glycogen levels of in the
remaining muscle mass on the defected limb were similar to glycogen levels in the defect repair
and both were significantly lower than non-stimulated muscle. Thus indicating that the nascent
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myofibers within the defect area underwent glycogen depletion and were therefore
innervated.(Corona et al., 2013b) The authors also identified several challenges and limitations
to autologous transfer of MM to treat VML, the primary challenge being the introduction of a
second surgical site on the patient to harvest skeletal muscle tissue. Nevertheless, since few other
strategies to repair VML exist, Corona et al. concluded that “the use of minced muscle autografts
is an appropriate standard for the future advancement of VML therapies.”(Corona et al., 2013b)
The United States Army Institute of Surgical Research at Fort Sam Houston has
conducted further studies exploring the regenerative potential of MM by expanding the minced
autograft in a collagen hydrogel. The rationale for this 2015 study, authored by Ward et al., was
that donor muscle tissue was limited and expansion and co-delivery with a collagen hydrogel
could limit the amount of donor tissue necessary to facilitate regeneration of a VML
injury.(Ward, Ji, & Corona, 2015) The goal of this study was to determine the minimum volume
of MM needed to obtain functional outcomes consistent with a 100% volume MM
autograft.(Ward et al., 2015) The treatment groups the authors tested were 0%, 25%, 50%, and
100% MM with a volume of collagen to equal 400μL, the estimated size of the defect created in
the TA muscle of male Lewis rats. The authors reported that the 50% autograft provided
functional outcomes similar to 100% autografts with respect to peak tetanic force. However, the
number of de novo fibers regenerating in the defect site of the 50% autograft were half the
number of myofibers developing in the defect site of the 100% autograft. Another key finding
was that the average fiber area was smaller in 50% and 100% autografts than fibers found in
uninjured, control muscle tissue.(Ward et al., 2015)
In addition to exploring the use of MM autografts to repair VML in animal models, the
United States Army Institute of Surgical Research at Fort Sam Houston, led by Dr. Corona has
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contributed to the field of skeletal muscle tissue engineering by providing evidence against the
use of acellular ECM implant alone to repair VML injuries. They have published several papers
providing evidence counter to many of the articles published by the Badylak research group,
who, as previously discussed, has promoted the use of porcine-derived SIS or UBM scaffolds to
repair skeletal muscle tissue.(Aurora, Roe, Corona, & Walters, 2015; Corona et al., 2013a) In
one study, authored by Aurora et al., the U.S. Army research group tested the regenerative
capacity of porcine UBM and rat-derived decellularized muscle ECM (m-ECM) and compared
functional outcomes and histological data to unrepaired muscle and muscle repaired using an
autograft.(Aurora et al., 2015) The autograft repair in this instance was simply the muscle
removed by creating the VML defect and suturing it orthotopically back into the defect site. The
UBM graft improved the functional strength of the muscle by 17% after 16 weeks of recovery
when compared to unrepaired muscle. However, the autograft repair group had significantly
higher functional recovery than the acellular repair and after 16 weeks had produced 83% of the
force generated by an uninjured contralateral limb. Histological analysis of the defect site for the
treatment groups provided evidence that very little de novo fiber development was taking place
in muscles repaired with acellular grafts.(Aurora et al., 2015) The authors reported that the
number of myosin+ fibers was 100 times higher in the defect area of autograft repaired muscles
compared to the defect area of muscles repaired with either UBM or m-ECM acellular grafts.
They also noted that fiber formation in acellular graft repaired muscle at eight weeks postimplantation was only taking place within 200-300μm of the defect margins and that by 16
weeks, there were no early developing muscle fibers. The collagen deposition measured in the
defect area of UBM repaired muscles remained consistent with values seen in unrepaired muscle,
whose self-repair mechanism is permanent fibrosis. These observations led researchers to
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conclude that acellular scaffolds, while providing modest functional recovery, do not facilitate
myogenesis.(Aurora et al., 2015) Moreover, any improvements in muscular force output are
likely due to the creation of functional fibrotic tissue that lacks the contractility of normal
skeletal muscle tissue but stabilizes and links remaining contractile myofibers.(Aurora et al.,
2015)
Another aspect within studies conducted by Dr. Corona’s group which adds value to the
field of skeletal muscle tissue engineering is that they investigate the effect rehabilitation has on
functional recovery in animal VML models. They have reported that exercise, such as running
wheels for rodents, does not seem to improve functional recovery for defected muscles repaired
with acellular scaffolds.(Aurora et al., 2015) Animals receiving the same therapeutic intervention
but with one half of the group having access to a voluntary running wheel and the other half
having no access to an exercise wheel, had no significant differences in force production or
tissue composition.(Aurora et al., 2015) In a previous study, Aurora et al. found that physical
rehabilitation improved force production (17% improvement in peak isometric torque) and led to
a 13% increase in muscle weight of animals that had an unrepaired VML injury.(Aurora, Garg,
Corona, & Walters, 2014) But, wheel running did not alter the morphological characteristics of
the unrepaired muscle; there was no additional myogenesis nor fiber hypertrophy in the muscles
receiving a VML injury, regardless of rehabilitation.(Aurora et al., 2014) There was, however, an
up-regulation of pro-fibrotic genes (Collagen I and TGF-β) in the unrepaired muscles of rats who
had access to the running wheel.(Aurora et al., 2014)
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Synthetic Scaffold Based Repair Strategies
Synthetic materials manufactured into scaffolds for skeletal muscle tissue engineering
have been and are currently being investigated for their regenerative capacity as a therapy for
VML. Synthetic scaffolds have several key advantages over biologic scaffolds from an
engineering standpoint. They can be manufactured with precise specifications with respect to
composition and architecture, and materials used in synthetic scaffolds have been better
characterized that many biologic scaffolds.(Wolf et al., 2015) While these are advantages for the
consistent, customizable, and high-throughput manufacture of tissue engineering scaffolds and
allow for more precise characterization, synthetic scaffolds have not had more success than
biologic scaffolds when used in animal models for skeletal muscle tissue engineering. Several
types of polymers have been considered and evaluated for their potential as repair modalities for
skeletal muscle trauma, they include: poly(glycolic acid) (PGA), poly(lactic acid) (PLA),
poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), polypropylene, and
polyurethanes.(Wolf et al., 2015)
Polypropylene was one of the first biomaterials used for tissue engineering due to its
relative bio-inertness. However, in recent years, it has not been used prevalently as bioabsorbable materials have been shown to be more appropriate due to the tendency of a host’s
immune system to encapsulate any material that does not degrade readily.(Anderson, Rodriguez,
& Chang, 2008) Permanent encapsulation with fibrotic tissue would preclude the primary
function of any material used to facilitate the regeneration of contractile muscle tissue.
PGA scaffolds have been in use for the past 17 years to repair skeletal muscle tissue. The
initial PGA study, authored by Saxena et al., found that by seeding a primary cell line of
myoblasts onto PGA absorbable mesh and implanting the construct into a Fisher 344 rat, they
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could regenerate tissue that resembled skeletal muscle.(Saxena, Marler, Benvenuto, Willital, &
Vacanti, 1999) Immunohistochemistry revealed that 45 days post-implantation, cells within the
stands of the degrading synthetic graft stained positive for α-sarcomeric actin and desmin. The
graft was also vascularized, however, the implantation site used in this study was the
omentum.(Saxena et al., 1999) Although this paper provides evidence of the biocompatibility of
the construct, it cannot be extrapolated to include myoblast-seeded PGA as an appropriate
scaffold for VML unless functional testing and/or orthotopic implantation within a defected
skeletal muscle is performed.
PLA has only been used as a substrate upon which C2C12 (mouse skeletal muscle cell
line) and HSKM5 (human skeletal muscle cell line) were attached and their viability and
proliferative response was observed and reported in a paper authored by Cronin et al..(Cronin et
al., 2004) The PLA, as a fiber and as a film, was coated with either ECM gel, gelatin,
fibronectin, or laminin before cells were seeded. ECM-coated PLA outperformed other scaffolds
with respect to cell attachment and expression of skeletal muscle related genes.(Cronin et al.,
2004) However, the in vitro nature of this study limits the impact PLA could potentially have as
a therapeutic scaffold for skeletal muscle tissue engineering.
PLGA scaffolds are an attractive material for scaffold fabrication due to the nontoxicity
of its degradation products: lactic acid and glycolic acid. Many studies have been performed
under in vitro conditions to fabricate biomimetic constructs for a variety of applications,
including skeletal muscle repair. A paper, authored by Shandalov et al., reported promising
results with a stem cell seeded PLA-PLGA scaffold implanted into an abdominal wall defect
model in a mouse.(Shandalov et al., 2014) Before orthotopic implantation into the abdominal
wall, the researchers implanted the scaffold around the femoral artery and vein and isolated the
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construct from surrounding tissue. This in vivo preconditioning initiated vessel formation within
the scaffold and the new vasculature survived through the subsequent removal and reimplantation into the abdominal wall.(Shandalov et al., 2014) They observed anastomosis with
the host vasculature and robust perfusion of the scaffold 2 weeks postimplantation. There have
other in vivo studies in animal models using PLGA scaffolds, although results from these studies
have no provided evidence of functional recovery from extremity VML repair.(Laschke et al.,
2008; Levenberg et al., 2005b)
PCL is another promising synthetic biomaterial that has been investigated for its
compatibility as a scaffold for skeletal muscle tissue engineering. Some of the best examples of
PCL scaffolds are ones that have been fabricated using electrospinning, a method that is used to
arrange synthetic constructs by extruding a polymer onto a charged plate. By varying the charge
and deposition rate, researchers are able to create a scaffold with aligned microstructure, suitable
for muscle progenitor cell adhesion and proliferation.(Choi, Lee, Christ, Atala, & Yoo, 2008a)
Electrospun PCL scaffolds have been fabricated with aligned fibers, which has been shown to be
important for myotube formation in vitro.(Choi et al., 2008a)
Polyurethane scaffolds have also been developed using electrospinning fabrication
techniques. Researchers have reported that multiple skeletal muscle cell lines, such as: C2C12,
L6, and human satellite cells, have proliferated and differentiated on polyurethane scaffolds.(S.
A. Riboldi, Sampaolesi, Neuenschwander, Cossu, & Mantero, 2005) Polyesterurethane scaffolds
have been developed and explored due to their favorable mechanical properties. PLA, PGA, and
PLGA fibers have a high tensile modulus and researchers have suggested that this would prevent
them from being used in the dynamic niche of skeletal muscle tissue engineering.(S. A. Riboldi
et al., 2005) Polyesterurethane fibers are elastomeric and have been shown to provide a suitable
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substrate for skeletal muscle progenitor cell attachment, proliferation, and differentiation.(S.
Riboldi et al., 2008; S. A. Riboldi et al., 2005; Sirivisoot & Harrison, 2011)
One benefit to using synthetic scaffolds is that their morphology can be tuned for a
specific application. Synthetic biomaterials used for skeletal muscle tissue engineering have been
fibers, mesh, hydrogels, and foams. Synthetic scaffolds are designed to mimic the ECM with
respect to the alignment of fibers and pore size.(Klumpp, Horch, Kneser, & Beier, 2010)
Although synthetic scaffolds may not have the exact biochemical composition of native ECM,
researchers are able to direct the organization of the fibers.(Aviss, Gough, & Downes, 2010;
Choi et al., 2008a) Hydrogels lack any organization for cell attachment and researchers must
modify the surface with microfabrication techniques if a hydrogel is to be used in skeletal muscle
tissue engineering. Micropatterning with soft photolithography, a technique used in
microfluidics, can create channels on which cells can adhere and proliferate.(Huang, Lee, & Li,
2010a)
Many synthetic scaffolds proposed as alternatives to repair skeletal muscle tissue trauma
have only been characterized under in vitro conditions and only with a cursory knowledge of
skeletal muscle tissue morphology and physiology. Although cell viability and proliferation is
important to establish for any skeletal muscle scaffold suggested for implantation into even a
small animal model, more rigorous in vivo testing must be undertaken before synthetic and tissue
engineered skeletal muscle have any translational applications. Skeletal muscle regeneration
after a VML injury is a complicated process with many spatio-temporal considerations to
address. Synthetic scaffold research to this point has been focused on developing in vitro
biomimetic skeletal muscle, but little advancement has taken place in terms of in vivo testing
within skeletal muscle tissue beyond biocompatibility and host cell infiltration analysis,
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excluding work done in abdominal wall defect models. However, there are some tissue
engineered constructs that have been studied for contractile force production in vivo and even
within a VML injury.

Engineered Skeletal Muscle Tissue
In addition to developing scaffolds, some researchers have sought to engineer skeletal
muscle tissue from cells. Tissue engineered skeletal muscle can function as a model for
pharmacological research, a tool for understanding embryological development and/or
myogenesis, or a therapeutic intervention for repairing skeletal muscle trauma. Two separate
groups have been using tissue engineered skeletal muscle under in vivo conditions and, more
importantly, within skeletal muscle tissue. Dr. Juhas and Dr. Bursac from Duke University and
Dr. Larkin from the University of Michigan have developed constructs that produce contractile
force and, in the case of Dr. Larkin’s research, have successfully integrated into damaged host
muscle. Juhas et al. fabricated engineered skeletal muscle by first molding a MatriGel hydrogel
with primary rat myoblasts in a PDMS mold. The authors noted the first objective was to create
an in vitro environment that more accurately reproduces the in vivo environment of the
myogenic tissue niche. Satellite cell proliferated and differentiated under in vitro conditions and
the researchers directed the development of cells into an engineering skeletal muscle tissue. The
engineered construct was capable of contractile force generation before it was implanted into a
dorsal window on a rat. At 2 week postimplantation, the construct was producing 3.5x more
contractile force than the pre-implanted engineered muscle. The engineered muscle also showed
robust vascular ingrowth from the host vasculature and a 40.7% increase in myofiber diameter.
The authors reported that engineered muscle appeared to have a myogenic response to
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implantation even though it was not within a skeletal muscle niche. In addition, the authors
reported vigorous recovery from an in vitro cardiotoxin injury. Juhas et al. concluded that the
results from their research supports using in vitro engineered muscle as a tool for drug and
toxicology studies.
Dr. Larkin’s group has also developed tissue engineered muscle tissue and have used
their construct to specifically repair VML in an animal model. In a paper authored by VanDusen
et al., they report that a rat TA muscle with a VML injury receiving therapeutic intervention with
their construct produced significantly more in vivo tetanic contractile force than an unrepaired
TA.(VanDusen, Syverud, Williams, Lee, & Larkin, 2014a) The fabrication of their engineered
muscle used techniques similar to those by Dr. Bursac’s group. Muscle progenitor cells, along
with isolated bone marrow cells, were harvested from the soleus muscle of 120 – 150 g female
Fisher 344 rats. Bone marrow cells were cultured in appropriate media to produce engineered
bone-tendon anchors used to implant the engineered muscle tissue. The muscle progenitor cells
were grown to confluence until elongating myotubes began to form and the monolayer was
delaminated and rolled into a cylindrical muscle construct. In addition to determining in vivo
peak tetanic force, the researchers also evaluated the regenerative potential of the engineered
muscle through histological data. Fluorescent imaging revealed aligned myofibers that had
developed advanced sarcomeric structure. At 28 days post-implantation, there was evidence of
innervation of the engineered construct through IHC staining for pan-axonal filaments and the
presence of ACh receptors through α-bungarotoxin staining. Immunostaining with CD-31 also
showed the presence of a well-developed capillary network throughout the engineered muscle
tissue. The capillary network was morphologically similar to those found in native muscle, with
vessels running parallel to the muscle fibers. The results from this study and others performed by
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Dr. Larkin’s group have motivated further investigations using engineered muscle tissue to repair
VML in larger volume models and to explore entire muscle replacement.
As previously discussed, skeletal muscle tissue is highly aligned and the force production
of a muscle is heavily influenced by the muscles architecture. Muscle architecture, the
arrangement of muscle fibers in relation to the axis of force generation, is constrained by the
length of the muscle, the length of myofibers, the pennation angle, and the physiological cross
sectional area (PCSA).(Lieber & Friden, 2000) Even in pennate muscles, adjacent myofibers
have parallel alignment and the surrounding ECM is highly uniform in direction. When
designing bioreactors for tissue engineered skeletal muscle, researchers are deliberate in
developing alignment within their constructs.(Aubin et al., 2010; Aviss et al., 2010; Huang, Lee,
& Li, 2010b; Vandenburgh & Karlisch, 1989) Parallel alignment of myofibers has been shown to
be important for developing phenotypically normal muscle tissue under in vitro
conditions.(Aubin et al., 2010; Lam, Huang, Birla, & Takayama, 2009; Vandenburgh &
Karlisch, 1989; Wang, Wu, Guo, & Ma, 2015) Researchers obtain parallel alignment through
micropatterning(Cimetta et al., 2009; Flaibani et al., 2009; Huang et al., 2010a; Shimizu, Fujita,
& Nagamori, 2009), aligned deposition of fibers(Aviss et al., 2010; Choi, Lee, Christ, Atala, &
Yoo, 2008b; Wang et al., 2015), or by selecting a scaffold that has native parallel alignment.
Myofiber alignment indicative of a mature muscle phenotype has also been induced in vitro
using bioreactors that deliver mechanical or electrical stimulation to cells and/or tissue
constructs.(Ahadian et al., 2013; Boonen et al., 2010a; Donnelly et al., 2010; Flaibani et al.,
2009; Grossi, Yadav, & Lawson, 2007; Langelaan et al., 2011; Powell, Smiley, Mills, &
Vandenburgh, 2002; Vandenburgh & Karlisch, 1989)
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Table 2: Highlighted VML repair studies.
VML Repair
Strategy
DSM + MSCs

Animal
Model
Rat (Gastroc.)

SIS

Canine (Gastroc.)

DSM

Murine (TA)
(Whole muscle)

SIS

Murine
(Quadriceps)

DSM

Rat
(Abdominal wall)

SIS
MM

Rat (TA)

Engineered
Skeletal
Muscle

Rat (TA)

MM + collagen
hydrogel

Rat (TA)

Autograft

Rat (TA)

UBM

DSM

Outcome

Authors

Improved contractile force.
Evidence of myogenesis
with addition of MSCs.
No improvement in
contractile force.
Neovascularization and
formation of isolated
myofibers within defect.
Gradual degradation of ECM
scaffold. Myoblast migration
to defect. Centrally located
nuclei in myofibers.
Rapid degradation of ECM
scaffold. Vascularization and
nascent myofiber formation
at the defect site.
No remarkable difference
between SIS and DSM.
Isolated de novo myofiber
formation and fibrosis at
defect site.
Greater contractile force.
Motor endplates in new
myofibers.
Signficant improvement in
contractile force when
compared to unrepaired
VML muscle. Blood vessel
ingrowth and innervation.
50% MM produced
contractile force similar to
100% MM, but had fewer
new myofibers. Average
fiber area smaller than
control muscle.
Autograft had greatest force
recovery (83%) compared to
acellular scaffolds. Myofiber
formation only 200-300μm
from defect margins. UBM
treated muscle had fibrosis
similar to unrepaired muscle.

Merritt et al., 2010

32

Turner et al., 2010

Perniconi et al., 2011

Sicari et al., 2012

Wolf et al., 2012

Corona et al., 2013

VanDusen et al., 2014

Ward et al., 2015

Aurora et al., 2015

E. Objective

The foundational goal of this research is to provide additional evidence to the following
hypothesis: ECM provides a therapeutic platform to aid in the regeneration of skeletal muscle
after volumetric muscle loss.
What is proposed is to improve methods of obtaining DSM, use DSM to repair VML in
an animal model, and to explore the effect of alignment and misalignment of VML repair
strategies within a defected muscle. We will use minced muscle as a source of cells and
additional signaling molecules to improve muscle regeneration. The use of minced muscle alone
has been shown to improve muscle regeneration and we intend to further explore its potential
when co-delivered with DSM. We will then explore the microenvironment between an autograft
and a muscle with a VML injury. In doing so, we hope to study the effect alignment has on
fibrosis and/or myogenesis at the interface of the graft and damaged muscle.
We seek to further explore VML repair by investigating the effect scaffold alignment has
at the interface of the damaged muscle and tissue repair construct. While many researchers have
established the importance of alignment when engineering or selecting an effective scaffold, no
studies have investigated the effect of alignment or misalignment between the myofibers of the
autograft and the myofibers of muscle that has sustained a VML injury. By first investigating the
effect of autograft alignment within a VML defect on the functional recovery, we hope to guide
our future repair strategies including DSM and cell-derived ECM scaffolds.
A brief outline of the approach is as follows:
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•

A perfusion decellularization system will be developed to produce skeletal muscle ECM

scaffolds.
•

Scaffolds (diffusion and perfusion decellularized) will be characterized to ensure the

perfusion process does not negatively alter ECM.
•

DSM with and without the addition of MM will be implanted within a defected muscle to

repair VML in an animal model.
•

The final portion of this study will be to explore the effect of alignment has on the

regenerative potential of an autograft to repair VML.

34

References
Ahadian, S., Ramon-Azcon, J., Ostrovidov, S., Camci-Unal, G., Kaji, H., Ino, K., . . . Matsue, T.
(2013). A contactless electrical stimulator: Application to fabricate functional skeletal
muscle tissue. Biomedical Microdevices, 15(1), 109-115. doi:10.1007/s10544-012-9692-1;
10.1007/s10544-012-9692-1
Alfaro, L. A. S., Dick, S. A., Siegel, A. L., Anonuevo, A. S., McNagny, K. M., Megeney, L. A., .
. . Rossi, F. (2011). CD34 promotes satellite cell motility and entry into proliferation to
facilitate efficient skeletal muscle regeneration. Stem Cells, 29(12), 2030-2041.
Allen, R. E., Sheehan, S. M., Taylor, R. G., Kendall, T. L., & Rice, G. M. (1995). Hepatocyte
growth factor activates quiescent skeletal muscle satellite cells in vitro. Journal of Cellular
Physiology, 165(2), 307-312.
Alter, J., Rozentzweig, D., & Bengal, E. (2008). Inhibition of myoblast differentiation by tumor
necrosis factor alpha is mediated by c-jun N-terminal kinase 1 and leukemia inhibitory
factor. The Journal of Biological Chemistry, 283(34), 23224-23234.
doi:10.1074/jbc.M801379200 [doi]
Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008). Foreign body reaction to biomaterials.
Seminars in Immunology, , 20(2) 86-100.
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., . . . Chazaud, B.
(2007). Inflammatory monocytes recruited after skeletal muscle injury switch into
antiinflammatory macrophages to support myogenesis. The Journal of Experimental
Medicine, 204(5), 1057-1069. doi:jem.20070075 [pii]
Aubin, H., Nichol, J. W., Hutson, C. B., Bae, H., Sieminski, A. L., Cropek, D. M., . . .
Khademhosseini, A. (2010). Directed 3D cell alignment and elongation in microengineered
hydrogels. Biomaterials, 31(27), 6941-6951.
Aurora, A., Roe, J. L., Corona, B. T., & Walters, T. J. (2015). An acellular biologic scaffold does
not regenerate appreciable de novo muscle tissue in rat models of volumetric muscle loss
injury. Biomaterials, 67, 393-407.
Aurora, A., Garg, K., Corona, B. T., & Walters, T. J. (2014). Physical rehabilitation improves
muscle function following volumetric muscle loss injury. BMC Sports Science, Medicine
and Rehabilitation, 6(1), 41-1847-6-41. eCollection 2014. doi:10.1186/2052-1847-6-41
[doi]
Aviss, K. J., Gough, J. E., & Downes, S. (2010). Aligned electrospun polymer fibres for skeletal
muscle regeneration. Euro. Cells and Mater., 19, 193-204.

35

Badylak, S. F., Dziki, J. L., Sicari, B. M., Ambrosio, F., & Boninger, M. L. (2016). Mechanisms
by which acellular biologic scaffolds promote functional skeletal muscle restoration.
Biomaterials, 103, 128-136.
Badylak, S. F., Lantz, G. C., Coffey, A., & Geddes, L. A. (1989). Small intestinal submucosa as
a large diameter vascular graft in the dog. Journal of Surgical Research, 47(1), 74-80.
Badylak, S. F., Tullius, R., Kokini, K., Shelbourne, K. D., Klootwyk, T., Voytik, S. L., . . .
Simmons, C. (1995). The use of xenogeneic small intestinal submucosa as a biomaterial for
achille's tendon repair in a dog model. Journal of Biomedical Materials Research, 29(8),
977-985.
Badylak, S., Meurling, S., Chen, M., Spievack, A., & Simmons-Byrd, A. (2000). Resorbable
bioscaffold for esophageal repair in a dog model. Journal of Pediatric Surgery, 35(7), 10971103.
Bi, H., & Jin, Y. (2013). Current progress of skin tissue engineering: Seed cells, bioscaffolds,
and construction strategies doi:10.4103/2321-3868.118928
Boonen, K. J., Langelaan, M. L., Polak, R. B., van der Schaft, Daisy WJ, Baaijens, F. P., & Post,
M. J. (2010). Effects of a combined mechanical stimulation protocol: Value for skeletal
muscle tissue engineering. Journal of Biomechanics, 43(8), 1514-1521.
Bursac, N., Juhas, M., & Rando, T. A. (2015). Synergizing engineering and biology to treat and
model skeletal muscle injury and disease. Annual Review of Biomedical Engineering, 17,
217-242. doi:10.1146/annurev-bioeng-071114-040640 [doi]
Carlson, B. M. (1968). Regeneration of the completely excised gastrocnemius muscle in the frog
and rat from minced muscle fragments. Journal of Morphology, 125(4), 447-471.
Chen, J., Xu, J., Wang, A., & Zheng, M. (2009). Scaffolds for tendon and ligament repair:
Review of the efficacy of commercial products. Expert Review of Medical Devices, 6(1), 6173.
Choi, J. S., Lee, S. J., Christ, G. J., Atala, A., & Yoo, J. J. (2008a). The influence of electrospun
aligned poly(epsilon-caprolactone)/collagen nanofiber meshes on the formation of selfaligned skeletal muscle myotubes. Biomaterials, 29(19), 2899-2906.
doi:10.1016/j.biomaterials.2008.03.031 [doi]
Choi, J. S., Lee, S. J., Christ, G. J., Atala, A., & Yoo, J. J. (2008b). The influence of electrospun
aligned poly(epsilon-caprolactone)/collagen nanofiber meshes on the formation of selfaligned skeletal muscle myotubes. Biomaterials, 29(19), 2899-2906.
doi:10.1016/j.biomaterials.2008.03.031; 10.1016/j.biomaterials.2008.03.031

36

Cimetta, E., Pizzato, S., Bollini, S., Serena, E., De Coppi, P., & Elvassore, N. (2009). Production
of arrays of cardiac and skeletal muscle myofibers by micropatterning techniques on a soft
substrate. Biomedical Microdevices, 11(2), 389-400.
Cizkova, D., Vávrová, J., Micuda, S., Filip, S., Brcakova, E., Bruckova, L., & Mokry, J. (2011).
Role of transplanted bone marrow cells in response to skeletal muscle injury. Folia
Biologica, 57(6), 232.
Clarke, M. S., & Feeback, D. L. (1996). Mechanical load induces sarcoplasmic wounding and
FGF release in differentiated human skeletal muscle cultures. FASEB Journal : Official
Publication of the Federation of American Societies for Experimental Biology, 10(4), 502509.
Cobb, M. A., Badylak, S. F., Janas, W., Simmons-Byrd, A., & Boop, F. A. (1999). Porcine small
intestinal submucosa as a dural substitute. Surgical Neurology, 51(1), 99-104.
Corona, B. T., Wu, X., Ward, C. L., McDaniel, J. S., Rathbone, C. R., & Walters, T. J. (2013a).
The promotion of a functional fibrosis in skeletal muscle with volumetric muscle loss injury
following the transplantation of muscle-ECM. Biomaterials, 34(13), 3324-3335.
Corona, B. T., Garg, K., Ward, C. L., McDaniel, J. S., Walters, T. J., & Rathbone, C. R. (2013b).
Autologous minced muscle grafts: A tissue engineering therapy for the volumetric loss of
skeletal muscle. American Journal of Physiology.Cell Physiology, 305(7), C761-75.
doi:10.1152/ajpcell.00189.2013 [doi]
Cossu, G., Previtali, S. C., Napolitano, S., Cicalese, M. P., Tedesco, F. S., Nicastro, F., . . .
Ciceri, F. (2015). Intra-arterial transplantation of HLA-matched donor mesoangioblasts in
duchenne muscular dystrophy. EMBO Molecular Medicine, 7(12), 1513-1528.
doi:10.15252/emmm.201505636 [doi]
Coulet, B., Boch, C., Boretto, J., Lazerges, C., & Chammas, M. (2011). Free gracilis muscle
transfer to restore elbow flexion in brachial plexus injuries. Orthopaedics & Traumatology:
Surgery & Research, 97(8), 785-792.
Cronin, E. M., Thurmond, F. A., Bassel‐Duby, R., Williams, R. S., Wright, W. E., Nelson, K. D.,
& Garner, H. R. (2004). Protein‐coated poly (l‐lactic acid) fibers provide a substrate for
differentiation of human skeletal muscle cells. Journal of Biomedical Materials Research
Part A, 69(3), 373-381.
Davie, J. K., Cho, J., Meadows, E., Flynn, J. M., Knapp, J. R., & Klein, W. H. (2007). Target
gene selectivity of the myogenic basic helix–loop–helix transcription factor myogenin in
embryonic muscle. Developmental Biology, 311(2), 650-664.
DeQuach, J. A., Lin, J. E., Cam, C., Hu, D., Salvatore, M. A., Sheikh, F., & Christman, K. L.
(2012). Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle

37

cell infiltration in a hindlimb ischemia model. European Cells & Materials, 23, 400-12;
discussion 412. doi:vol023a31 [pii]
DiMario, J., Buffinger, N., Yamada, S., & Strohman, R. C. (1989). Fibroblast growth factor in
the extracellular matrix of dystrophic (mdx) mouse muscle. Science (New York, N.Y.),
244(4905), 688-690.
Donnelly, K., Khodabukus, A., Philp, A., Deldicque, L., Dennis, R. G., & Baar, K. (2010). A
novel bioreactor for stimulating skeletal muscle in vitro. Tissue Engineering.Part C,
Methods, 16(4), 711-718. doi:10.1089/ten.TEC.2009.0125; 10.1089/ten.TEC.2009.0125
Dumont, N. A., Bentzinger, C. F., Sincennes, M., & Rudnicki, M. A. (2015). Satellite cells and
skeletal muscle regeneration. Comprehensive Physiology,
Dziki, J. L., Sicari, B. M., Wolf, M. T., Cramer, M. C., & Badylak, S. F. (2016).
Immunomodulation and mobilization of progenitor cells by extracellular matrix bioscaffolds
for volumetric muscle loss treatment. Tissue Engineering Part A, 22(19-20), 1129-1139.
Dziki, J., Badylak, S., Yabroudi, M., Sicari, B., Ambrosio, F., Stearns, K., . . . Brown, E. H.
(2016). An acellular biologic scaffold treatment for volumetric muscle loss: Results of a 13patient cohort study. Npj Regenerative Medicine, 1, 16008.
Erices, A., Conget, P., & Minguell, J. J. (2000). Mesenchymal progenitor cells in human
umbilical cord blood. British Journal of Haematology, 109(1), 235-242.
Fan, C., Jiang, P., Fu, L., Cai, P., Sun, L., & Zeng, B. (2008). Functional reconstruction of
traumatic loss of flexors in forearm with gastrocnemius myocutaneous flap transfer.
Microsurgery, 28(1), 71-75.
Fischer, J. P., Elliott, R. M., Kozin, S. H., & Levin, L. S. (2013). Free function muscle transfers
for upper extremity reconstruction: A review of indications, techniques, and outcomes. The
Journal of Hand Surgery, 38(12), 2485-2490.
Fisher, M. B., & Mauck, R. L. (2013). Tissue engineering and regenerative medicine: Recent
innovations and the transition to translation. Tissue Engineering Part B: Reviews, 19(1), 113.
Flaibani, M., Boldrin, L., Cimetta, E., Piccoli, M., Coppi, P. D., & Elvassore, N. (2009). Muscle
differentiation and myotubes alignment is influenced by micropatterned surfaces and
exogenous electrical stimulation. Tissue Engineering Part A, 15(9), 2447-2457.
Fredsted, A., Gissel, H., Madsen, K., & Clausen, T. (2007). Causes of excitation-induced muscle
cell damage in isometric contractions: Mechanical stress or calcium overload? American
Journal of Physiology.Regulatory, Integrative and Comparative Physiology, 292(6), R224958. doi:00415.2006 [pii]

38

Gang, E. J., Darabi, R., Bosnakovski, D., Xu, Z., Kamm, K. E., Kyba, M., & Perlingeiro, R. C.
(2009). Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not
accompanied by functional recovery. Experimental Cell Research, 315(15), 2624-2636.
Garg, K., Ward, C. L., Hurtgen, B. J., Wilken, J. M., Stinner, D. J., Wenke, J. C., . . . Corona, B.
T. (2015). Volumetric muscle loss: Persistent functional deficits beyond frank loss of tissue.
Journal of Orthopaedic Research, 33(1), 40-46.
Gilbert, T. W., Sellaro, T. L., & Badylak, S. F. (2006). Decellularization of tissues and organs.
Biomaterials, 27(19), 3675-3683. doi:http://dx.doi.org/10.1016/j.biomaterials.2006.02.014
Gillies, A. R., & Lieber, R. L. (2011). Structure and function of the skeletal muscle extracellular
matrix. Muscle & Nerve, 44(3), 318-331.
Gillies, A. R., Smith, L. R., Lieber, R. L., & Varghese, S. (2010). Method for decellularizing
skeletal muscle without detergents or proteolytic enzymes. Tissue Engineering Part C:
Methods, 17(4), 383-389.
Grogan, B. F., Hsu, J. R., & Skeletal Trauma Research Consortium. (2011). Volumetric muscle
loss. The Journal of the American Academy of Orthopaedic Surgeons, 19 Suppl 1, S35-7.
doi:19/suppl_1/S35 [pii]
Grossi, A., Yadav, K., & Lawson, M. A. (2007). Mechanical stimulation increases proliferation,
differentiation and protein expression in culture: Stimulation effects are substrate dependent.
Journal of Biomechanics, 40(15), 3354-3362.
Guérette, B., Asselin, I., Skuk, D., Entman, M., & Tremblay, J. P. (1997). Control of
inflammatory damage by anti-LFA-l: Increase success of myoblast transplantation. Cell
Transplantation, 6(2), 101-107.
Huang, N. F., Lee, R. J., & Li, S. (2010a). Engineering of aligned skeletal muscle by
micropatterning. American Journal of Translational Research, 2(1), 43-55.
Huang, N. F., Lee, R. J., & Li, S. (2010b). Engineering of aligned skeletal muscle by
micropatterning. American Journal of Translational Research, 2(1), 43-55.
Huard, J., Bouchard, J., Roy, R., Malouin, F., Dansereau, G., Labrecque, C., . . . Tremblay, J.
(1992). Human myoblast transplantation: Preliminary results of 4 cases. Muscle & Nerve,
15(5), 550-560.
Huard, J., Roy, R., Guérette, B., Verreault, S., Trèmblay, G., & Tremblay, J. P. (1994). Human
myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of
rejection. Muscle & Nerve, 17(2), 224-234.
Huard, J., Li, Y., & Fu, F. H. (2002). Muscle injuries and repair: Current trends in research. The
Journal of Bone and Joint Surgery.American Volume, 84-A(5), 822-832.
39

Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X.
R., . . . Blackstad, M. (2002). Pluripotency of mesenchymal stem cells derived from adult
marrow. Nature, 418(6893), 41-49.
Kaar, J. L., Li, Y., Blair, H. C., Asche, G., Koepsel, R. R., Huard, J., & Russell, A. J. (2008).
Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomaterialia, 4(5), 14111420.
Kang, Y., Park, C., Kim, D., Seong, C., Kwon, K., & Choi, C. (2010). Unsorted human adipose
tissue-derived stem cells promote angiogenesis and myogenesis in murine ischemic
hindlimb model. Microvascular Research, 80(3), 310-316.
Karalaki, M., Fili, S., Philippou, A., & Koutsilieris, M. (2009). Muscle regeneration: Cellular
and molecular events. In Vivo (Athens, Greece), 23(5), 779-796. doi:23/5/779 [pii]
Kasper, C. E. (1995). Sarcolemmal disruption in reloaded atrophic skeletal muscle. Journal of
Applied Physiology (Bethesda, Md.: 1985), 79(2), 607-614.
Kesireddy, V. (2016). Evaluation of adipose-derived stem cells for tissue-engineered muscle
repair construct-mediated repair of a murine model of volumetric muscle loss injury.
International Journal of Nanomedicine, 11, 1461.
Kim, T., Kim, I., Kim, Y., & Lee, J. (2012). Reconstruction of lower extremity complex wounds
with combined free tissue transfer using the anterolateral thigh flap as a link. Microsurgery,
32(7), 575-579.
Kinoshita, I., Vilquin, J., GuéRette, B., Asselin, I., Roy, R., & Tremblay, J. P. (1994). Very
efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle &
Nerve, 17(12), 1407-1415.
KJÆR, M. (2004). Role of extracellular matrix in adaptation of tendon and skeletal muscle to
mechanical loading. Physiological Reviews, 84(2), 649-698.
doi:10.1152/physrev.00031.2003
Klebuc, M., & Menn, Z. (2013). Muscle flaps and their role in limb salvage. Methodist DeBakey
Cardiovascular Journal, 9(2), 95-99.
Klumpp, D., Horch, R. E., Kneser, U., & Beier, J. P. (2010). Engineering skeletal muscle tissue-new perspectives in vitro and in vivo. Journal of Cellular and Molecular Medicine, 14(11),
2622-2629. doi:10.1111/j.1582-4934.2010.01183.x; 10.1111/j.1582-4934.2010.01183.x
Knoblich, J. A. (2008). Mechanisms of asymmetric stem cell division. Cell, 132(4), 583-597.
Kropp, B. P., Eppley, B. L., Prevel, C., Rippy, M., Harruff, R., Badylak, S., . . . Keating, M.
(1995). Experimental assessment of small intestinal submucosa as a bladder wall substitute.
Urology, 46(3), 396-400.
40

Kropp, B. P., Rippy, M. K., Badylak, S. F., Adams, M. C., Keating, M. A., Rink, R. C., & Thor,
K. B. (1996). Regenerative urinary bladder augmentation using small intestinal submucosa:
Urodynamic and histopathologic assessment in long-term canine bladder augmentations.
The Journal of Urology, 155(6), 2098-2104.
Lam, M. T., Huang, Y. C., Birla, R. K., & Takayama, S. (2009). Microfeature guided skeletal
muscle tissue engineering for highly organized 3-dimensional free-standing constructs.
Biomaterials, 30(6), 1150-1155. doi:10.1016/j.biomaterials.2008.11.014;
10.1016/j.biomaterials.2008.11.014
Langelaan, M. L., Boonen, K. J., Rosaria‐Chak, K. Y., van der Schaft, Daisy WJ, Post, M. J., &
Baaijens, F. (2011). Advanced maturation by electrical stimulation: Differences in response
between C2C12 and primary muscle progenitor cells. Journal of Tissue Engineering and
Regenerative Medicine, 5(7), 529-539.
Lantz, G. C., Badylak, S. F., Coffey, A. C., Geddes, L. A., & Blevins, W. E. (1990). Small
intestinal submucosa as a small-diameter arterial graft in the dog. Journal of Investigative
Surgery, 3(3), 217-227.
Laschke, M., Rücker, M., Jensen, G., Carvalho, C., Mülhaupt, R., Gellrich, N., & Menger, M.
(2008). Incorporation of growth factor containing matrigel promotes vascularization of
porous PLGA scaffolds. Journal of Biomedical Materials Research Part A, 85(2), 397-407.
Laumonier, T., & Menetrey, J. (2016). Muscle injuries and strategies for improving their repair.
Journal of Experimental Orthopaedics, 3(1), 15.
Levenberg, S., Rouwkema, J., Macdonald, M., Garfein, E. S., Kohane, D. S., Darland, D. C., . . .
D'Amore, P. A. (2005a). Engineering vascularized skeletal muscle tissue. Nature
Biotechnology, 23(7), 879-884.
Levenberg, S., Rouwkema, J., Macdonald, M., Garfein, E. S., Kohane, D. S., Darland, D. C., . . .
D'Amore, P. A. (2005b). Engineering vascularized skeletal muscle tissue. Nature
Biotechnology, 23(7), 879-884.
Li, N., Yuan, R., Chen, T., Chen, L., & Jin, X. (2009). Effect of platelet-rich plasma and
latissimus dorsi muscle flap on osteogenesis and vascularization of tissue-engineered bone
in dogs. Journal of Oral and Maxillofacial Surgery, 67(9), 1850-1858.
Li, Y. P. (2003). TNF-alpha is a mitogen in skeletal muscle. American Journal of
Physiology.Cell Physiology, 285(2), C370-6. doi:10.1152/ajpcell.00453.2002 [doi]
Li, Z. B., Kollias, H. D., & Wagner, K. R. (2008). Myostatin directly regulates skeletal muscle
fibrosis. The Journal of Biological Chemistry, 283(28), 19371-19378.
doi:10.1074/jbc.M802585200 [doi]

41

Lieber, R. L., & Friden, J. (2000). Functional and clinical significance of skeletal muscle
architecture. Muscle & Nerve, 23, 1647-1666.
Lin, C. H., Lin, Y. T., Yeh, J. T., & Chen, C. T. (2007). Free functioning muscle transfer for
lower extremity posttraumatic composite structure and functional defect. Plastic and
Reconstructive Surgery, 119(7), 2118-2126. doi:10.1097/01.prs.0000260595.85557.41 [doi]
Lohse, G. R., Lee, D. H., & Watson, J. T. (2014). Muscle transfer to restore elbow flexion. The
Journal of Hand Surgery, 39(4), 761-764. doi:10.1016/j.jhsa.2013.12.029 [doi]
Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., & MuñozCánoves, P. (2011). Aberrant repair and fibrosis development in skeletal muscle. Skeletal
Muscle, 1(1), 1.
Mase, V. J., Hsu, J. R., Wolf, S. E., Wenke, J. C., Baer, D. G., Owens, J., . . . Walters, T. J.
(2010). Clinical application of an acellular biologic scaffold for surgical repair of a large,
traumatic quadriceps femoris muscle defect. Orthopedics, 33(7)
Masquelet, A. (2003). Muscle reconstruction in reconstructive surgery: Soft tissue repair and
long bone reconstruction. Langenbeck's Archives of Surgery, 388(5), 344-346.
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. The Journal of Biophysical and
Biochemical Cytology, 9, 493-495.
Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E., & Rudnicki, M. A. (1996). MyoD is
required for myogenic stem cell function in adult skeletal muscle. Genes & Development,
10(10), 1173-1183.
Meng, J., Chun, S., Asfahani, R., Lochmüller, H., Muntoni, F., & Morgan, J. (2014). Human
skeletal muscle-derived CD133 cells form functional satellite cells after intramuscular
transplantation in immunodeficient host mice. Molecular Therapy, 22(5), 1008.
Merritt, E. K., Cannon, M. V., Hammers, D. W., Le, L. N., Gokhale, R., Sarathy, A., . . . Farrar,
R. P. (2010). Repair of traumatic skeletal muscle injury with bone-marrow-derived
mesenchymal stem cells seeded on extracellular matrix. Tissue Engineering.Part A, 16(9),
2871-2881. doi:10.1089/ten.TEA.2009.0826; 10.1089/ten.TEA.2009.0826
Meyer, G. A., & Lieber, R. L. (2012). Skeletal muscle fibrosis develops in response to desmin
deletion. American Journal of Physiology.Cell Physiology, 302(11), C1609-20.
doi:10.1152/ajpcell.00441.2011 [doi]
Montarras, D., L'honoré, A., & Buckingham, M. (2013). Lying low but ready for action: The
quiescent muscle satellite cell. FEBS Journal, 280(17), 4036-4050.
Muñoz-Cánoves, P., & Serrano, A. L. (2015). Macrophages decide between regeneration and
fibrosis in muscle. Trends in Endocrinology & Metabolism, 26(9), 449-450.
42

Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., . . .
Rosenthal, N. (2001). Localized igf-1 transgene expression sustains hypertrophy and
regeneration in senescent skeletal muscle. Nature Genetics, 27(2), 195-200.
Nishimura, T., Nakamura, K., Kishioka, Y., Kato-Mori, Y., Wakamatsu, J., & Hattori, A. (2008).
Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells.
Journal of Muscle Research and Cell Motility, 29(1), 37-44.
Olguin, H. C., Yang, Z., Tapscott, S. J., & Olwin, B. B. (2007). Reciprocal inhibition between
Pax7 and muscle regulatory factors modulates myogenic cell fate determination. The
Journal of Cell Biology, 177(5), 769-779. doi:jcb.200608122 [pii]
Otis, J. S., Niccoli, S., Hawdon, N., Sarvas, J. L., Frye, M. A., Chicco, A. J., & Lees, S. J.
(2014). Pro-inflammatory mediation of myoblast proliferation. PloS One, 9(3), e92363.
Ott, H. C., Matthiesen, T. S., Goh, S., Black, L. D., Kren, S. M., Netoff, T. I., & Taylor, D. A.
(2008). Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial
heart. Nature Medicine, 14(2), 213-221.
Ott, H. C., Clippinger, B., Conrad, C., Schuetz, C., Pomerantseva, I., Ikonomou, L., . . . Vacanti,
J. P. (2010). Regeneration and orthotopic transplantation of a bioartificial lung. Nature
Medicine, 16(8), 927-933.
Page, R. L., Malcuit, C., Vilner, L., Vojtic, I., Shaw, S., Hedblom, E., . . . Dominko, T. (2011).
Restoration of skeletal muscle defects with adult human cells delivered on fibrin
microthreads. Tissue Engineering.Part A, 17(21-22), 2629-2640.
doi:10.1089/ten.TEA.2011.0024; 10.1089/ten.TEA.2011.0024
Perdiguero, E., Ruiz-Bonilla, V., Serrano, A. L., & Muñoz-Cánoves, P. (2007). Genetic
deficiency of p38α reveals its critical role in myoblast cell cycle exit: The p38α-JNK
connection. Cell Cycle, 6(11), 1298-1303.
Perniconi, B., Costa, A., Aulino, P., Teodori, L., Adamo, S., & Coletti, D. (2011). The promyogenic environment provided by whole organ scale acellular scaffolds from skeletal
muscle. Biomaterials, 32(31), 7870-7882.
Pesce, M., Orlandi, A., Iachininoto, M. G., Straino, S., Torella, A. R., Rizzuti, V., . . .
Capogrossi, M. C. (2003). Myoendothelial differentiation of human umbilical cord bloodderived stem cells in ischemic limb tissues. Circulation Research, 93(5), e51-62.
doi:10.1161/01.RES.0000090624.04507.45 [doi]
Powell, C. A., Smiley, B. L., Mills, J., & Vandenburgh, H. H. (2002). Mechanical stimulation
improves tissue-engineered human skeletal muscle. American Journal of Physiology.Cell
Physiology, 283(5), C1557-65. doi:10.1152/ajpcell.00595.2001 [doi]

43

Prevel, C. D., Eppley, B. L., Summerlin, D., Jackson, J. R., McCarty, M., & Badylak, S. F.
(1995). Small intestinal submucosa: Utilization for repair of rodent abdominal wall defects.
Annals of Plastic Surgery, 35(4), 374-380.
Prevel, C. D., Eppley, B. L., Summerlin, D., Sidner, R., Jackson, J. R., McCarty, M., & Badylak,
S. F. (1995). Small intestinal submucosa: Utilization as a wound dressing in full-thickness
rodent wounds. Annals of Plastic Surgery, 35(4), 381-388.
Qazi, T. H., Mooney, D. J., Pumberger, M., Geissler, S., & Duda, G. N. (2015). Biomaterials
based strategies for skeletal muscle tissue engineering: Existing technologies and future
trends. Biomaterials, 53, 502-521.
Riboldi, S., Sadr, N., Pigini, L., Neuenschwander, P., Simonet, M., Mognol, P., . . . Mantero, S.
(2008). Skeletal myogenesis on highly orientated microfibrous polyesterurethane scaffolds.
Journal of Biomedical Materials Research Part A, 84(4), 1094-1101.
Riboldi, S. A., Sampaolesi, M., Neuenschwander, P., Cossu, G., & Mantero, S. (2005).
Electrospun degradable polyesterurethane membranes: Potential scaffolds for skeletal
muscle tissue engineering. Biomaterials, 26(22), 4606-4615.
Riederer, I., Negroni, E., Bencze, M., Wolff, A., Aamiri, A., Di Santo, J. P., . . . Mouly, V.
(2012). Slowing down differentiation of engrafted human myoblasts into immunodeficient
mice correlates with increased proliferation and migration. Molecular Therapy, 20(1), 146154.
Rossi, C. A., Pozzobon, M., & De Coppi, P. (2010). Advances in musculoskeletal tissue
engineering: Moving towards therapy. Organogenesis, 6, 1-6.
Sabourin, L. A., Girgis-Gabardo, A., Seale, P., Asakura, A., & Rudnicki, M. A. (1999). Reduced
differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal
muscle. The Journal of Cell Biology, 144(4), 631-643.
Sampaolesi, M., Blot, S., D’antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., . . .
Barthélémy, I. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic
dogs. Nature, 444(7119), 574-579.
Sandusky Jr, G., Badylak, S., Morff, R., Johnson, W., & Lantz, G. (1992). Histologic findings
after in vivo placement of small intestine submucosal vascular grafts and saphenous vein
grafts in the carotid artery in dogs. The American Journal of Pathology, 140(2), 317.
Saxena, A. K., Marler, J., Benvenuto, M., Willital, G. H., & Vacanti, J. P. (1999). Skeletal
muscle tissue engineering using isolated myoblasts on synthetic biodegradable polymers:
Preliminary studies. Tissue Engineering, 5(6), 525-531.

44

Scherjon, S. A., Kleijburg‐van der Keur, C., de Groot‐Swings, G. M., Claas, F. H., Fibbe, W. E.,
& Kanhai, H. H. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin
from human placenta. Stem Cells, 22(7), 1338-1345.
Schultz, E., Jaryszak, D. L., & Valliere, C. R. (1985). Response of satellite cells to focal skeletal
muscle injury. Muscle & Nerve, 8(3), 217-222.
Serrano, A. L., & Muñoz-Cánoves, P. (2010). Regulation and dysregulation of fibrosis in skeletal
muscle. Experimental Cell Research, 316(18), 3050-3058.
Shandalov, Y., Egozi, D., Koffler, J., Dado-Rosenfeld, D., Ben-Shimol, D., Freiman, A., . . .
Levenberg, S. (2014). An engineered muscle flap for reconstruction of large soft tissue
defects. Proceedings of the National Academy of Sciences of the United States of America,
111(16), 6010-6015. doi:10.1073/pnas.1402679111 [doi]
Shi, X., & Garry, D. J. (2006). Muscle stem cells in development, regeneration, and disease.
Genes & Development, 20(13), 1692-1708. doi:20/13/1692 [pii]
Shimizu, K., Fujita, H., & Nagamori, E. (2009). Alignment of skeletal muscle myoblasts and
myotubes using linear micropatterned surfaces ground with abrasives. Biotech. and Bioeng.,
103, 631-638.
Sicari, B. M., Agrawal, V., Siu, B. F., Medberry, C. J., Dearth, C. L., Turner, N. J., & Badylak,
S. F. (2012). A murine model of volumetric muscle loss and a regenerative medicine
approach for tissue replacement. Tissue Engineering Part A, 18(19-20), 1941-1948.
Sicari, B. M., Dearth, C. L., & Badylak, S. F. (2014). Tissue engineering and regenerative
medicine approaches to enhance the functional response to skeletal muscle injury. The
Anatomical Record, 297(1), 51-64.
Sicari, B. M., Rubin, J. P., Dearth, C. L., Wolf, M. T., Ambrosio, F., Boninger, M., . . . Badylak,
S. F. (2014). An acellular biologic scaffold promotes skeletal muscle formation in mice and
humans with volumetric muscle loss. Science Translational Medicine, 6(234), 234ra58.
doi:10.1126/scitranslmed.3008085 [doi]
Siegel, A. L., Atchison, K., Fisher, K. E., Davis, G. E., & Cornelison, D. (2009). 3D timelapse
analysis of muscle satellite cell motility. Stem Cells, 27(10), 2527-2538.
Sirivisoot, S., & Harrison, B. S. (2011). Skeletal myotube formation enhanced by electrospun
polyurethane carbon nanotube scaffolds. International Journal of Nanomedicine, 6, 24832497. doi:10.2147/IJN.S24073 [doi]
Skuk, D. (2012). Acute rejection of myofibers in nonhuman primates: Key histopathologic
features. Journal of Neuropathology and Experimental Neurology, 71(5), 398-412.
doi:10.1097/NEN.0b013e31825243ae [doi]

45

Skuk, D., Goulet, M., Roy, B., Chapdelaine, P., Bouchard, J. P., Roy, R., . . . Tremblay, J. P.
(2006). Dystrophin expression in muscles of duchenne muscular dystrophy patients after
high-density injections of normal myogenic cells. Journal of Neuropathology and
Experimental Neurology, 65(4), 371-386. doi:10.1097/01.jnen.0000218443.45782.81 [doi]
Studitsky, A. (1965). Free auto‐and homografts of muscle tissue in experiments on animals.
Annals of the New York Academy of Sciences, 120(2), 789-801.
Suckow, M. A., Voytik-Harbin, S., Terril, L., & Badylak, S. (1999). Enhanced bone regeneration
using porcine small intestinal submucosa. Journal of Investigative Surgery, 12(5), 277-287.
Sullivan, D. C., Mirmalek-Sani, S., Deegan, D. B., Baptista, P. M., Aboushwareb, T., Atala, A.,
& Yoo, J. J. (2012). Decellularization methods of porcine kidneys for whole organ
engineering using a high-throughput system. Biomaterials, 33(31), 7756-7764.
doi:http://dx.doi.org/10.1016/j.biomaterials.2012.07.023
Sun, L., Ma, K., Wang, H., Xiao, F., Gao, Y., Zhang, W., . . . Wu, Z. (2007). JAK1-STAT1STAT3, a key pathway promoting proliferation and preventing premature differentiation of
myoblasts. The Journal of Cell Biology, 179(1), 129-138. doi:jcb.200703184 [pii]
Swinehart, I. T., & Badylak, S. F. (2016). Extracellular matrix bioscaffolds in tissue remodeling
and morphogenesis. Developmental Dynamics,
Tatsumi, R. (2010). Mechano‐biology of skeletal muscle hypertrophy and regeneration: Possible
mechanism of stretch‐induced activation of resident myogenic stem cells. Animal Science
Journal, 81(1), 11-20.
Tatsumi, R., Anderson, J. E., Nevoret, C. J., Halevy, O., & Allen, R. E. (1998). HGF/SF is
present in normal adult skeletal muscle and is capable of activating satellite cells.
Developmental Biology, 194(1), 114-128.
Thompson, N. (1971). Autogenous free grafts of skeletal muscle: A preliminary experimental
and clinical study. Plastic and Reconstructive Surgery, 48(1), 11-27.
Tidball, J. G., & Wehling‐Henricks, M. (2007). Macrophages promote muscle membrane repair
and muscle fibre growth and regeneration during modified muscle loading in mice in vivo.
The Journal of Physiology, 578(1), 327-336.
Tidball, J. G. (1995). Inflammatory cell response to acute muscle injury. Medicine and Science
in Sports and Exercise, 27(7), 1022-1032.
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002). Myofibroblasts
and mechano-regulation of connective tissue remodelling. Nature Reviews Molecular Cell
Biology, 3(5), 349-363.

46

Toumi, H., & Best, T. M. (2003). The inflammatory response: Friend or enemy for muscle
injury? British Journal of Sports Medicine, 37(4), 284-286.
Turner, N. J., & Badylak, S. F. (2012). Regeneration of skeletal muscle. Cell and Tissue
Research, 347(3), 759-774.
Turner, N. J., Yates Jr, A. J., Weber, D. J., Qureshi, I. R., Stolz, D. B., Gilbert, T. W., &
Badylak, S. F. (2010). Xenogeneic extracellular matrix as an inductive scaffold for
regeneration of a functioning musculotendinous junction. Tissue Engineering Part A,
16(11), 3309-3317.
Uygun, B. E., Soto-Gutierrez, A., Yagi, H., Izamis, M., Guzzardi, M. A., Shulman, C., . . .
Berthiaume, F. (2010). Organ reengineering through development of a transplantable
recellularized liver graft using decellularized liver matrix. Nature Medicine, 16(7), 814-820.
Vandenburgh, H. H., & Karlisch, P. (1989). Longitudinal growth of skeletal myotubes in vitro in
a new horizontal mechanical cell stimulator. In Vitro Cellular & Developmental Biology,
25(7), 607-616.
VanDusen, K. W., Syverud, B. C., Williams, M. L., Lee, J. D., & Larkin, L. M. (2014).
Engineered skeletal muscle units for repair of volumetric muscle loss in the tibialis anterior
muscle of a rat. Tissue Engineering Part A, 20(21-22), 2920-2930.
Vekris, M. D., Beris, A. E., Lykissas, M. G., Korompilias, A. V., Vekris, A. D., & Soucacos, P.
N. (2008). Restoration of elbow function in severe brachial plexus paralysis via muscle
transfers. Injury, 39(3), 15-22.
Wang, L., Wu, Y., Guo, B., & Ma, P. X. (2015). Nanofiber yarn/hydrogel Core–Shell scaffolds
mimicking native skeletal muscle tissue for guiding 3D myoblast alignment, elongation, and
differentiation. ACS Nano, 9(9), 9167-9179.
Ward, C. L., Ji, L., & Corona, B. T. (2015). An autologous muscle tissue expansion approach for
the treatment of volumetric muscle loss. BioResearch Open Access, 4(1), 198-208.
Wilson, K., Terlouw, A., Roberts, K., & Wolchok, J. C. (2016). The characterization of
decellularized human skeletal muscle as a blueprint for mimetic scaffolds. Journal of
Materials Science: Materials in Medicine, 27(8), 1-15.
Winkler, T., von Roth, P., Matziolis, G., Mehta, M., Perka, C., & Duda, G. N. (2008). Dose–
response relationship of mesenchymal stem cell transplantation and functional regeneration
after severe skeletal muscle injury in rats. Tissue Engineering Part A, 15(3), 487-492.
Wittenberg, J. B. (1970). Myoglobin-facilitated oxygen diffusion: Role of myoglobin in oxygen
entry into muscle. Physiological Reviews, 50(4), 559-636.

47

Wolf, M. T., Dearth, C. L., Sonnenberg, S. B., Loboa, E. G., & Badylak, S. F. (2015). Naturally
derived and synthetic scaffolds for skeletal muscle reconstruction. Advanced Drug Delivery
Reviews, 84, 208-221.
Wolf, M. T., Daly, K. A., Reing, J. E., & Badylak, S. F. (2012). Biologic scaffold composed of
skeletal muscle extracellular matrix. Biomaterials, 33(10), 2916-2925.
doi:10.1016/j.biomaterials.2011.12.055
Wu, X., Corona, B. T., Chen, X., & Walters, T. J. (2012). A standardized rat model of
volumetric muscle loss injury for the development of tissue engineering therapies.
BioResearch Open Access, 1(6), 280-290.
Zheng, B., Cao, B., Crisan, M., Sun, B., Li, G., Logar, A., . . . Cassino, T. (2007). Prospective
identification of myogenic endothelial cells in human skeletal muscle. Nature
Biotechnology, 25(9), 1025-1034.
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., . . . Hedrick, M. H.
(2001). Multilineage cells from human adipose tissue: Implications for cell-based therapies.
Tissue Engineering, 7(2), 211-228.

48

Chapter 2

Development of an Infusion Bioreactor for the Accelerated
Preparation of Decellularized Skeletal Muscle Scaffolds

Submitted as an original article by:

Ben Kasukonis1, John Kim1, Tyrone Washington2, and Jeffrey Wolchok1

1

2

Department of Biomedical Engineering, College of Engineering, University of Arkansas
Department of Health, Human Performance, and Health Professionals, College of Education
and Health Professionals, University of Arkansas

Corresponding Author:
Jeff Wolchok
125 Engineering Hall
Department of Biomedical Engineering
University of Arkansas
Fayetteville, AR 72701
jwolchok@uark.edu
479 575-2850

49

Abstract
The implantation of decellularized tissue has shown effectiveness as a strategy for the treatment
of volumetric muscle loss (VML) injuries. The preparation of decellularized tissue typically
relies on the diffusion driven removal of cellular debris. For bulky tissues like muscle, the
process can be lengthy, which introduces opportunities for both tissue contamination and
degradation of key ECM molecules. In this study we report on the accelerated preparation of
decellularized skeletal muscle (DSM) scaffolds using a infusion system and examine scaffold
performance for the repair of VML injuries. The preparation of DSM scaffolds using infusion
was dramatically accelerated. As the infusion rate (1% SDS) was increased from 0.1 to 1 and
10ml/hr, the time needed to remove intracellular myoglobin and actin decreased from a
maximum of 140±3hrs to 45±3hrs and 10±2hrs respectively. Although infusion appeared to
remove cellular debris more aggressively, it did not significantly decrease the collagen or
glycosaminoglycan composition of DSM samples when compared to un-infused controls.
Infusion prepared DSM samples retained the aligned network structure and mechanical integrity
of control samples. Infusion prepared DSM samples supported the attachment and in-vitro
proliferation of myoblast cells and was well tolerated by the host when examined in-vivo.

Keywords: decellularization, extracellular matrix, skeletal muscle, scaffold
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A. Introduction

Our group is pursuing the development of biomaterials targeting the repair of damaged
skeletal muscle tissue. Skeletal muscle has a strong capacity for repair, yet this capacity can be
overwhelmed when damage is severe. Following mild injuries like strains and contusions, in
which the myocytes are damaged but the underlying muscle structure and satellite cell
population is preserved, regeneration is robust and surgical intervention is not indicated (Mauro
1961, Hill, Wernig et al. 2003). However, when significant muscle volume is lost (trauma or
surgical resection) the underlying structure and progenitor cell pool is absent and regeneration is
poor. Termed volumetric muscle loss (VML), the bulk loss (>20%) of muscle tissue overwhelms
the capacity for repair, leading to the formation of non-contractile scar tissue at the defect site
and functional impairment for the patient (Terada, Takayama et al. 2001). The poor outcome
following VML injury, motivates the need for a treatment option. A promising approach is
restoration of the chemical and physical cues provided by the extracellular matrix (ECM).
To restore these cues, our group is exploring the use of ECM biomaterials derived from
skeletal muscle. To improve the isolation of ECM from whole muscle tissue, a new
decellularization approach was explored in this study. Commonly, the decellularization of whole
tissues employs detergents (ex: sodium dodecyl sulfate) to lyse cell membranes and remove
intracellular proteins, followed by DNAse/RNAse rinses to remove residual nucleic acids
(Gilbert, Sellaro et al. 2006, Badylak, Freytes et al. 2009). The initial removal of intracellular
proteins using detergents is typically a diffusion driven process, which for thicker tissues like
skeletal muscle can be lengthy, requiring two weeks or more(Merritt, Cannon et al. 2010). This
introduces opportunities for both tissue contamination and degradation of key ECM molecules.
51

In an effort to accelerate the process, the active delivery of detergents into whole organs has been
achieved via vascular perfusion. The major inlets and outlets (arteries and veins) along with
capillary networks are utilized to perfuse the entire organ. Perfusion decellularization has been
used to produce whole organ scaffolds for the heart (Ott, Matthiesen et al. 2008), liver (Uygun,
Soto-Gutierrez et al. 2010), lungs (Ott, Clippinger et al. 2010), kidneys (Sullivan, Mirmalek-Sani
et al. 2012), and recently even entire limbs (Jank, Xiong et al. 2015).
Skeletal muscle tissue lacks the easily accessible major arteries and veins that are found
in whole organs, motivating an alternative delivery approach. The common utilization of
intramuscular injection would suggest that fluid infusion through skeletal muscle might provide a
viable delivery route for decellularization agents. Towards this end, our group has developed a
scalable bench top infusion platform that uses a needle rather than the vascular system to deliver
detergents deep into muscle tissue with the goal of accelerating the removal of intracellular
proteins. The system also explores the distinct color change (red to white) that occurs within
skeletal muscle tissue as myoglobin is removed during decellularization as a means to noninvasively monitor the removal of intracellular proteins. The design/fabrication of the device,
characterization of its performance, and measurement of infusion prepared decellularized
skeletal muscle (DSM) properties are described in this report. Ultimately, we believe these
materials could find utility as scaffolds for the repair of VML injuries.
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B. Methods
Absorbance Properties of Skeletal Muscle
A visible light absorbance sweep was performed on rat (Sprague Dawley) gastrocnemius
muscle samples in order to characterize the optical properties of whole and decellularized
skeletal muscle. The changes in muscle absorbance properties that occur with decellularization
would be utilized during the subsequent design of an optical monitoring approach. Rat muscle
was selected based on its past use in muscle regeneration animal studies and the anticipated area
of application for this device (Merritt, Hammers et al. 2010). All whole muscle tissues used in
this study were collected from cadaveric animals that had been previously euthanized using
methods approved by the University of Arkansas Institutional Animal Care and Use Committee
(IACUC) approved study (protocol #12026). All tissues were stored at -20°C until required for
testing. In preparation for testing, gastrocnemius muscle samples were dissected, and from each
whole muscle sample a central core was harvested using a biopsy punch (diameter = 6mm) and
trimmed to a thickness of 2mm. Cylindrical muscle sample cores were incubated in a 1% sodium
dodecyl sulfate (SDS) solution (10mM Tris HCL) with agitation for 24 and 48 hours at room
temperature following published protocols(Mirsadraee, Wilcox et al. 2006). Untreated muscle
samples were maintained as controls (n=4 / sample group). At the prescribed time points (24, and
48 hours) muscle core samples were loaded into 96 well plates (one sample per well) and a
spectral sweep of tissue absorbance was measured (400-900nm, step size = 5nm) with the aid of
a spectrophotometer (Synergy H1, BioTek, Winooski, VT). For comparison, the absorbance of
myoglobin, an abundant intracellular skeletal muscle protein, was also characterized (0.1, 0.3,
and 0.6% in phosphate buffered saline). Absorbance versus wavelength data for all muscle and
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myoglobin samples were plotted and examined for the presence of decellularization sensitive
absorbance features.

Infusion Bioreactor Design and Fabrication
The design goal was to combine continuous tissue infusion and real time optical
monitoring into a single bench top device. The two primary components of the device are the
muscle infusion units and optical detection collars with integrated data collection hardware and
software. The infusion units, optical monitoring collars, and data collection hardware are housed
within and mounted onto a custom fabricated (Replicator 2, MakerBot Industries, New York
City, NY) two-piece enclosure (Figure 1). The enclosure was designed to accommodate four
individual infusion units each capable of accommodating a single muscle tissue sample. The
closure also isolates the optical monitoring collars from ambient light. Each of the four modular
infusion units consists of a rigid acrylic cylinder (ID = 10mm; length = 40mm) that forms a
translucent infusion chamber. The inlet and outlet of each chamber is enclosed by watertight
ports fashioned with Leur lock style fittings and fabricated in acrylic with the aid of a 3-D printer
(Objet 30, Objet, Israel). The inlet port incorporates a removable 26-ga stainless steel
hypodermic needle (length = 20 mm). The needle is used to deliver solution into the interior of
individual whole muscle samples. The flow of fluid into each infusion unit was controlled via a
commercial multi-syringe pump (#552219, Harvard Apparatus, Holliston, MA) capable of
delivering fluid to all four chambers over the range of flow rates (0.1 to 10ml/hr) that would be
evaluated during device characterization. Waste decellularization solution is collected in a
reservoir for disposal or evaluation.
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The optical collar was fitted with a single light emitting diode (LED) producing a peak
emittance centered at 535nm. Peak LED wavelength selection was motivated by the results of
the previously described muscle optical property characterization. The light output of the LED is
directed across the diameter of the optical collar. A light detecting resistor (LDR) was positioned
opposite to the LED. The LDR converts light intensity in photons to resistance in ohms. The
optical collar with integrated LED and LDR can be positioned along the length of the infusion
unit. During infusion, the collar is positioned over the muscle sample, such that muscle tissue
impedes the light path from the LED emitter to the LDR detector. Analog voltages collected
from the LDR were converted to digital values using an 8-bit analog-to-digital converter (ADC)
(Adafruit Industries, New York, NY). A miniaturized single board computer (Raspberry Pi
Foundation, United Kingdom) was used to power the LEDs and to control collection of the
digitized LDR voltage signal from the ADC. Custom designed software (Python) was created to
collect the voltage data and log it to an online spreadsheet. Optical data was collected from the
LDR every five minutes. The complete system, including syringe pump and flat screen monitor,
occupies a 0.5m X 0.5m footprint, a space that is compatible with typical laboratory
workbenches.

Bioreactor Characterization
For all device characterization testing, medial gastrocnemius muscle tissue was harvested
from cadaveric Sprague Dawley rats and stored at -20°C until needed for testing. Prior to testing
all muscles were thawed and rinsed briefly in DI water to remove any superficial blood or
loosely adhered tissue. Whole muscle samples were loaded into infusion chambers, one muscle
per chamber. The position of the muscle was adjusted until the needle tip was located at the mid55

belly (thickest) region of the muscle. Based on static decellularization pilot testing and guided by
published methods (Mirsadraee, Wilcox et al. 2006), muscle samples (n=4) were infused using a
1% SDS solution at a flow rate of 1ml/hr while LDR output was recorded and plotted. Samples
were collected when muscle optical properties (LDR output) were unchanged (<0.1% difference
from the previous recording) for five continuous recordings (25 minutes).
To examine the effectiveness of infusion treatment as a method for intracellular protein
removal, representative infusion treated and untreated whole muscle samples were embedded in
tissue freezing media (Triangle Biomedical Sciences, Durham, NC), sectioned at 8µm with a
cryostat, and mounted onto glass microscope slides. Mounted sections were immune-reacted for
the presence of myoglobin (rabbit IgG1, 1:500, Sigma, St. Louis, MO) and actin (phalloidin,
1:40, Sigma, St. Louis, MO) followed by incubation with the appropriate fluorescently labeled
secondary antibodies (Alexafluor, 1:500, Fisher Scientific). Sections were counterstained with
the nuclear staining reagent DAPI, and then microscopically imaged (Ci-L, Nikon, Troy, NY).
Digital images were captured, stored, and examined for the presence of intracellular proteins and
nuclear remnants.
To explore the influence of key infusion parameters (flow rate and SDS solution
concentration) on myoglobin removal, medical gastrocnemius muscle samples were perfused at
flow rates of either 0.1, 1, or 10ml/hr using SDS solutions at concentrations of 0.2% or 1%. A
total of 6 parameter combinations were explored (n= 4/ parameter condition). Throughout
infusion testing the optical properties of each muscle was measured and digitally logged every 5
minutes. As previously described, the time at which intracellular protein removal was considered
complete and samples were removed was recorded as the time at which sample optical properties
were unchanged for five continuous recording.
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From the infusion data, the time to reach steady state optical properties (y) was modeled
with a two factor (1: flow rate, 2: SDS concentration) regression model of the type
y = b0 + b1x1 + b2x2 + b12x1x2

(1)

The regression coefficients (bi) were solved for using commercially available data analysis
software (JMP, SAS Institute, Cary, NC). From the model, the relationship of infusion time to
each of the infusion parameters was calculated.
To determine whether infusion influenced the retention of key ECM molecules, the
sulfated glycosaminoglycans (sGAG) concentration was quantified using a published
procedure(Barbosa, Garcia et al. 2003). For comparison, control DSM samples were statically
(non-infused) incubated in 1% SDS at room temperature with gentile agitation using rocker
platform, for a duration of two weeks (Merritt, Cannon et al. 2010). All infusion and control
samples were lyophilized and stored at -20°C until needed for analysis. To extract sGAG.
lyophilized samples (n=4/sample group) were digested in a solution containing 50 µg/mL
proteinase K in 100 mM K2HPO4 at a pH of 8.0 at 55ºC for 16 hours. The samples were then
centrifuged and filtered to isolate tissue fragments. A 1,9-dimethylmethylene blue (DMMB)
solution was added to produce an insoluble GAG-DMMB complex. The solution was
centrifuged, the supernatant was removed, and the GAG-DMMB complex was dissolved with a
decomplexation solution. The absorbance of the resulting solution was read at 656 nm with the
aid of a microplate reader (Synergy H1, BioTek, Winooski, VT). Samples were tested in
triplicate and compared against a standard curve to determine sGAG concentration.
The collagen content of control and infusion samples (n=4/sample group) was quantified
using a modified version of the hydroxyproline assay procedure reported by Edwards (Edwards
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and O'Brien 1980). Briefly, all tissue samples were hydrolyzed in 6N HCl for 16-20 hours at
115ºC, then cooled to room temperature and diluted 1:5 in distilled water. Hydrolyzed samples
were mixed with a chloramine T solution (1:2) and incubated at room temperature for 20
minutes. A dimethyl-aminobenzaldehyde assay solution was added (1:2) and the mixture was
incubated at 60°C for 15 minutes to develop a red chromophore. Sample absorbance was read at
570 nm using a microplate reader. Samples were tested in triplicate and compared against a
standard curve to determine collagen concentration. To visualize and validate the retention of
collagen within infusion prepared tissue, a representative sample was immunoreacted for the
presence of collagen type I (mouse IgG1, 1:500, Sigma, St. Louis, MO) and type III (rabbit IgG1,
1:1000, AbCam, UK) followed by incubation with the appropriate fluorescently labeled
secondary antibodies (Alexafluor, 1:500, Fisher Scientific).
To explore the influence of infusion treatment on DSM physical properties, control and
infusion (1% SDS for 12 hours at 10ml/hr) DSM sample (n=4/sample group) mechanical
properties were measured with the aid of a uni-axial tensile tester (UStretch, CellScale, Ontario,
Canada) using techniques familiar to our group (Wolchok, Brokopp et al. 2009, Lasher, Wolchok
et al. 2010, Wolchok and Tresco 2010). Hydrated (PBS, pH=7.4) sample strips (12 mm X 3 mm)
were deformed at a constant strain rate of 1%/s until failure using a 5N load cell while the load
and displacement values were recorded. For each sample, engineering stress versus strain curves
were generated from load and elongation data. Strain was determined using grip displacement
values. From each curve the tangent modulus was calculated from a linear fit to the stress-strain
curve. The ultimate strength was calculated as the peak stress achieved by each sample prior to
failure.
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Additional control and infusion prepared DSM samples (n=4/sample groups) were
embedded in tissue freezing medium and sectioned transversely (8um) with the aid of a cryostat.
Sections were mounted onto glass slides, stained with hematoxylin and eosin (H&E) and
microscopically imaged (100x). Three representative images from each sample were used to
measure porosity (% open space) and network alignment (average orientation angle) using image
analysis software (ImageJ) and guided by published techniques (Liu, Qu et al. 2008, Huang, Lee
et al. 2010). For DSM sample orientation analysis, the direction of muscle contraction (long axis
of the gastrocnemius muscle) was selected to correspond to an orientation angle of 0 degrees.

In-Vitro and in-Vivo Biocompatibility
To create DSM samples for implantation, Sprague Dawley tibialis anterior (TA) muscle
was infusion treated (1% SDS for 12 hours at 10ml/hr) using the previously described and
characterized system. Following infusion treatment, samples were statically incubated overnight
in a DNAse / RNAse solution (1kU/ml DNAse in a 10mM Tris-HCL buffer; 2.5mM MgCL2 +
0.5mM CaCl2) and then incubated (8 hours) in a 1X penicillin/streptomycin solution to reduce
the risk of infection. Samples were rinsed thoroughly (a total of six 24 hour wash steps) in PBS
following each preparation step (Figure 2). Following completion of the entire decellularization
protocol, the DNA concentration of representative DSM implants (n=3) was measured with the
aid of a commercial quantification kit (Qubit, Fisher Scientific). DSM implants were lyophilized
and stored at -20C until needed for implantation.
A direct contact assay was used to evaluate cellular attachment and proliferation upon
infusion prepared DSM substrates. DSM material islands (diameter = 6mm) were created on
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glass microscope slides. DSM islands were seeded with skeletal muscle myoblasts (L6, ATCC,
Manassas, VA) at a density of 7K cells per island. Cell viability was evaluated at 3 and 7 days
(n= 3 islands / time point) using calcein AM (Life Technologies). Three representative fields
were imaged (100x) from each island and captured digitally. From the digital images, cell
confluency (% surface coverage) was calculated at each time point with the aid of image analysis
software (ImageJ).
In-vivo host response was examined using a dorsal subcutaneous implant site. In-vivo
biocompatibility was assayed at short-term (4 weeks) and long-term (12 weeks) time points.
Mature male Sprague Dawley rats (300+g) were used (Harlan, IN). All surgical procedures were
performed in accordance with protocols approved by the University of Arkansas Institutional
Animal Care and Use Committee. Anesthesia was induced using isoflurane (2-4%) in oxygen.
The subcutaneous implant site was surgically exposed through a 2 cm left-right incision placed 2
finger widths caudal to the scapulae. A subcutaneous pouch was created in each animal by blunt
dissection. A single perfusion prepared DSM disk (6mm diameter X 1mm thick) was implanted
into each pouch (Incisions were closed using surgical adhesive (VetBond, 3M). Following
surgery all animals were housed in the University of Arkansas Central Laboratory Animal
Facility. At the prescribed time-points (4 and 12 weeks) all animals (n=3 / timepoint) were
euthanized via inhalation of carbon dioxide. The implant site with surrounding soft tissue was
harvested, fixed in 4% paraformaldehyde, paraffin embedded, sectioned (10um), and stained
with H&E with the aid of the University of Arkansas Histological Core Facility. Stained
sections were imaged and examined for evidence of material degradation.
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Statistics
All data is represented by the mean and standard deviation Comparisons between
infusion flow rate and SDS concentration (time to stable optical properties, collagen, and sGAG
analysis) were evaluated with a two-factor ANOVA. Post hoc comparisons were made using
Tukey’s test. The effect of treatment (infusion version control) on alignment, porosity, and
mechanical properties was evaluated using a two-way student’s t-test. A standard 0.05 level of
significance was used for all statistical tests.

C. Results
Absorbance Properties of Skeletal Muscle
The absorbance sweeps collected from myoglobin solution samples (0.6%) were
characterized by an observable peak centered at 505±4nm (Figure 2). As the myoglobin
concentration was decreased to 0.3% and 0.1%, the absorbance peak heights decreased by 58%
and 85% respectively and the peak profiles tended to broaden. The absorbance sweeps recorded
from hydrated whole muscle samples were characterized by a more modest absorbance shoulder,
which when compared to myoglobin was less pronounced and shifted modestly towards a higher
wavelength (541±7nm). The whole muscle peak wavelength was positioned within the green
region of the visible light spectrum. Following 24 hours of SDS incubation, the absorbance
shoulder was still detectable but less pronounced. Visually, 24 hour muscle samples showed
residual evidence of intracellular myoglobin (retention of a pinkish color), suggesting partial but
still incomplete removal. After 48 hours of SDS treatment, the absorbance shoulder present in
whole muscle samples was no longer detected and myoglobin was no longer visualized, as
evidenced by a translucent appearance. Generally, the absorbance of skeletal muscle tissue at
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541nm decreased as samples were progressively incubated in SDS, suggesting a valuable target
wavelength for optical monitoring of intracellular myoglobin retention.

Bioreactor Characterization
Muscle sample absorbance logs (LDR voltage versus time) were characterized by a
progressive reduction in tissue absorbance (decreased LDR output voltage) with increased
infusion time as more light (535nm) emitted by the LED was capable of transmitting through the
muscle samples and reaching the LDR. Whole muscle samples transitioned from a characteristic
red color to translucent during the infusion driven removal of intracellular proteins. (Figure 3).
LDR voltage eventually reached a steady state minimum for all samples tested, which was
defined for all subsequent tests as the time to myoglobin removal. Prior to infusion treatment,
intracellular myoglobin, as well as actin and nuclear remnants where visible within whole muscle
sections. Once the LDR had reached a steady minimum, identified as the time at which LDR
output voltage was unchanged for 25 minutes, infusion treated muscle samples (n=4) were no
longer immunoreactive to myoglobin or actin. Furthermore, although not treated with nucleases
during the infusion process, DAPI positive nuclei could not be detected. Overall, the histological
examination of infusion treated samples suggests that the LDR voltage minimum was an
effective metric of intracellular myoglobin and actin removal.
The infusion solution flow rate and SDS concentration had a statistically significant
effect on the removal of intracellular myoglobin (Figure 4). The average infusion time required
to remove myoglobin, as measured by LDR voltage and further validated through histology, was
shortened in response to increases to both flow rate and SDS concentration. Flow rate had a
strong influence on myoglobin removal. The removal time decreased from a maximum of
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143±8hrs at the lowest flow rate of 0.1 ml/hr (0.2%SDS) to 42±3hrs and 9±1hr as the flow rate
was increased to 1ml/hour and 10ml/hour respectively. Increased SDS concentration had a
significant but less dramatic influence when compared to flow rate. Increasing the SDS
concentration from 0.2% to 1% shortened the time from 143±8hrs to 107±6 at the lowest flow
rate tested (0.1ml/hr), a reduction of 24%. At higher flow rates (1 and 10ml/hr) the effect of SDS
concentration on myoglobin removal was less pronounced, but still statistically significant.
When viewed as a whole, the removal of intracellular myoglobin was more responsive to flow
rate than SDS concentration, however the range of flow rates tested (100 fold difference between
lowest and highest) was larger than the range of SDS concentrations tested (5 fold difference).
From the data collected, the relationship of myoglobin removal time (in hours) to flow rate
(ml/hr) and SDS concentration (%) was modeled (eq. 2). When plotted over the parameter ranges
tested (Figure 4B & C), the model accurately describes the increased influence of flow rate on
myoglobin removal time observed during benchtop testing.

Time = 99 – 8.3 x [Flow] –18.0 x [SDS] + 2.7 x (Flow - 0.6) x (SDS - 3.7)

(2)

Although SDS infusion accelerated the removal of intracellular myoglobin and actin, it
did not significantly decrease collagen or sGAG concentration when compared to non-infused
controls. No statistically significant differences in collagen or sGAG concentration were detected
for any of the flow rates and SDS concentrations examined (Figure 5). All infusion treated
collagen and GAG composition values were within 10% of control samples. Furthermore, trends
indicating a relationship between ECM composition and infusion flow rate were not observed.
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Infusion decellularized samples retained the highly aligned network organization
characteristic of skeletal muscle (Figure 6). The dominant orientation angle of DSM samples
following infusion decellularization (7±6°) was not significantly different from controls (11±5°).
Both infusion prepared and control samples were aligned in the direction of contraction
(designated as 0°). Control and infusion prepared samples were robust and easily tolerated
handling and tensile testing. Stress versus strain curves for both materials were characterized by
in initial toe-in region out to approximately 10-15% strain followed by a nearly linear (R2>0.9)
increase is stress extending out to failure at approximately 100-125% for both infusion and
control DSM samples. The average tangent modulus measured from the linear region extending
from 20% (post toe-in) to material failure was 225±44kPa and 189±32kPa for infusion and
control samples respectively. Average infusion prepared DSM sample elastic moduli was not
significantly different from control samples. Similarly, average ultimate strength differences
between infusion and control DSM materials were not statistically significant.

In-Vitro and in-Vivo Biocompatibility
Average infusion prepared DSM sample DNA content (2.9±0.6ng of DNA / mg of tissue)
were well below the preferred implantation threshold (< 50-70ng/mg) reported by others (Zhang,
He et al. 2009, Crapo, Gilbert et al. 2011). The DSM samples supported the attachment and invitro proliferation of cultured myoblast cells. Viable cells were attached to all cell seeded DSM
islands at both time points. Seventy-two hours after seeding, viable cells covered, on average,
8±2% of the DSM sample surface (Figure 7). By seven days post seeding, average cell coverage
increased to 60±6% of the DSM sample surface. Cells cultured on DSM materials appeared well
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spread and expanded upon the DSM surface at a coverage rate of approximately 13% / day. The
average cell coverage difference between day three and seven was statistically significant.
All implanted animals tolerated the subcutaneous implantation surgery well and reached
the prescribed study endpoints without complications (n=4 / endpoint). At four weeks post
implantation, DSM materials were well incorporated into the surrounding tissue and host cells
had densely penetrated the material (Figure 8). While signs of active inflammation could be
observed there were no signs of tissue necrosis or exudate (pus) accumulation at the implant site.
The dense cellular penetration into the DSM material was suggestive of active remodeling of the
implant site. The breakdown of whole DSM disks into smaller fragments was observed. There
were no signs suggesting formation of a dense fibrous encapsulation layer surrounding DSM
materials. By twelve weeks post implantation, DSM materials appeared fully degraded. No
evidence of DSM material could be identified in any of the implanted animals, although some
residual cellularity could be seen at the implant site.

D. Discussion
As chemical decellularization schemes continue to mature and gain acceptance, the
development of effective delivery platforms deserves research investment. With that goal in
mind, what was explored in this study is a device and method for the preparation of
decellularized skeletal muscle tissue using a non-vascular infusion delivery method. Overall, the
utilization of infusion on skeletal muscle samples was highly effective at accelerating the
removal of intracellular proteins. Specifically, with the aid of the infusion device, the time to
clear rat lower limb gastrocnemius and TA muscles of intracellular proteins reduced from two

65

weeks to a short as 10 hours. This is a notable finding, and the first we are aware of that
demonstrated the accelerated removal of cellular debris from bulk tissue samples using a nonvascular infusion technique. It may be possible to translate this process to other tissues,
particularly musculoskeletal tissues including, tendons (Lee, Lee et al. 2013), ligaments
(Harrison and Gratzer 2005), cartilage (Sutherland, Beck et al. 2015), and menisci (Chen, Chen
et al. 2015) in which vascular perfusion would be difficult. The time reduction is not just
important from the standpoint of process efficiency, but also may help reduce the degradation of
key ECM proteins that could occur with time throughout the decellularization process. The
decellularization of tissue using SDS, the most common process, is typically performed at room
temperature, and while the presence of SDS limits bacterial and fungal growth, the degradation
of proteins that can occurs with time at room temperature is a concern (Pasella, Baralla et al.
2013, Wang, Zhu et al. 2015). Shortening the amount of time tissue is exposed to room
temperatures in aqueous solutions may reduce the degradation of key ECM proteins during
decellularization and improve scaffold quality.
While the device described in this study was designed for the processing of small animal
tissues for use in pre-clinical research, the future application of infusion to accelerate the
preparation of human or large animal tissue for clinical applications is anticipated. Particularly
since the complete removal of cellular debris from large skeletal muscle tissues, like the
quadriceps which can be several centimeters thick, may be prohibitively lengthy using diffusion
alone. It should also be noted that human skeletal muscle tissue is rarely if ever tissue banked,
and therefore represents an untapped source for implantable human ECM. Device scale-up for
the processing of larger muscle tissue will require design adaptations beyond just increasing the
size of the chambers. The single needle infusion chambers developed in this study were designed
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for the processing of single rat hind limb skeletal muscles. The volume of rat gastrocnemius and
tibialis anterior muscles (1-2 cm3) was well suited to the delivery of decellularization solution via
a single hypodermic needle. However, the processing of larger animal and potentially cadaveric
human muscle samples for clinical applications would require modification to incorporate a
multi-needle approach. While clearly more complex, our experience with the current single
needle system suggests that expansion to a multi-needle system is achievable, and in fact the
current system uses multiple needles to process muscle samples in parallel. What remains
unknown, is the optimal relationship between needle quantity, spacing, and tissue volume.
Future bench top measurement and computer modeling of the relationship between time to
decellularization and tissue volume would help determine ideal infusion needle density.
It should be possible to utilize lower SDS concentrations than those explored in this
study, while still maintaining overnight to at most 1 day myoglobin removal times. At an
infusion flow rate of 10ml/hr, the highest rate tested, a 5 fold decrease in SDS concentration
(0.2% versus 1%) only increased the time from 7 to 9 hours suggesting an even lower SDS
concentration might still be effective. A reduction in SDS concentration could be beneficial
when one considers that removing SDS from tissue is challenging and the presence of residual
SDS within implanted scaffolds can be cytotoxic (Cebotari, Tudorache et al. 2010). Furthermore,
it is well established that exposure to SDS during the decellularization process can have a
detrimental effect on tissue properties (Faulk, Carruthers et al. 2014). Eventually it may be
beneficial to transition towards SDS-free decellularization approaches. If so, it seems reasonable
to suggest that infusion could be utilized to decrease process duration for other solution based
decellularization strategies, including SDS-free techniques that employ osmotic or physical
means to disrupt cell membranes and liberate intracellular debris (Greco, Francis et al. 2015,
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Xing, Yates et al. 2015). Alternatively, it may be possible to utilize a short SDS incubation step
to initially lyse cells and bind intracellular proteins, followed by a longer SDS-free infusion step
to wash away the intracellular debris and residual SDS. Whatever the method, it should be
possible to utilize infusion as a means to minimize both the SDS concentration and exposure
time during the decellularization process.
The monitoring of skeletal muscle optical properties provided a non-destructive real time
means to evaluate decellularization progression. The histological results from this study suggest
that the monitoring of muscle optical properties is a good indicator of intracellular myoglobin
concentration. While we only looked at one additional intracellular protein (actin) it seems
reasonable to speculate that if these two proteins were effectively removed other intracellular
proteins were as well. One limitation is that optical monitoring of the type used the current
device was designed to detect the progressive removal of the muscle specific intracellular protein
myoglobin. The progressive removal of myoglobin produced an obvious shift in tissue
appearance from red to clear, which could be detected in the visible region of the light spectrum
using a low cost LED and LDR pairing. However, it has been suggested that removal of the
nuclear debris is more crucial to implant performance than the intracellular proteins, suggesting
that development of a means to monitor the removal DNA and RNA would be valuable (Gilbert,
Sellaro et al. 2006). Unfortunately, the optical properties of muscle within the visible region are
not affected by the removal of nuclear debris. As an adjunct to the currently monitoring
approach, it may be possible to examine the optical properties of tissues at DNA/RNA sensitive
wavelengths (260/280nm) to monitor the removal of nuclear debris, although using low cost
LEDs to do so is not feasible.
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The co-delivery of muscle progenitor (satellite) cells in combination with ECM could
also help stimulate a pro-regenerative environment following VML injury. The loss of muscle
tissue following VML eliminates a substantial pool of progenitor cells. The remaining satellite
cell population available for migration from surrounding healthy tissue may be inadequate, and
therefore supplementation of the repair site with additional progenitor cells could enhance
regeneration. Towards this end, the in-vitro seeding of ECM implants with progenitor cells has
been shown to improve the restoration of peak contractile force (Merritt, Cannon et al. 2010,
Corona, Ward et al. 2014). With this approach in mind, infusion flow could be used as a means
to seed DSM implants with progenitor cells in preparation for implantation. Infusion could help
distribute cells evenly throughout the DSM network, rather than densely at the surface as is
generally observed following manual seeding(Kennedy, McCandless et al. 2011). Satellite cells
are difficult to amass in great quantities, and can lose their regenerative capacity when expanded
in vitro (Montarras, Morgan et al. 2005) so improving the efficiency of in-vitro progenitor cell
delivery has value.
The average DSM modulus values measured in this study are similar in magnitude to
other decellularized tissue scaffolds, including commercially available porcine intestinal and
bladder tissue (Dahms, Piechota et al. 1998, Tottey, Johnson et al. 2011), as well as human facial
DSM material (Wang, Johnson et al. 2013). The relationship between scaffold modulus and
VML repair outcome has not been investigated, but in-vitro studies have shown that muscle
progenitor cells sense and respond to substrate stiffness. Muscle progenitor cell myogenesis is
significantly enhanced when the cells are grown on soft substrates like ECM and reduced on stiff
substrates like tissue culture plastic (Rao, Grover et al. 2013, Morrissey, Cheng et al. 2015).
Similar cell-substrate stiffness interactions have been noted for other cell types including
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cardiomyocytes (Ribeiro, Ang et al. 2015). Furthermore, the robust mechanical properties of
DSM and other ECM scaffolds facilitate attachment (suturing) to the surrounding healthy tissue
during surgical VML repair. Surgical reattachment is clinically important, because it will enable
the transfer of contractile force through the repair site during healing and regeneration. This is
potentially critical, since force and substrate strain have been shown to enhance muscle
progenitor cell myogenesis (Egusa, Kobayashi et al. 2013, Heher, Maleiner et al. 2015).
While the ideal VML repair scheme still awaits discovery, it appears the restoration of a
pro-myogenic environment may require a multifactorial approach, combining biocompatible
scaffolds, with progenitor cells, soluble myogenic signaling molecules, and postoperative
rehabilitation (Aurora, Garg et al. 2014, Garvey, Russ et al. 2015). The accelerated removal of
intracellular proteins from skeletal muscle tissues, without sacrificing chemical or physical
properties, makes the infusion preparation platform described in this study an attractive scaffold
preparation strategy. Furthermore pilot study biocompatibility testing suggesting that infusion
prepared DSM both supported cell attachment and was well tolerated by the host, motivates
further in-vivo examination using a peer accepted muscle regeneration animal model (Wu,
Corona et al. 2012).

E. Conclusions
The key findings of this study suggest that:
1) The delivery of SDS into skeletal muscle via infusion removed intracellular proteins
including myoglobin and actin.
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2) The monitoring of myoglobin absorbance was effective as an inexpensive means to noninvasively

monitor

the

progression

of

intracellular

protein

removal

during

decellularization.
3) Infusion flow rate and SDS concentration could be adjusted to modulate the removal rate
of intracellular proteins from whole muscle samples.
4) Infusion did not reduce the collagen or sGAG composition of DSM scaffolds.
5) Infusion did not influence the native network alignment or reduce the mechanical
properties of DSM scaffolds.
6) Infusion prepared material supported the attachment and proliferation of cells and was well
tolerated by the host following subcutaneous implantation.
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Figure Legend:

Figure 1: The primary components of the as built device are the muscle infusion chambers and
optical detection collars (A and B). SDS solution is delivered into muscle tissue via a
hypodermic needle (not seen), infused through the muscle, and outflows to waste collection.
Light produced by the LED travels across the chamber and though the muscle sample (B: dashed
arrow) where it is detected and converted to a voltage output by the LDR. Infusion units, optical
monitoring collars, and data collection hardware are housed within and mounted onto a custom
fabricated enclosure (C and D). The enclosure was designed to accommodate four side-by-side
decellularization units each capable of accommodating a single muscle tissue sample. LDR
output voltage was converted to a digital signal (8-bit) and stored with the aid of integrated data
collection hardware (Raspberry Pi) and software (Python).

Figure 2: Representative visible light absorbance spectra for myoglobin solutions (A) and
skeletal muscle tissue samples (B). The myoglobin absorbance peak (505±4nm) decreased as
protein concentration was diluted from a high of 0.6% (in PBS) to a low of 0.1%. A less
pronounced absorbance shoulder (541±7nm) was observed for whole muscle tissue samples. The
absorbance shoulder for whole muscle samples (M) was similarly reduced as muscle samples
were incubated in decellularization solution (1% SDS) for either 24 or 48 hours.

Figure 3: Representative LDR voltage output (Vo) collected during whole muscle infusion
treatment (A). The change in muscle color that occurs during infusion (removal of myoglobin)
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permitted increased transmission of LED light (535nm) through the tissue, decreasing LDR
resistance (A:inset). Decreased LDR resistance was measured and recorded as a change in output
voltage (Vo). Prior to infusion, whole muscle tissue samples (B) were strongly reactive (D: left
split) to antibodies/molecules directed against actin (red) myoglobin (green) and nuclei (blue).
Following infusion treatment (C), recorded as the time to reach a stable output voltage minimum
(A: arrow), actin, myoglobin and nuclei could not be detected in any of the samples tested (D:
right split). Infusion prepared DSM samples retained the highly aligned structure of native
muscle ECM (E) and were strongly immunoreactive to antibodies directed again collagen I and
III (F & G). Unless noted, scale bar = 100um

Figure 4: Both infusion flow rate (ml/hr) and SDS concentration (%) had a significant effect on
removal of intracellular myoglobin (A). Values shown are mean+sd. Increases in both flow rate
and SDS concentration significantly reduced the time needed to remove myoglobin. * = p<0.05;
two factor ANOVA. The measured effects of flow (B) and concentration (C) were described
using a linear model (see equation 2). Interaction effects between flow and concentration were
not observed with the model or detected with ANOVA analysis.

Figure 5: Infusion treatment did not significantly decrease the collagen or sGAG concentration
of DSM samples when compared to non-infused controls. Values shown are mean+sd. p<0.05,
two factor (flow and concentration) ANOVA.

Figure 6: H&E stained longitudinal (A) sections prepared from infusion DSM samples (0° =
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direction of muscle contraction). Representative infusion prepared DSM sample stress versus
strain curve (B). When compared to controls, infusion treatment did not significantly influence
(t-test P>0.05) DSM sample modulus, ultimate strength or alignment values (C). Values shown
are mean+sd. Scale bar = 100um.

Figure 7: DSM material substrates supported the in-vitro attachment and proliferation (A and B)
of viable (calcein AM) myoblast cells. The percent surface coverage (B) was evaluated at 3 and
7 days post cell seeding. Values shown are mean+sd. * p<0.05 compared to day 3, n=4/sample
group, Scale bar = 100um

Figure 8: DSM implants were prepared for implantation using the infusion device to first
remove intracellular debris followed by incubation in a DNAse/RNAse solution to remove
nuclear debris and penicillin/streptomycin to reduce the risk of implant infection. DSM samples
were rinsed in PBS (a total of five 24-hour PBS washes) to remove residual SDS, nuclease, and
antibiotic solutions (A). Stained (H&E) tissue sections collected four (B) and twelve weeks (C),
following subcutaneous implantation of infusion prepared DSM scaffolds into Sprague Dawley
rats. Infusion prepared DSM scaffold fragments were observed within the dorsal subcutaneous
implantation site at 4 weeks (*) but were degraded by 12 weeks (**) in all animals examined
(n=3/time point). Scale bar = 100µm
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Abstract
Skeletal muscle is capable of robust self-repair following mild trauma, yet in cases of
traumatic volumetric muscle loss (VML), where more than 20% of a muscle’s mass is lost, this
capacity is overwhelmed. Current autogenic whole muscle transfer techniques are imperfect,
which has motivated the exploration of implantable scaffolding strategies. In this study, the use
of an allogeneic decellularized skeletal muscle (DSM) scaffold with and without the addition of
minced muscle (MM) autograft tissue was explored as a repair strategy using a lower-limb VLM
injury model (n=8 / sample group). We found that the repair of VML injuries using DSM+MM
scaffolds significantly increased recovery of peak contractile force (81±3% of normal
contralateral muscle) when compared to unrepaired VML controls (62±4%). Similar significant
improvements were measured for restoration of muscle mass (88±3%) in response to DSM+MM
repair when compared to unrepaired VML controls (79±3%). Histological findings revealed a
marked decrease in collagen dense repair tissue formation both at and away from the implant site
for DSM+MM repaired muscles. The addition of MM to DSM significantly increased MyoD
expression, when compared to isolated DSM treatment (21 fold increase) and unrepaired VML
(37 fold) controls. These findings support the further exploration of both DSM and MM as
promising strategies for the repair of VML injury.

Keywords: extracellular matrix; scaffold; regenerative medicine; orthopedics; musculoskeletal
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A. Introduction
Our group is exploring the development of strategies designed to treat volumetric muscle
loss (VML) injuries. The substantial loss (>20%) of skeletal muscle tissue, either through trauma
or surgical resection, appears to overwhelm the normal wound healing mechanisms that function
effectively following minor muscle injuries (Terada, Takayama et al. 2001). It is generally
recognized that to properly restore muscle function following VML injury, surgical intervention
is required. Unfortunately, there are limited surgical options available to treat these clinically
challenging VML injuries. The currently accepted surgical approach for the replacement of lost
skeletal muscle is autologous muscle flap transfer (Vekris, Beris et al. 2008, Oishi and Ezaki
2010, Terzis and Kostopoulos 2010). Although frequently successful, muscle flap transfer is a
highly invasive procedure that introduces significant donor site morbidity and is therefore only
rarely indicated. The search for a less invasive VML repair strategy warrants research
investment. Towards this end, several groups, including ours, are exploring the development of
engineered extracellular matrix (ECM) scaffolds targeting VML repair (Bian and Bursac 2009,
Chiron, Tomczak et al. 2012, Juhas, Engelmayr et al. 2014, Hurd, Bhatti et al. 2015, Wilson,
Terlouw et al. 2016).
ECM scaffolds prepared from a variety of tissue sources have been utilized to repair a
wide range of damaged tissues in animal models (Merritt, Cannon et al. 2010, Perniconi, Costa et
al. 2011, Wolf, Daly et al. 2012, Corona, Ward et al. 2014) and recently in humans (Mase, Hsu et
al. 2010, Sicari, Rubin et al. 2014). Within this class of tissue-derived ECM scaffolds, the
application of decellularized skeletal muscle (DSM) as a repair strategy for VML injury has
shown some promise (Merritt, Cannon et al. 2010, Wolf, Daly et al. 2012). The multi-molecular
composition and highly aligned network architecture of DSM scaffolds are ideally suited for the
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restoration of physical and chemical cues that are lost following VML injury. To improve the
preparation of DSM scaffolds, our group has recently reported on a novel infusion method,
which can accelerate the decellularization process, without compromising the physical, chemical,
and biocompatibility properties (Kasukonis, Kim et al. 2016). Our goal is to explore the utility of
these infusion prepared DSM scaffolds for the repair of VML injuries. Yet, the implantation of
DSM scaffolds alone, particularly when explored in the lower extremity, appear to offer an
incomplete intervention for the repair of VML injuries (Aurora, Roe et al. 2015), suggesting that
other elements may be needed.
Evidence suggests that restoration of a robust pro-myogenic environment may require a
multifactorial approach, which includes combining ECM scaffolds with the appropriate
progenitor cells. In animal studies, the co-delivery of muscle progenitor cells in combination
with ECM scaffolds has been shown to improve functional recovery following VML injury when
compared to ECM scaffold delivery alone (Merritt, Cannon et al. 2010, Corona, Ward et al.
2014). The premise is that progenitor cells reestablish a needed pool of myogenic cells, which
utilize the ECM implant as a substrate upon which to initiate regeneration of contractile
myofibers. Cellular co-delivery has yielded promising VML regenerative results, but does
introduce increased clinical complexity, as it would require surgical collection and expansion of
the patient’s progenitor cells prior to implantation. Our group is interested in exploring
alternatives to in-vitro progenitor cell expansion and cultivation, with the aim of creating a single
stage VML repair strategy. An attractive source of muscle progenitor cells is the collection and
implantation of minced muscle (MM) autografts. MM contains several components, most
notably satellite cells, necessary for the regeneration of skeletal muscle and has been shown to
successfully regenerate damaged muscle tissue when examined in animal models of VML injury
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(Corona, Garg et al. 2013, Ward, Ji et al. 2015). Of particular interest to our group, MM
autografts can be harvested from normal muscle tissue and seeded back into the injury site
during a single stage surgical procedure.
An anticipated roadblock to the clinical translation of MM autografts is the large volume
of healthy muscle tissue that would be needed for grafting into a VML defect. At present the
implantation of MM in quantities prepared using less than 50% of the VML defect mass has not
been effective at restoring muscle function (Ward, Ji et al. 2015). While potentially less invasive
than a full muscle flap transfer, the harvest of muscle tissue in volumes required to fill half the
VML defect would still introduce significant donor site morbidity. Therefore, a repair strategy
that reduces the amount of MM needed to stimulate functional muscle recovery would improve
the clinical utility of MM autografts. Towards this end, our team is interested in exploring the codelivery of MM autografts with infusion prepared DSM scaffolds as a VML repair strategy. We
suspect that the use of DSM material as a carrier material could reduce the amount of MM
autograft needed to stimulate recovery following VML injury. Specifically, the study was
designed to test the hypothesis that delivery of a DSM scaffold carrier combined with a MM
autograft prepared using 25% of the defect mass (1/2 the current threshold for recovery) will
significantly improve functional muscle recovery (increased contractile force) and myogenesis
(increased MyoD expression) following hind limb VML injury in a small animal model.
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B. Methods
DSM Scaffold Preparation
To prepare DSM samples for implantation, whole tibialis anterior (TA) muscle was
infusion decellularized using the previously reported (Kasukonis, Kim et al. 2016) infusion
system (Figure 1). TA muscles were harvested from rats that had been euthanized at the
completion of an unrelated study. Briefly, the wide mid-belly region of the TA muscle was
positioned onto the infusion needle (27 gauge) and enclosed within a single decellularization
chamber. Four TA muscles were prepared in parallel during each run. The TA samples were
infused overnight (approximately 12 hours) with 1% SDS at a flow rate of 5mL/hr. Following
infusion treatment, samples were incubated overnight in a DNAse solution (1kU/ml DNAse in a
10mM Tris-HCL buffer; 2.5mM MgCL2 + 0.5mM CaCl2) and then incubated (8 hours) in a 1X
penicillin/streptomycin solution to reduce the risk of infection. Samples were rinsed thoroughly
(a total of six 24 hour wash steps) in PBS between each preparation step. Following completion
of the entire decellularization protocol, the DNA concentration of representative DSM implants
(n=4) was measured with the aid of a commercial quantification kit (Qubit, Fisher Scientific).
DSM implants were lyophilized and stored at -20C until utilized for implantation.

Animal Implantation
Fischer 344 rats (Harlan, Indianapolis, IN), weighing approximately 300-325g were used
as the animal model for all implantation studies. Surgical procedures and DSM implant
preparation methods were performed in accordance with protocols approved by the University of
Arkansas IACUC (protocol #14044) and guided by published methods (Wu, Corona et al. 2012,
Kim, Kasukonis et al. 2016). Anesthesia was induced using isoflurane (1-3%) in oxygen. The
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implant site was surgically exposed through a 1-2 cm incision running parallel to the tibia. The
TA was identified and a partial thickness VML defect (8 mm diameter x 3 mm deep) was created
using a sterile biopsy punch (Figure 2). The muscle tissue removed from the defect site was
weighed and the weight was adjusted (increased only) if needed to ensure consistent defect mass
across all animals (Average defect weight = 93.4 mg). Muscle defect mass values (20% of TA
mass) were based on pilot study TA muscle mass measurements (average TA mass = 470±17
mg). Muscle defect plugs were retained for use as MM autografts. Animals were randomly
assigned to one of three treatment groups (n=8 animals / treatment groups)
Group 1: Unrepaired VML defect
Group 2: VML defect repaired with an isolated DSM scaffold
Group 3: VML defect repaired with a DSM scaffold supplemented with MM autograft
tissue (25% of the VML defect mass)

A single infusion-prepared DSM scaffold was cut to size (average DSM mass = 4.9±0.7
mg) using surgical scissors and implanted into freshly prepared VML defects (Group 2). For
animals in the DSM+MM experimental group (Group 3), 25% of the defect muscle plug was
hand minced into a loose paste using a scalpel and scissors until MM fragments larger than
~1mm3 could not be visually detected. The white DSM scaffolds were manually rolled in the
pink MM autograft paste until all surfaces were visibly coated. DSM+MM constructs were
implanted into the VML defect. Care was taken to ensure that DSM implant network alignment
was matched to TA alignment. Unrepaired VML defects (group 1) served as negative controls
(n=8/ experimental group). The contralateral limb was left untreated to serve as an internal
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comparative control. To remain consistent with previous MM repair techniques, the DSM
scaffolds were sized to fill, but were not sutured to the surrounding muscle tissue. The deeper
fascia and surface skin layers were separately closed using an interrupted stich with a 5-0
absorbable suture (Vicryl, Ethicon, Summerville, MA). A single surgeon (BK) performed all
implantation procedures including the preparation of MM autografts. Postoperative analgesia
consisted of 0.1mg/kg buprenorphine administered subcutaneously via injection twice daily for
two days. Animals also had access to the anti-inflammatory medication (Carprofen) via a single
dietary gel cup (Medigel CPF, ClearH2O, Westbrook, ME) added to each cage following
surgery. Animal consumption of the gel was voluntary and any uneaten gel was removed from
the cage at 1-week post surgery. Following surgery, animals were housed in standard-sized rat
cages with unrestricted movement. The animals were allowed to bear weight on the operative
extremity as tolerated. All animals were housed for a 12-week recovery period.

Contractile Force Measurement
At the completion of the 12 week recovery period, the peak tetanic contractile force was
measured in situ as described in Corona et al (Corona, Garg et al. 2013). Animals were
anesthetized and the lower limb was stabilized at 90° of knee flexion (tibia parallel to the
benchtop) using a custom made alignment jig (Supplemental Figure 1). The ankle was flexed to
90° and the foot was secured (surgical tape) to the lever arm of a dual-mode muscle lever
systems (Aurora Scientific, Ontario, Canada,). To isolate the contribution of the TA during force
measurement, distal tenotomies were performed on the extensor digitorum longus (EDL) and
extensor halluces longus (EHL). TA peak isometric tetanic force was measured by stimulating
the peroneal nerve with the aid of a physiological stimulator (Grass; S88). Optimal voltage (2 – 5
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V) was determined using a series of tetanic contractions (150Hz, 0.1 ms pulse width, 400 ms
train). Average peak tetanic force for each animal was calculated from an average of 5
contractions. All contractions were separated by one minute of rest. Raw peak tetanic contractile
force (N) was recorded from both the treated and contralateral control limb of each animal and
normalized to animal weight (N/kg). The weight normalized force data (N/kg) is reported in the
results section. At the conclusion of electrophysiological testing, all animals were euthanized
through carbon dioxide inhalation in accordance with guidelines provided by the 2013 AVMA
Panel on Euthanasia of Animals.

Tissue Histology
Unrepaired and repaired TA muscles along with contralateral untreated TA muscles were
harvested and trimmed to remove the periosteum and tendon. EDL muscles were also collected
and weighed for comparison between treated and contralateral control limbs. Muscles were
rinsed in sterile PBS, dabbed dry, and then weighed. Muscles were then immediately flash frozen
in liquid nitrogen cooled isopentane. Frozen TA tissue samples (n=4/experimental group) were
sectioned (7μm) transversely through the mid-portion of the defect site with the aid of a cryostat.
Sections were mounted onto microscopic slides and immuno-stained for the presence of myosin
heavy chain (αMHC, 1:40, Iowa Hybridoma Bank), a muscle specific protein marker, collagen
type I (αColI, 1:750, Sigma), collagen type III (αColIII, 1:000, Abcam) or laminin 1 (αLn, 500:1,
Sigma) followed by incubation in the appropriate fluorescently labeled secondary antibodies
(Alexfluor, 500:1, Life Technologies). Additional tissue sections were stained using a
commercial Masson’s Trichrome kit following manufacturers guidelines (Sigma). All sections
were mounted onto microscope slides and digitally imaged. Treated sections were evaluated for
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myofiber formation and organization as well as the formation and extent of repair tissue
formation for comparison to untreated contralateral muscle tissue sections.
Measures of collagen type I accumulation, a potential indicator of diffuse muscle fibrosis,
in tissue regions away from the VML defect area were estimated from collagen I
immunoreactivity and guided by published methods (Bedair, Liu et al. 2007). Tissue
immunoreactivity to collagen I was calculated from fluorescent microscopic images (200X)
using image analysis software (Image J). A total of three non-consecutive tissue sections
collected from three representative animals (n=3/treatment group) were used for all calculations.
From each section, three images were obtained from the posterior half of the TA muscle at
regions located distant to (> 3 mm) the anterior defect/repair site. A total of nine images were
analyzed for each animal. All images were converted to 8-bit, grey scale, and uniformly
thresholded across all samples to isolate collagen type I positive tissue regions. From these
images the percent collagen type I positive tissue area was calculated for all treatment and
control sections.

MyoD and ECM Gene Expression
Real-time PCR was performed using the protocol described in Washington et al.
(Washington, Brown et al. 2013) Tissue samples (approximately 30mg) collected from the
defect/repair site (n=4/sample group) were homogenized with Trizol (Ambion, Carlsbad, CA),
chloroform (Sigma Aldrich, St. Louis, MO), and treated with DNase (Invitrogen, Carlsbad, CA).
RNA was extracted using the RNeasy kit (Invitrogen, Carlsbad, CA). RNA concentration and
purity was determined by UV spectrophotometry. RNA with a 260-to-280-nm ratio ≥ 1.8 was
used for subsequent analysis. cDNA was reverse transcribed from 1 µg of total RNA using the
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Superscript Vilo cDNA synthesis kit (Life Technologies, Carlsbad, CA, USA). cDNA was
amplified in a 25 µL reaction containing appropriate primer pairs and TaqMan Universal
Mastermix (Applied Biosystems, Grand Island, NY). Commercially available TAQMAN primers
(Invitrogen, Carlsbad, CA) for MyoD, Timp-1, Collagen I, Collagen III, TGF-β1, MMP2, and
18s ribosomal housekeeping were used to quantify the expression of desired matrix and matrix
regulatory genes. Samples were incubated at 95°C for 4 minutes, followed by 40 cycles of
denaturation, annealing, and elongation at 95°C, 55°C, and 72°C, respectively. TaqMan
fluorescence was measured at the end of the extension step each cycle. Experimental group
samples were normalized to 18s and then referenced to the contralateral normal limb. Gene
expression levels are reported as fold change using the 2-(Δ ΔCt) method.

Data Analysis
Based on an a priori power analysis, the implantation of 8 animals per group was
determined to be sufficient to detect a 15% increase in contractile force between treatment and
control animals. This level of detection was designed to detect physiologically relevant and
functionally meaningful increases is muscle contractile force. Pilot testing mean and standard
deviation contractile force values (2.10±0.15 N/kg) collected from intact TA muscle samples
were used. All data are represented by the mean and standard error unless noted. Data were
tested for normality using the Shapiro-Wilk Test. Comparisons between treatment groups (VML,
DSM, and DSM+MM) for each of the outcome measures (peak force, muscle mass, collagen I %
area, and gene expression) were evaluated with a one-way ANOVA using a commercial
statistical software package (JMP). Post hoc comparisons were made using Tukey’s test. A
standard 0.05 level of significance was used for all statistical tests.
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C. Results
Average DSM sample DNA content (1.0±0.1ng of DNA / mg of tissue) was well below
the preferred implantation threshold (< 50-70ng/mg) reported by others (Zhang, He et al. 2009,
Crapo, Gilbert et al. 2011). Isolated DSM implantation took approximately 30 minutes to
complete. The addition of MM preparation and coating steps added approximately 10 minutes
the procedure. Both DSM and DSM+MM treatment groups tolerated the implantation surgery
well. All animals gained weight throughout the observation period at a rate (8.3±0.5 and 8.5±0.3
grams/week) that was not significantly different from un-repaired VML defect animals (8.8±0.6
grams/week). There were no signs of post-surgical infection. At one week post-implantation, all
animals were fully ambulatory with no noticeable gait differences between groups. Carprofen
dietary gel cups were typically consumed within the first 3 days of surgery (effective dosage
(5/mg/kg/day). All animals reached the 12-week study end point without complications.
After the 12-week recovery period, bilateral measurements of the isometric TA muscle
tetanic contractile force were obtained. Tetanic contraction plots for all muscles were
characterized by a sharp rise in force, followed by a plateau at the peak force, and then a return
to a no force resting state (Figure 3). The average peak tetanic force produced by normal
contralateral TA muscles was 2.0±0.1 N/kg when normalized to animal mass. Following VML
injury without repair, the average peak tetanic force dropped to 1.4±0.1 N/kg, which is
equivalent to 62±3% of normal contralateral TA muscles values, a statistically significant
reduction (p<0.05). Following repair with isolated DSM, TA muscles produced an average
contractile force of 1.5±0.1 N/kg, which represents a 17% recovery of the peak force when
compared to the unrepaired VML muscle group. Although elevated, the peak force recovery
following isolated DSM repair was not statistically significant when compared to the unrepaired
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VML group. In response to repair with combined DSM+MM, the average peak tetanic force
increased to 1.7±0.2N/kg, which represents a 50% recovery in force production when compared
to unrepaired VML values. The recovery of peak tetanic force following DSM+MM repair was
statistically significant when compared to the unrepaired VML group (p<0.05).
For all muscles harvested there was no evidence of implant site infection or gross
deformity at the treatment site following 12 weeks of recovery. Generally, each of the treatment
group muscles appeared smaller than contralateral normal muscle and the defect site could often
be identified grossly (Figure 4). The muscles repaired with DSM and DSM+MM appeared to
have less fibrosis at the treatment site and less atrophy overall when compared to the unrepaired
muscles, but still had a less organized surface morphology at the treatment site when compared
to the ordered striations of normal muscle. Untreated VML sample animals had a body weight
normalized average TA mass of 1.27±0.1 g/kg, which is 79±3% of the contralateral normal TA
mass. TA muscle defects repaired with isolated DSM had an average normalized mass of
1.33±0.1g/kg, which is 82±3% of contralateral normal muscle mass and represents a 14%
recovery in muscle mass when compared to the unrepaired VML group. The group of TA
muscles repaired with combined DSM+MM had an average mass of 1.40±0.1g/kg, which is
equivalent to 88±3% of contralateral normal values. DSM+MM muscle mass was significantly
increased when compared to the unrepaired VML treatment group (p<0.05), but not
significantly greater than the isolated DSM repair group. On average, DSM+MM treated muscles
recovered 43% of the muscle mass lost following VML injury (79% vs. 88% of normal). Of
note, EDL muscles collected from the treated limb were on average larger than contralateral
EDL muscles for each treatment group (VML, DSM, and DSM+MM), suggesting compensatory
hypertrophy.
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At 12 weeks post surgery, the defect sites were detectable in histological sections
prepared from all treatment groups. Transverse histological images of the defect sites for all
treatment groups were characterized by the accumulation of repair tissue at the muscle surface
(Figure 5). Unrepaired VML and isolated DSM repair defect site tissues were strongly
immunoreactive to collagen type I, suggesting collagen-enriched connective tissue deposition
(fibrosis) at the defect/repair site. Additional ECM proteins, including fibronectin, collagen type
III, and laminin were each detected within the repair tissue (Figure 6). While the general
composition of the repair tissue layer was similar across all treatment groups, the size/thickness
of the layer was notably different between groups. Specifically, it was generally noted that the
repair tissue layer observed in DSM+MM treated samples layer was distinctly thinner than both
unrepaired VML and isolated DSM repair groups. The repair layer was often difficult to locate in
many tissue sections. For all treatment groups, MHC positive muscle fibers were present up to
the border of the repair layer, but were not observed within the layer itself. For all groups, the
collagen dense repair layer was notably thinner (50-500um) than the original VML defect
(3mm), suggesting atrophy of the transected muscle tissue proximal and distal to the defect site.
The Masson’s trichrome staining revealed signs of increased collagen deposition (blue
staining) around muscle fibers in tissue regions that extended beyond the defect site for both
unrepaired VML and isolated DSM repaired tissue sections. Similar qualitative increases in
collagen staining were not observed in DSM+MM Masson’s stained tissue sections. Subsequent
quantitative analysis of collagen type I immunoreactivity supported the Masson’s Trichorme
observations. When measured using tissue sections prepared from normal contralateral skeletal
muscle samples, collagen I positive immunostaining regions occupied, on average, 6.2±1.3% of
the total tissue section area (Figure 7). For sections prepared from unrepaired VML and isolated
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DSM repaired samples the percent surface area increased to 6.5±0.8%, and 8.6±0.5%, of the total
surface area respectively. The elevated collagen type I area values detected following isolated
DSM repair represents a 33% increase over normal tissue values. Alternatively, DSM+MM
repair group collagen I percent area (5.4±0.7%) was below all other groups including normal
muscle. On average, DSM+MM treated collagen I percent area values were 12% and 37% below
VML and isolated DSM repair values respectively. The difference between DSM+MM and
isolated DSM values was statistically significant.
Six key genes associated with ECM structural proteins (collagen I and III), ECM
regulatory cytokines (TGF-β1, MMP2, and TIMP-1) and myogenesis (MyoD) were examined
with the aid of rt-PCR. (Figure 8). Muscle tissue samples collected from both unrepaired VML
defect sites and isolated DSM repair sites produced approximately one tenth the relative
expression of MyoD when compared to normal contralateral TA muscle, with fold changes of
0.08±0.04 and 0.14±0.06 respectively. Alternatively, the DSM+MM repaired muscle group
produced a statistically significant increase (p<0.05) in the expression of MyoD with a fold
change of 2.95±0.47 when compared to normal TA muscle samples. Analysis of tissue collected
from both the VML and isolated DSM repair groups revealed modestly increased structural and
regulatory ECM gene expression values when compared to normal tissue controls. Collagen type
I expression levels measured from unrepaired VML, and isolated DSM, muscle samples were
1.55±0.14 and 2.60±0.89 of normal muscle respectively. The expression pattern for each of the
ECM regulatory genes followed a similar trend; MMP2, TGF-β, and TIMP-1 expression was
typically doubled within VML and Isolated DSM repair tissue samples. Expression levels for
each of the structural and regulatory ECM genes were markedly increased in response to
combined DSM+MM repair. The expression level for DSM+MM repaired samples exceeded
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both the VML and isolated DSM treatment groups by statistically significant margins for each of
the genes examined (p<0.05) and were generally an order or magnitude greater than normal
contralateral TA tissue expression values.
The gene expression ratios for each of the five ECM genes to the MyoD gene (e.g. Col
I:MyoD) were calculated across all treatment groups for comparison to normal muscle (Figure
9). Generally, normal muscle samples produced ECM to MyoD expression ratios that clustered
around a value of 13 and ranged from a low of 10±5 (Col1/MyoD) to a high of 16±8
(Col3/MyoD). Unrepaired VML and isolated DSM repair gene expression ratios were all
significantly elevated (3 to 4 fold) in comparison to normal muscle values, and clustered between
values of 30 and 50. Alternatively, DSM+MM gene expression values were generally lower than
normal muscle values ranging from a low of 4±2 (TGFB1;MyoD) to a high of 11±5
(Col1/MyoD). DSM+MM gene expression ratios calculated for Col I and Col III to MyoD were
closely matched to normal muscle values and represented the only ratio values across all
treatment groups that were not significantly different from normal muscle. The main outcome
measures for each of the treatment groups are summarized in Table 1.

D. Discussion

The key findings from this study suggest that the use of an acellular DSM scaffold
improved functional recovery from a VML injury and the addition of a MM paste further
enhanced regeneration. Specifically, the combination of a DSM scaffold with MM paste restored
approximately half the contractile force that was lost to VML injury, a finding that was
consistent with the measured increases in TA muscle weight following DSM+MM repair.
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Secondary findings suggest that the presence of the MM increases myogenesis, indirectly
assessed through MyoD expression analysis, and decreased the accumulation of collagen
enriched repair tissue at the site of the defect. When taken together the electrophysiological,
histological, and gene expression data provided evidence suggesting that the addition of MM to a
DSM graft can be utilized to improve muscle regeneration following VML injury.
The infusion bioreactor utilized in this project is a new approach developed by our lab to
accelerate muscle tissue decellularization. Although perfusion decellularization has been
performed on the entire forelimb of a rat (Jank, Xiong et al. 2015) and whole organs, such as the
liver (Uygun, Soto-Gutierrez et al. 2010), heart (Ott, Matthiesen et al. 2008), kidneys (Sullivan,
Mirmalek-Sani et al. 2012), and lungs (Ott, Clippinger et al. 2010), muscle tissue lacks the easily
accessible vasculature needed for perfusion, motivating a different approach whereby
decellularization solution was infused into the bulk tissue via a needle. In our recently published
work, it was demonstrated that DSM scaffolds produced through infusion decellularization retain
the composition, mechanics, and architecture of native muscle ECM. The major advantage of our
infusion device is that it produces a decellularized scaffold in under 10 hours compared to
standard diffusion based (incubation with agitation) methods that can take up to two weeks for a
similarly sized muscle (Merritt, Cannon et al. 2010). Moving forward, a single needle system
could be scaled up to create a multi-needle infusion device capable of decellularizing bulkier
muscle samples needed for large animal models or eventually human tissue for clinical studies.
Furthermore, while we currently don’t use the infusion process during the DNAse and rinse
steps, we could certainly anticipate utilizing the system to accelerate all process steps.
Ultimately, we believe the infusion prepared DSM scaffolds are an appropriate material from
which to explore VML repair strategies.
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The MM co-delivery with DSM was initially motivated by findings reported by Corona
et al (Corona, Garg et al. 2013). The harvest of MM autografts in a clinical setting makes it an
intriguing source of implantable satellite cells for co-delivery with DSM. Rather than utilizing
satellite cells which are first harvested, purified, expanded, and then ultimately implanted using a
two stage surgical strategy, MM can be acquired and delivered along with allogeneic DSM in a
single stage procedure. While a single procedure strategy may simplify surgical planning, we
clearly recognize that the MM volume (25% of the defect mass) utilized in this study, although
far less than the full defect size, would still produce harvest challenges and donor site morbidity
concerns. To minimize morbidity, it may be possible to collect subcritical muscle biopsies from
contralateral muscle sources. Ultimately, the use of a MM grafting may have the greatest utility
for the repair of smaller muscles like those of the face (Cardenas-Mejia, Covarrubias-Ramirez et
al. 2015) and hands (Lin, Zhu et al. 2012) where a therapeutic volume of MM muscle could be
harvested from the larger muscle of the lower limbs in a manner consistent with the harvest or
the middle third of the patellar tendon during anterior cruciate ligament reconstruction (McGuire
and Wolchok 1997).
The encouraging signs of functional regeneration that were observed in response to
minced muscle implantation hint at additional cellular implantation factors that may enhance
myogenesis within DSM implants. Specifically, the use of minced muscle may do more to
enhance muscle regeneration than simply increase the available pool of satellite cells at the
injury site. Following muscle sprains and strains, the presence of injured myocytes within the
wound site provides pro-regenerative cues. Specifically, it is understood that signaling cascades
initiated in response to myofiber injury activate inflammatory and myogenic cells that stimulate
the muscle repair process during the essential early phases of regeneration (McClung, Davis et
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al. 2007). Inclusion of the signaling cues initiated by myofibers injury may provide opportunities
for novel repair strategies. These cues could be provided directly through seeding of DSM
scaffolds with myofibers (minced muscle) as was examined in this study, or alternatively by
identifying the key chemical signals produced in response to myofiber injury and engineering
them into a biomimetic repair strategy.
The selection of a MM graft prepared using 25% of the VML defect mass was motivated
by Corona’s recent work showing that MM seeded in a collagen hydrogel did not effectively
repair VML injury when the mass of MM was prepared using less than 50% of the tissue
collected from the muscle defect (Ward, Ji et al. 2015). Others have utilized the entire defect to
produce significant regenerative results (Corona, Garg et al. 2013). By exploring the use of a
25% volume MM graft, the low end of what has been explored by others thus far, we hoped to
determine whether DSM scaffolds could improve the muscle regenerative performance of MM
autografts beyond that which has been achieved to date. The lack of an isolated MM
implantation controls group was a regrettable shortcoming to this study. It would have been
valuable to know the contribution of the MM graft, and help elucidate whether the improved
functional recovery measured following combined DSM+MM delivery was simply additive or
whether there were interaction effects that enhanced regenerative performance when combined.
Yet, while the effect of isolated MM was not evaluated in this study, what is clear, is two
strategies that showed modest effectiveness when used separately (isolated DSM or <50% MM
grafting) stimulated significant functional muscle recovery when used in combination,
suggesting to us that infusion prepared DSM material is a MM carrier scaffold worthy of
continued investigation.
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Towards this end, an improved understanding of the interactions between the MM paste
and DSM scaffold is warranted. In particular, it would be of interest to know whether the DSM
scaffolds are serving as simply a carrier material for the delivery of satellite cells, or whether the
scaffold creates a pro-myogenic environment that enhances satellite cell expansion. DSM+MM
interactions could be explored over the short term using in-vitro models, or in-vivo utilizing
earlier time points. The longer 12-week time point used in this study, while appropriate for the
detection of force recovery, missed the key regenerative events that occur during early wound
healing. Research suggests that a one-week time point may be more appropriate for the detection
of regenerative satellite cell activity (Tian, Jiang et al. 2016).
The increased effectiveness of the DSM+MM scaffold when compared to the collagen
hydrogel + MM examined by Corona could potentially be attributed to the architecture of the
DSM scaffold. Scaffolds composed of decellularized skeletal muscle, including the infusion
prepared scaffolds explored in this study, are unique because they retain the parallel alignment of
the native muscle from which they were obtained (Hinds, Bian et al. 2011). We, as well as
others, anticipate that scaffolds with muscle mimetic network alignment will improve muscle
regeneration by providing the appropriate topographical cues during healing (Bian and Bursac
2009, Lam, Huang et al. 2009). In whole muscle, ECM surrounds and supports multinucleated
myofibers which are highly aligned in the direction of muscle contraction. The individual fibers
range from 5 to 100 um in diameter, and can be as long as several centimeters (Maier and
Bornemann 1999). During implantation we were careful to orient the DSM scaffolds in the
direction of TA contraction. In-vitro models indicate that muscle progenitor cells utilize
alignment cues during myogenesis (Jana, Leung et al. 2014, Patel, Mukundan et al. 2016).
Similar alignment-sensitive responses have been reported for other cells, including cardiac
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muscle and tendons (English, Azeem et al. 2015, Morez, Noseda et al. 2015). Yet, while the
many in-vitro alignment studies support the motivation of aligned regenerative scaffolds, we
recognize that in-vivo evidence indicating that scaffold alignment is critical to muscle implant
success does not yet exist. The lack of in-vivo data supporting the importance of scaffold
alignment in muscle regenerative therapies would appear to motivate future studies.
VML repair with DSM+MM dramatically increased gene expression for each of the
structural and regulatory ECM genes explored in this study. However, the histological
appearance of defect/repair site tissue for both VML and isolated DSM repair groups would
suggest that ECM deposition and gene expression should be increased in these groups when
compared to the DSM+MM group. We suspect that ECM gene expression levels for both VML
and isolated DSM groups were elevated during earlier time points; an expression pattern that is
consistent with muscle fibrosis (Davis, Korn et al. 2015). Once a stable fibrotic scar was formed,
the genes returned to the lower expression values we measured at 12 weeks. It is also important
to note that the collagen I immunoreactivity and PCR analysis were conducted on samples taken
from different tissue regions. Collagen immunoreactivity was assessed within tissue regions
located distant to the repair/defect site, while the tissue used for PCR analysis was collected from
the repair site. As a result, the collagen immunoreactivity measures are likely an indicator of
tissue wide ECM adaptation to differences in force generation and transmission between
treatment groups (Hjorth, Norheim et al. 2015), while the PCR results are indicative of the
regenerative and remodeling processes occurring at the site of repair.
The PCR data suggests that the addition of MM to DSM scaffolds prolongs myogenesis
and ECM production at the repair site following VML injury repair. The increased expression of
ECM related genes and MyoD at 12 weeks could be indicative of active remodeling and
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adaptation at the defect site in response to muscle activity (Hyldahl, Nelson et al. 2015).
Alternatively, the prolonged upregulation of ECM genes at 12 weeks could be indicative of
ongoing fibrosis (Mann, Perdiguero et al. 2011). To determine whether the expression patterns
we observed at 12-weeks are beneficial or pathological, longer recovery time points may need to
be explored to determine whether contractile recovery is maintained. Additionally, it may be of
interest to explore gene expression profiles both within and away from the repair site to gain a
better understanding of muscle wide responses to each repair scheme.
We explored the ratio of the relative gene expression for each of the ECM genes to
MyoD in order to elucidate differences that may exist between normal muscle homeostasis and
each of the treatment groups. The relationships between key repair genes may provide additional
insights into the repair process, and in fact gene expression ratios have been utilized to examine
tissue healing trends in musculoskeletal tissues including bone (Chow, Leung et al. 2014) and
ligament (Canseco, Kojima et al. 2012). In this study, normal TA muscle tissue ratios
(ECM:MyoD) ranged between 10 and 15 for each of the ECM genes measured. Repair strategies
that increase expression ratios away from normal TA values might suggest a shift in the repair
process towards increased ECM production and/or decreased myogenesis. In contrast, repair
strategies that cause expression ratios to fall below normal TA values might alternatively suggest
a shift towards decreased ECM production and/or increased myogenesis. With that hypothesis in
mind, the DSM+MM repaired muscle groups expressed ratios that were at or below normal
muscle for each of the genes tested. Conversely, muscles that received VML defects and those
that were repaired with isolated DSM had ratios ranging from 32.9-51.5 and 28.6-38.1
respectively. Potentially, these and other gene expression ratios could be used to evaluate VML
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repair strategies in future animal models, and may provide insights into treatment strategies that
target gene pairs.
The co-delivery of DSM with MM restored approximately half of the peak contractile
force lost following VML injury (81% versus 62%). The question then remains; what additional
strategies could be utilized to restore the last twenty percent? Existing animal studies show that
physical rehabilitation in the form of voluntary wheel running after VML injury and subsequent
minced muscle transplant can improve maximal isometric torque, without causing significant
damage to healing muscle (Corona, Garg et al. 2013). These results suggest that the application
of force to the repair site during healing can contribute to muscle regeneration. This is supported
by in-vitro findings that have shown force and substrate strain enhances muscle progenitor cell
myogenesis (Egusa, Kobayashi et al. 2013, Heher, Maleiner et al. 2015). Motivated by a desire
to closely replicate previously reported MM treatment strategies, DSM implants were not sutured
to the surrounding TA muscle tissue during implantation. In the future we plan to incorporate
surgical attachment into the repair strategy, as it will enable the transfer of contractile force
through the repair site during healing and regeneration. In addition to physical stimuli, the
delivery of soluble stimuli in the form of growth factors has been found to enhance functional
recovery after muscle injury. Specifically, fibroblast growth factor (bFGF), insulin growth factor
(IGF), and nerve growth factor (NGF) have been shown to aid in muscle regeneration (Baoge,
Van Den Steen et al. 2012). If necessary these key molecules could be injected into the repair
site at the time of surgery to deliver short-term effects, or physically linked to DSM scaffolds to
potentially prolong their myogenic activity (Ramazanoglu, Lutz et al. 2013).
The Fischer 344 rats used in this study had not reached skeletal maturity and continued to
gain weight throughout the recovery period. As a result, the findings reported in this study might
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more accurately model the response of young adults to VML repair with DSM and MM
implants. Surgical muscle removal resulting from soft tissue sarcoma resection is another
anticipated target for VML repair strategies like that described in this study (Fischer, Soimaru et
al. 2015). This group of patients is typically older, and to date the regenerative response of MM
in an aged model has not been investigated. Age related changes in muscle biology might be a
limiting factor for MM usage in older patients. It is well established that muscle resident satellite
cells account for the majority of skeletal muscle’s regenerative capacity (Conboy and Rando
2005). However, aging leads to an overall decrease in myogenic capacity mostly in part due to
reduced satellite cell activity (Snow 1977, Conboy and Rando 2005, Brack and Rando 2007). In
future studies it would be useful to understand whether the regenerative benefits of MM
autografts are maintained when harvested from aged muscle. Yet, while the use of MM
autografts may not be suitable for all VML repair scenarios, the findings reported herein add to
the growing body of evidence supporting its potential as a VML treatment strategy that warrants
continued investigation.

E. Conclusions

The key findings of this study suggest that:
1. The addition of MM to DSM significantly increased peak TA tetanic contractile force
when compared to unrepaired VML controls.
2. DSM+MM repair significantly increased TA muscle mass, restoring approximately half
of the muscle mass lost to VML injury.
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3. Histological analysis revealed a reduced fibrotic response at the repair site in response to
DSM+MM repairs, when compared to either unrepaired VML or isolated DSM repair
strategies.
4. MyoD, ECM (Col I and Col III), and ECM regulatory (TGFB1, CTGF, and TIMP-1)
gene expression levels were significantly increased over all other treatment groups in
response to DSM+MM repair.
5.

Analysis of gene expression ratios may provide a useful indicator of VML treatment
efficacy and restoration of normal muscle homeostasis.
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Figure Legend

Figure 1: DSM scaffolds were infusion decellularized using a custom-built infusion bioreactor.
During decellularization, SDS solution was delivered via a hypodermic needle (A) which was
positioned into the wide mid-belly region of the TA muscle (B). SDS solution was infused via a
syringe pump (5 ml/hr for 12 hours) through each muscle and outflowed to waste collection. The
bioreactor was designed to accommodate four side-by-side decellularization units each capable of
accommodating a single muscle tissue sample (C). Representative whole TA muscle appearance
prior to and following infusion decellularization treatment (D & E), illustrates the dramatic color
change (red to white) following removal of intracellular myoglobin. Infusion prepared DSM
scaffolds, when viewed in thin section (scale bar = 100um) with H&E staining, retained the highly
aligned architecture of native muscle ECM (F). (arrow = direction of contraction)

Figure 2: To create the VML injury model, the mid-belly region of the TA muscle in a Fischer
344 rat was visualized through a 1-2cm incision (A) and approximately 20% of the TA muscle
(average defect weight = 94±6mg) was excised using an 8mm biopsy punch inserted to a depth of
3mm (B-D). During isolated DSM repair a single scaffold was cut to size and implanted into the
TA defect (E). To prepare each MM autograft, 25% of the previously removed defect plug was
minced with a scalpel and scissors and then used to coat the surface of a single DSM scaffold (F).
The combined DSM scaffold and MM paste construct was implanted into the TA defect (G). The
deep fascia and skin (H). were closed separately using absorbable sutures.

Figure 3: Twelve-weeks after treatment, TA peak contractile force was assessed for both
unrepaired and DSM repaired groups (n=8/group). Representative tetanic force responses for
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normal, unrepaired VML, DSM, and DSM+MM repaired TA muscles (A). Peak tetanic force was
normalized to animal weight (N/kg) and computed as a percentage of the untreated contralateral
limb for each animal tested (B). Box and whisker plot values shown are the median, 1st and 3rd
quartile, as well as maximum and minimum. The increase in peak contractile force in response to
DSM+MM implantation was statically significant when compared to both un-repaired VML and
isolated DSM repaired samples. (n=7-8 / sample group). # distinguishes significant difference from
VML group. p<0.05; ANOVA with post hoc Tukey’s test.

Figure 4: Gross morphology of normal, unrepaired VML, DSM, and DSM+MM repaired whole
TA muscles harvested 12 weeks post treatment (A). TA weight, calculated as the percent normal
contralateral muscle, was significantly increased in response to repair with combined DSM+MM
implants (B). The EDL muscle mass was similarly increased in response to treatment, suggesting
compensatory hypertrophy. Box and whisker plot values shown are the median, 1st and 3rd quartile,
as well as maximum and minimum. (n=8/sample); # distinguishes significant difference from
VML group, p<0.05; ANOVA with post hoc Tukey’s test.

Figure 5: Representative normal (A, E, I), unrepaired VML (B, F, J), DSM (C, G, K) and
DSM+MM (D, H, L) repaired histological sections (panel E inset indicates approximate section
location). Sections were stained with either Masson’s Trichrome or immunostained for the
presence of MHC (red) and collagen type I (green). The defect/repair site (*) for unrepaired VML
and isolated DSM repaired samples showed evidence of a thick, collagen enriched, connective
tissue repair layer. DSM+MM repair site tissue showed markedly less connective tissue formation
then VML or DSM groups. Dotted line highlights the boundary between collagen dense repair
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tissue and MHC positive muscle tissue . Scale bar = 250um unless noted Arrow indicates anterior
direction.

Figure 6: Representative normal (A, E), unrepaired VML (B, F), DSM (C, G) and DSM+MM (D,
H) tissue sections. Repair site tissue was immunoreactive to antibodies directed against collagen I
and III (A-D) as well as laminin and fibronectin (E-F). Scale bar = 100um. Arrow indicates anterior
direction.

Figure 7: Representative DSM (A) and DSM+MM repaired (B) tissue sections immunostained
for the presence of collagen type I. The sectional area immunoreactive to collagen type I was
calculated using sections prepared from tissue regions located at least 3mm away from the anterior
surface of the muscle. Tissue samples collected from DSM+MM repair samples exhibited a
significantly lower immunoreactivity to collagen type I when compared to isolated DSM repair
samples. Scale bar = 100um; n=3/sample group; * distinguishes significant difference from the
DSM treatment group; p<0.05 ANOVA with Tukey’s

Figure 8. RT-PCR results (fold change compared to normal muscle) for the ECM structural
proteins Collagen I and III, the ECM regulatory cytokines TGFB1, MMP2, and TIMP-1, and the
myogenic marker MyoD Values shown are mean+sem; n=4/sample group;. # distinguishes
significant difference from both VML and DSM groups; p<0.05 ANOVA with Tukey’s test.

Figure 9: Collagen I to MyoD gene expression ratio versus percent normal contractile force (A)
for VML, DSM, DSM+MM, and normal TA sample groups. The average expression ratios
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calculated for VML and DSM samples clustered near an elevated value of 30, while the DSM+MM
repair sample ratio was better aligned with normal TA muscle. Average expression ratios (B) for
each of the ECM structural and ECM regulatory genes to MyoD. Expression ratio values shown
are mean+sem; n=4/sample group.

Supplemental Figure 1: To record peak tetanic contractile force, the hind foot of an anesthetized
rat was secured to a foot plate with the knee was immobilized at 90° (A). A tenotomy was
performed on the distal tendons of the EDL and EHL (B & C) to isolate the contribution of TA
muscle to force production. Needle electrodes were used to stimulate the peroneal nerve (D).
During stimulation, ankle dorsiflexion force in Newtons versus time was recorded.

122

Figures

Figure 1

123

Figure 2

124

Figure 3

125

Figure 4

126

Figure 5

127

Figure 6

128

Figure 7

129

Figure 8

130

Figure 9

131

Supplemental Figure 1

132

Chapter 4
Autograft Relative Alignment Impacts the Regenerative Response of Skeletal
Muscle After Volumetric Muscle Loss in a Rat Model

To be submitted as an original article by:

Ben Kasukonis1, John Kim1, Tyrone Washington2, and Jeffrey Wolchok1

1

Department of Biomedical Engineering, College of Engineering, University of Arkansas,

Fayetteville, AR
2

Department of Health, Human Performance, and Recreation, College of Education and Health
Professions, University of Arkansas, Fayetteville, AR

133

Abstract:
Minor trauma, such as contusions and small lacerations, to a skeletal muscle has no lasting effect
on the force production or morphological structure of the tissue due to the self-repair capabilities
of skeletal muscle. When trauma is severe and results in a decrease of bulk tissue, the
characteristic repair mechanisms are overwhelmed resulting in permanent fibrosis and reduction
in contractile force production. Tissue engineering has yielded several cell and scaffold based
therapies, and many scaffolds or tissue constructs used in VML repair mimic the parallel
alignment of myofibers and underlying ECM in skeletal muscle tissue. While the alignment of
the biomaterial or engineered muscle is addressed in many studies, the relative alignment
between the tissue engineering construct and the myofibers of the damaged muscle has not been
thoroughly investigated. This goal of this study was to provide evidence towards the hypothesis
that the relative alignment of an autograft used to repair VML in an animal model will affect the
regenerative response of the damaged skeletal muscle tissue. A rat VML model was used with 3
treatment groups: aligned, 45° unaligned, and 90° unaligned studied at 2 time points: 2 weeks
(n=6/group) and 12 weeks (n=9) of recovery. We observed significant upregulation of MyoD
(2.5 fold increase) and Pax7 (1.7 fold increase) expression at 2 weeks post-implantation in VML
defected muscles repaired with aligned autografts, which provides evidence that congruent
alignment of a scaffold within a defect contributes to the myogenic response of the repaired
tissue. After 12 weeks, aligned autografts had greater functional recovery (74.8±10.5%) when
compared to 45° and 90° unaligned autografts (63.7±10.2% and 60±11.0%, respectively). The
importance of relative alignment has been demonstrated with this study but the underlying
mechanisms require further exploration.
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A. Introduction

Volumetric muscle loss (VML) is a skeletal muscle injury in which more than 20% of a
muscles volume is lost to traumatic injury.(Grogan et al., 2011)Innate mechanisms to repair
skeletal muscle are overwhelmed and patients are left with permanent fibrosis and functional
deficiencies. The current standard of care for patients presenting with a VML injury is the use of
muscle flap autografts. However, there are currently multiple therapeutic interventions being
developed and tested in animal models, as well as two small clinical studies. Some of the more
successful strategies include the use of ECM scaffolds. The source of the ECM varies from
decellularized skeletal muscle (DSM) to porcine small intestine submucosa (SIS). There are
several differences between the two scaffolds including: pore size, pore alignment, and
embedded growth factors. Skeletal muscle is a highly aligned tissue with a hierarchical
arrangement of ECM, and after decellularization the resulting scaffold is anisotropic.(Meyer &
Lieber, 2011; Wilson et al., 2016) The architecture and mechanical properties of the ECM are
important not only to provide structure to myofibers, but to transmit mechanical stimuli to the
myofibers.(Kjaer, 2004) Perhaps more importantly from the standpoint of muscle regeneration,
mechanical stimuli are imperative for the differentiation of satellite cells and the fusion of
myoblasts.(Grossi et al., 2007; Tidball et al., 1998)
Skeletal muscle tissue is highly aligned and the force production of a muscle is heavily
influenced by the muscles architecture. Muscle architecture, the arrangement of muscle fibers in
relation to the axis of force generation, is constrained by the length of the muscle, the length of
myofibers, the pennation angle, and the physiological cross sectional area (PCSA).(Lieber &
Friden, 2000) Even in pennate muscles, adjacent myofibers have parallel alignment and the
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surrounding ECM is highly uniform in direction. When designing bioreactors for tissue
engineered skeletal muscle, researchers are deliberate in developing alignment within their
constructs.(Aubin et al., 2010; Aviss et al., 2010; Huang et al., 2010b; Vandenburgh & Karlisch,
1989) Parallel alignment of myofibers has been shown to be important for developing
phenotypically normal muscle tissue under in vitro conditions.(Aubin et al., 2010; Lam et al.,
2009; Vandenburgh & Karlisch, 1989; Wang et al., 2015) Researchers obtain parallel alignment
through micropatterning(Cimetta et al., 2009; Flaibani et al., 2009; Huang et al., 2010a; Shimizu
et al., 2009), aligned deposition of fibers(Aviss et al., 2010; Choi et al., 2008b; Wang et al.,
2015), or by selecting a scaffold that has native parallel alignment. Myofiber alignment
indicative of a mature muscle phenotype has also been induced in vitro using bioreactors that
deliver mechanical or electrical stimulation to cells and/or tissue constructs.(Ahadian et al.,
2013; Boonen et al., 2010a; Donnelly et al., 2010; Flaibani et al., 2009; Grossi et al., 2007;
Langelaan et al., 2011; Powell et al., 2002; Vandenburgh & Karlisch, 1989)
It has been suggested that parallel alignment is not only necessary for efficient contractile
force production, but for the arrangement of blood vessels and nerves as well as the migration of
macrophages, fibroblasts, and muscle progenitor cells during muscle repair. In response to
sarcolemma damage, satellite cells activate and migrate to the site of tissue insult. Satellite cells
are capable of migrating across the ECM to adjacent myofibers, but are more likely to travel
down the length of a myofiber.(Siegel, Atchison, Fisher, Davis, & Cornelison, 2009b) Migration
of satellite cells is dependent on the release of matrix metalloproteases (MMPs) to degrade the
basal lamina to allow for efficient chemotaxis to the site of injury.(Kaar et al., 2008) The action
of MMPs is attenuated by tissue inhibitors of metalloproteases (TIMPs) allowing for increased
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cell migration, while limiting the degradation of the supportive ECM.(Karalaki et al., 2009;
Nishimura et al., 2008)
The effects of alignment and misalignment on the regenerative response of skeletal
muscle, especially in cases of VML, are not understood and have not been explored. The
alignment of a biomaterial when selecting a therapeutic intervention for VML injuries is a
parameter that many researchers acknowledge.(Merritt et al., 2010; Perniconi et al., 2011b;
Wang, Johnson, Chang, & Zhang, 2013; Wolf et al., 2012) In another study, researchers used
autografts to repair VML in an animal model and attributed variance within treatment groups to
misalignment of the myofibers of the autograft with the myofibers of the VML defected
tissue.(M. T. A. Li, Willett, Uhrig, Guldberg, & Warren, 2014a) As the field of skeletal muscle
tissue engineering progresses towards effective treatment options for VML, the effect of relative
alignment must be understood.
This goal of this study is to provide evidence towards the hypothesis that the relative
alignment of an autograft used to repair VML in an animal model will affect the regenerative
response of the damaged skeletal muscle tissue. More specifically, aligned autografts will have
greater functional recovery and myogenic activity and decreased fibrosis when compared to
unaligned autografts. A rat model for VML will be used to assess the effect relative autograft
alignment has on VML repair.(Wu, Corona, Chen, & Walters, 2012b) Functional recovery will
be assessed through in vivo electrophysiological testing and repaired muscle mass which will be
compared to contralateral unaffected limbs. Evidence of myogenesis and fibrosis will be
ascertained using RT-PCR for quantitative measures of relative gene expression and histological
analysis will be used for qualitative assessment of the regenerative response of the defected
muscle. The two time points selected for this study will allow us to explore the initial fibrotic and
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myogenic response to alignment or misalignment of an autograft and the long-term recovery
outcomes for VML defected muscles repaired with aligned or unaligned autografts.

B. Methods

Animal Implantation
The implantation of 9 animals per group at 12 weeks was determined to be sufficient to
detect a 15% increase in contractile force between treatment and control animals using a power
analysis. This level of detection was designed to detect physiologically relevant and functionally
meaningful increases is muscle contractile force. Pilot testing mean and standard deviation
contractile force values (1.7±0.3 N/kg and 1.4±0.3 N/kg) collected from repaired and unrepaired
VML-injured TA samples, respectively, were used for the 2 sample equivalence test.
Fischer 344 rats (Harlan, Indianapolis, IN), weighing approximately 300-325g were used
as the animal model for all implantation studies. Surgical procedures and DSM implant
preparation methods were performed in accordance with protocols approved by the University of
Arkansas IACUC (protocol #14044) and guided by published methods (Wu, Corona et al. 2012,
Kasukonis, Kim et al. 2016). Anesthesia was induced using isoflurane (1-3%) in oxygen. The
implant site was surgically exposed through a 1-2 cm incision running parallel to the tibia. The
TA was identified and a sterile surgical marker was used to draw a thin line indicating the
dominant alignment of the myofibers. A partial thickness VML defect (8 mm diameter x 3 mm
deep) was created using a sterile biopsy punch (Figure 2). The muscle tissue removed from the
defect site was weighed (Average defect weight = 93.4 mg). Muscle defect mass values (20% of
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TA mass) were based on pilot study TA muscle mass measurements (average TA mass = 470±17
mg). Animals were randomly assigned to one of three treatment groups at
Group 1: VML repaired with an aligned autograft
Group 2: VML repaired with a 45° unaligned autograft
Group 3: VML repaired with a 90° unaligned autograft
Muscle defect plugs were immediately implanted in the defect site and sutured in place
with four interrupted stiches with 6-0 polypropylene sutures (Redilene, MYCO Medical, Cary,
NC). The contralateral limb was left untreated to serve as an internal comparative control. The
deeper fascia and surface skin layers were separately closed using an interrupted stich with a 5-0
absorbable suture (Vicryl, Ethicon, Summerville, MA). A single surgeon (BK) performed all
implantation procedures including the preparation of MM autografts. Postoperative analgesia
consisted of 0.1mg/kg buprenorphine administered subcutaneously via injection twice daily for
two days. Animals also had access to the anti-inflammatory medication (Carprofen) via a single
dietary gel cup (Medigel CPF, ClearH2O, Westbrook, ME) added to each cage following
surgery. Animal consumption of the gel was voluntary and any uneaten gel was removed from
the cage at 1-week post surgery. Following surgery, animals were housed in standard-sized rat
cages with unrestricted movement. The animals were allowed to bear weight on the operative
extremity as tolerated. All animals were housed for a 2 or 12 week recovery period.

Contractile Force Measurement
At the completion of the assigned 2 or 12 week recovery period, the peak tetanic
contractile force was measured in situ as described in Corona et al (Corona, Garg et al. 2013).
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Animals were anesthetized and the lower limb was stabilized at 90° of knee flexion (tibia parallel
to the benchtop) using a custom made alignment jig (Supplemental Figure 1). The ankle was
flexed to 90° and the foot was secured (surgical tape) to the lever arm of a dual-mode muscle
lever systems (Aurora Scientific, Ontario, Canada,). To isolate the contribution of the TA during
force measurement, distal tenotomies were performed on the extensor digitorum longus (EDL)
and extensor halluces longus (EHL). TA peak isometric tetanic force was measured by
stimulating the peroneal nerve with the aid of a physiological stimulator (Grass; S88). Optimal
voltage (2 – 5 V) was determined using a series of tetanic contractions (150Hz, 0.1 ms pulse
width, 400 ms train). Average peak tetanic force for each animal was calculated from an average
of 5 contractions. All contractions were separated by one minute of rest. Raw peak tetanic
contractile force (N) was recorded from both the treated and contralateral control limb of each
animal and normalized to animal weight (N/kg). The weight normalized force data (N/kg) is
reported in the results section. At the conclusion of electrophysiological testing and hindlimb
muscle harvest, all animals were euthanized through a two-part procedure with 4% isoflurane to
induce anesthesia followed by immediate carbon dioxide inhalation in accordance with
guidelines provided by the 2013 AVMA Panel on Euthanasia of Animals.

Tissue Histology
Autograft repaired TA muscles along with contralateral untreated TA muscles were
harvested and trimmed to remove the periosteum and tendon. EDL muscles were also collected
and weighed for comparison between treated and contralateral control limbs. Muscles were
rinsed in sterile PBS, dabbed dry, and then weighed. Muscles were then immediately flash frozen
in liquid nitrogen cooled isopentane. 12 week frozen TA tissue samples (n=4/experimental

140

group) were sectioned (10μm) transversely through the mid-portion of the defect site with the aid
of a cryostat. Sections were mounted onto microscopic slides and immuno-stained for the
presence of collagen type III (αColIII, 1:500, Abcam) followed by incubation in the appropriate
fluorescently labeled secondary antibody (Alexfluor, 1:500, Life Technologies). These sections
were analyzed using ImageJ to determine the average myofiber area. Other 12 week transverse
sections were stained with H&E (VWR) using standard protocols. Tissue sections from 2 week
time points were obtained by slicing the frontal plane of whole muscle. These 10μm sections
were stained using a commercial Masson’s Trichrome kit following manufacturers guidelines
(Sigma). All sections were mounted onto microscope slides and digitally imaged. Treated
sections were evaluated for myofiber formation and organization as well as the formation and
extent of repair tissue formation for comparison to untreated contralateral muscle tissue sections.
Myogenesis and ECM Gene Expression
Real-time PCR was performed using the protocol described in Washington et al.
(Washington, Brown et al. 2013) Tissue samples (approximately 30mg) collected from the
defect/repair site (n=4/sample group/time point) were homogenized with Trizol (Ambion,
Carlsbad, CA), chloroform (Sigma Aldrich, St. Louis, MO), and treated with DNase (Invitrogen,
Carlsbad, CA). RNA was extracted using the RNeasy kit (Invitrogen, Carlsbad, CA). RNA
concentration and purity was determined by UV spectrophotometry. RNA with a 260-to-280-nm
ratio ≥ 1.8 was used for subsequent analysis. cDNA was reverse transcribed from 1 µg of total
RNA using the Superscript Vilo cDNA synthesis kit (Life Technologies, Carlsbad, CA,
USA). cDNA was amplified in a 25 µL reaction containing appropriate primer pairs and TaqMan
Universal Mastermix (Applied Biosystems, Grand Island, NY). Commercially available
TAQMAN primers (Invitrogen, Carlsbad, CA) for MyoD, Pax7, Timp-1, Collagen I, Collagen
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III, TGF-β1, MMP2, and 18s ribosomal housekeeping were used to quantify the expression of
desired matrix and matrix regulatory genes. Samples were incubated at 95°C for 4 minutes,
followed by 40 cycles of denaturation, annealing, and elongation at 95°C, 55°C, and 72°C,
respectively. TaqMan fluorescence was measured at the end of the extension step each
cycle. Experimental group samples were normalized to 18s and then referenced to the
contralateral normal limb. Gene expression levels are reported as fold change using the 2-(Δ ΔCt)
method.

Data Analysis
All data are represented by the mean and standard error unless noted. Data were tested for
normality using the Shapiro-Wilk Test. Each time point was considered separately and no
comparisons were made between treatment groups of different recovery times. Comparisons
between treatment groups (Aligned, 45° Unaligned, and 90° Unaligned) for each of the outcome
measures (peak force, muscle mass, and gene expression) were evaluated with a one-way
ANOVA using a commercial statistical software package (JMP). Post hoc comparisons were
made using Tukey’s HSD. A standard 0.05 level of significance was used for all statistical tests.

C. Results

Defect Creation and Autograft Implantaion
The defect creation and autograft implantation took approximately 40 minutes to
complete.(Figure 2) All autograft treatment groups tolerated the implantation surgery well. All
animals gained weight throughout the first two weeks at a rate of 7.1±4.0grams/week. Animals
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gained an average of 7.2±1.1 grams/week over the long-term recovery period (12 weeks). There
were no signs of post-surgical infection. At one week post-implantation, all animals were fully
ambulatory with no noticeable gait differences between groups. Carprofen dietary gel cups were
typically consumed within the first 3 days of surgery (effective dosage (5/mg/kg/day). All
animals reached the assigned 2-week or 12-week study end point without complications.

Contractile Force Measurement
After the 2-week or 12-week recovery period, bilateral measurements of the isometric TA
muscle tetanic contractile force were obtained. Tetanic contraction plots for all muscles were
characterized by a sharp rise in force, followed by a plateau at the peak force, and then a return
to a no force resting state (Figure 3). The average peak tetanic force produced by normal
contralateral TA muscles was 2.5±0.1 N/kg at 2 weeks post-implantation when normalized to
animal mass and 2.5±0.2 N/kg after 12 weeks. Following VML injury with aligned autograft
repair, the average peak tetanic force dropped to 1.2±0.2 N/kg after two weeks, which is
equivalent to 48±8% of normal contralateral TA muscles values, a statistically significant
reduction (p<0.05). However, after 12 weeks of recovery, muscles repaired with aligned
autografts produced 1.8±0.3 N/kg of force, representing 75±11% of the peak tetanic contractile
force of normal muscle. Following repair with 45° unaligned autografts, TA muscles produced
an average contractile force of 1.3±0.3 N/kg after two weeks, which represents 51±11% of the
peak force of the control muscle group. After 12 weeks, the muscles repaired with 45° unaligned
autografts had 1.6±0.2 N/kg of force when normalized to body mass, representing 64±10% of
force of normal muscle at the same time point. In response to repair with 90° unaligned
autografts, the average peak tetanic force increased to only 1.5±0.3 N/kg after 12 weeks of
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recovery compared to 1.3±0.3 N/kg of force at 2 weeks, which represents 61% and 53% of the
force production of body mass normalized control muscle peak contractile force at the same time
points.
Muscles harvested at 2 weeks of recovery showed remarkable morphological differences
between all treatment groups and all treatment groups compared to the contralateral control
muscles.(Figure 4) There was minimal fibrosis around the polypropylene stitches and no
evidence of ineffective approximation of defect-autograft margins. Muscles repaired with a 90°
unaligned autograft displayed the most deformity at the defect site. A fibrotic strip of tissue
which occupied the entire defect vertically (8mm) and about 2-3mm in the horizontal direction
was observed in all of the 90° unaligned autograft treatment group at 2 weeks post-implantation
(Figure 4). The muscles repaired with the 45° unaligned autografts did not display any distinctive
features, but the defect site appeared to be generally more disorganized and fibrotic than normal
contralateral muscle. The defect site of muscles receiving the aligned autograft were closest to
contralateral muscle at 2 weeks post-implantation and the margins of the autograft were just
visible with the naked eye. For all muscles harvested following 12 weeks of recovery, there was
no evidence of implant site infection or gross deformity at the treatment site. There was no
obvious patterns of fibrosis in any of the treatment groups, although there appeared to be
progressively more atrophy as degree of misalignment increased. The muscles repaired with
aligned autografts appeared to have less atrophy at the treatment site and less disorganization
overall when compared to the unaligned autograft repaired muscles. Although the aligned
treatment group displayed evidence of repair at the defect site, treated muscle was remarkably
similar to contralateral normal muscle. At 12 weeks post-implantation, 45° and 90° unaligned
treatment groups were undistinguishable from each other and general appearance at the defect
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site was characterized by degenerated tissue and disorder of myofibers. Aligned treatment
animals had a body weight normalized average TA mass of 1.37±0.1 g/kg at 2 weeks and
1.39±0.1 g/kg at 12 weeks, which is 82±5% and 89±7% of the contralateral normal TA mass at
the respective time points. Two weeks after defect creation and repair, TA muscle defects
repaired with 45° unaligned autografts had an average normalized mass of 1.37±0.1g/kg, which
is 82±5% of contralateral normal muscle mass and after 12 weeks the muscles had an average
mass of 1.37±0.1g/kg, which is 88±7% of contralateral normal muscle mass when normalized to
body weight. The group of TA muscles repaired with 90° unaligned autografts had an average
mass of 1.30±0.2g/kg after 2 weeks and 1.35±0.1g/kg after 12 weeks, which is equivalent to
78±9% and 86±8% of contralateral normal values at the respective time points. All treatment
group muscle masses were significantly decreased when compared to contralateral control
groups of their respective time points (p<0.05), but were not significantly different from other
treatment groups of the same recovery length.
Six key genes associated with ECM structural proteins (collagen I and III), ECM
regulatory cytokines (TGF-β1, MMP2, and TIMP-1) and 2 genes related to myogenesis (MyoD
& Pax7) were examined with the aid of rt-PCR. (Figure 5). The muscles recovered at two weeks
post-implantation had an across the board upregulation of ECM associated genes for all
treatment groups. For TGF-β expression, the fold change was 4.4±0.8, 2.6±0.4, and 3.3±1.4 for
aligned, unaligned 45°, and unaligned 90°, respectively. Collagen I expression in the autograft
repaired muscles had the greatest fold change compared to normal muscle expression with
aligned having 11.6±4.2 fold change, unaligned 45° with a 8.1±1.7 fold change, and unaligned
90° had a 12.0±7.4 fold change. Collagen III expression in the autograft repaired muscles had
significant increases compared to normal muscle expression with aligned having 9.1±2.7 fold
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change, unaligned 45° with a 7.5±1.8 fold change, and unaligned 90° had a 7.6±4.1 fold change.
MMP2 had a significant increase in expression in all treatment groups compared to the uninjured
control muscle expression levels with fold changes of 7.3±1.4, 6.6±1.4, and 6.5±2.9 for aligned,
unaligned 45°, and unaligned 90°, respectively. Timp-1, an MMP inhibitor, also had significantly
increased expression in all treatment groups compared to uninjured muscle expression with
aligned having 10.2±3.5 fold change, unaligned 45° with a 7.9±2.1 fold change, and unaligned
90° had a 8.1±4.6 fold change. Alternatively, the aligned autograft repaired muscle group
produced a statistically significant increase (p<0.05) in the expression of MyoD with a fold
change of 2.5±0. 7 and of Pax7 with a fold change of 1.7±0.1 when compared to normal TA
muscle samples. The unaligned repaired muscle expression did not have a significant difference
with the uninjured TA expression of myogenic genes. After 12 weeks of recovery, the autograft
repaired muscle did not have any significant difference in ECM or myogenic gene expression
when compared to the relative expression of uninjured TA muscle.
At 2 weeks post-implantation, Masson’s trichrome staining revealed signs of increased
collagen deposition (blue staining) at the defect site in all treatment groups. The locations and
amount of collagen varied between treatment groups. (Figure 6) Muscles repaired with aligned
autografts had increased collagen at the margins of the defect but evidence of myofibers at the
most interior parts of the autograft. Alignment of the myofibers appeared to be in-line with
surrounding myofibers of the TA. Unaligned autograft repair led to an increase in collagen
deposition when compared to the aligned repair. Unaligned 90° repaired muscles were the most
fibrotic with defect sites characterized by disorganization and lack of myofibers. Collagen
deposition was not limited to the defect site but was more prevalent through most of the muscle.
Unaligned 45° repair had an intermediate amount of fibrosis at the defect site and there was
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evidence of myofibers at the defect with alignment incongruent with the surrounding tissue
orientation. As observed in the unaligned 90° repaired muscles, the unaligned 45° repair had
evidence of increased collagen deposition beyond the margins of the defect. The defect sites all
retained a small number of myofibers in the original implanted alignment.
At 12 weeks post surgery, the defect sites were detectable in histological sections
prepared from all treatment groups. There was evidence of fibrotic tissue at the surface of the
defect site for all treatment groups with little deviation between groups. (Figure 7) The average
fiber diameter was not significantly different between groups, suggesting that any functional
improvement observed in muscles repaired with aligned autografts was not due to hypertrophy.
(Figure 7)

D. Discussion

The results from this study indicate that the alignment of an autograft has a significant
effect on the regenerative response of the surviving muscle. By varying only the alignment of
fibers relative to the damaged muscle, we ensured that only relative fiber alignment could
generate differences between the treatment groups. After the creation of the VML injury and
weighing the autograft, the autograft was immediately placed back into the defect site while the
margins of the defected muscle were still bleeding. The autograft was aligned according to the
relative angle between the TA myofibers and the myofibers of the autograft as indicated by the
line drawn prior to defect creation. The alignment of the autografts was straightforward for the
aligned and 90° treatment groups, the 45° treatment group was an intermediate treatment
between the aligned and 90° groups. Although the angle was not measured, the intermediate
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nature of the 45° treatment group would allow us to determine if the repair response was
proportional to the relative alignment or, as was seen in contractile force measurements,
histological analysis, and gene expression data, muscle only regenerated in response to aligned
autografts and responded to any degree of misalignment with increased fibrosis and atrophy
resulting in a functional deficit.
Polypropylene sutures served as anchors to maintain the relative alignment of the
autografts and to allow for mechanical force transduction through the autograft and to the distal
myofibers which were severed upon creation of the VML injury. Four sutures were determined
to be the minimum required to preserve the prescribed alignment or misalignment while limiting
the incidence of foreign body response and encapsulation by the host immune system, which is a
concern for non-resorbable biomaterials.(Anderson et al., 2008) Polypropylene sutures were
selected as they would provide consistent and effective mechanotransduction through the
autograft. Mechanotransduction, the conversion of mechanical stimuli through tissue into
biochemical signals by cells, is known to improve myogenesis in vitro and in vivo.(Boonen et al.,
2010b; Martineau & Gardiner, 2001) Mechanotransduction may contribute to the response of the
host skeletal and immune systems to therapeutic interventions with varying mechanical
properties. Scaffolds and tissue constructs with mechanical properties incongruent to native
skeletal muscle could deliver mechanical stimuli outside the thresholds necessary for
myogenesis.(Courtney, Sacks, Stankus, Guan, & Wagner, 2006; Takaza, Moerman, Gindre,
Lyons, & Simms, 2013)
The fibrotic strip observed in the gross morphological analysis of the 90° unaligned
treatment group after 2 weeks of recovery provides evidence of ineffective skeletal muscle
repair. Studying the formation and subsequent disappearance of this feature could facilitate an
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investigation into the mechanisms by which relative misalignment affects the regenerative
response of VML injured muscle. Although the fibrotic strip was not clearly visible with
Masson’s trichrome stain, other staining protocols may yield better results. The increased
collagen deposition outside the margins of the defect may obfuscate a collagen-rich feature as
was observed with the Masson’s trichrome stained sections.
The significant upregulation of myogenic genes during the first 2 weeks of recovery and
the near significant improvement in peak tetanic contractile force after 12 weeks, provides
evidence that the relative alignment between an autograft and myofibers of a VML injured
muscle is significant to the determination of a fibrotic or myogenic response by the damaged
skeletal muscle. This cannot be extrapolated to conclude that a significant difference exists
between the regenerative response to anisotropic scaffolds with mechanical properties similar to
skeletal muscle, such as DSM,(Wilson et al., 2016) and to isotropic scaffolds, such as SIS or
UBM. Evidence published recently suggests that there is no significant differences with respect
to the regenerative capacity of repair with DSM compared to UBM, although the study used an
abdominal wall model which does not have the same design requirements and challenges as
extremity VML injury models with respect to volumetric repair and desired functional
outcomes.(Wolf et al., 2012)
The results of RT-PCR give evidence of a transient remodeling phase which was present
at 2 weeks as evidenced by the upregulation of ECM related genes in all treatment groups and a
return to baseline levels of gene expression after 12 weeks of recovery. The significant
upregulation of MyoD and the upward trend of Pax7 expression in VML defected muscles
repaired with aligned autografts provides evidence that congruent alignment of a scaffold within
a defect contributes to the myogenic response of the repaired tissue. There did not appear to be a
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continuum of responses in gene expression with respect to the relative angle of misalignment.
The unaligned scaffolds performed similarly to each other with upregulation of ECM related
genes at the 2 week time point and a return to baseline levels after 12 weeks. The disorganization
of the defect site in both unaligned treatment groups was evident at 2 and 12 weeks of recovery
The mechanisms by which alignment contributes to the regenerative response of host
muscle after VML cannot be elucidated by the methods of this current study. Further studies at
intermediate time points could track the facilitation or retardation of blood vessel in growth or
the infiltration of the autograft by macrophages, muscle progenitor cells, and myofibroblasts.
The use of GFP+ rats could provide a platform to investigate autograft fate, including cells and
damaged myofibers, after being implanted into a volumetric defect. An autograft from the
creation of a VML defect in a GFP+ rat could be implanted into the VML defect of a GFP- rat
and the reverse could be performed simultaneously. The use of an inbred strain of rat, such as
Fischer 344 rats, would eliminate the host rejection response and allow for innate regenerative
responses to predominate over foreign cell immune reactions. There still exists a knowledge gap
into the mechanisms that cause fibrosis at the defect site, yet allow for significant functional
recovery. The hypothesis of a functional fibrotic repair deserves further exploration, especially
exploring the muscle as a whole instead of limiting research simply to the defect site.The use of
unaligned grafts may help clarify the fibrotic response the VML repair and help guide more
effective strategies.
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E. Conclusions

The key findings of this study suggest that:
1. VML defected TA muscles repaired with aligned autografts had improved peak tetanic
force production over muscles repaired with unaligned autografts after 12 weeks of
recovery.
2. There was no significant difference in TA mass between aligned and unaligned treatment
groups at short-term or long-term recovery time points
3. At two weeks post-implantation, only muscles repaired with aligned autografts displayed
increased expression of myogenic genes (MyoD & Pax7), while all treatment groups had
increased expression of ECM/fibrotic genes (Col I, Col III, TGF-β, MMP2, and Timp-1)
4. By 12 weeks post-implantation, muscles had reached base line levels for all gene
expression and were morphologically similar with respect to fibrosis at the surface of the
defect site.
5.

The differences seen histologically at 2 weeks of recovery between aligned and 90°
unaligned autograft treated muscle warrant further study as to the mechanisms leading to
a fibrotic vs. myogenic regenerative response.
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Figure Legend
Figure 1: Experimental abstract. A VML defect was created in the left TA of Fisher 344 rats.
The defect was repaired with autografts from one of three treatment groups: Aligned, 45°, or 90°.
Autografts were secured in place with polypropylene sutures to maintain prescribed alignment.
Animals were assigned to one or two recovery periods, 2 weeks (n=6/group) or 12 weeks
(n=9/group). Electrophysiological data was collected for both the repaired TA muscle and the
contralateral control TA muscle. TA muscles were harvested, weighed, and prepared for RTPCR or histological analysis.

Figure 2: Surgical procedure. A ~1.5cm incision parallel to tibia was made in the left hind limb
of Fischer 344 rats (A). The skin and fascia was dissected to reveal the TA and a mark was
drawn onto the TA with a sterile surgical marker to indicate the direction of the myofiber
alignment (B). An 8mm biopsy punch was used to create a volumetric defect in the TA. A
PDMS ring was used to ensure a defect depth of 3mm (C). The defect plug was weighed and
then placed into defect as an autograft at the assigned alignment (90° unaligned pictured) (D).
The autograft was sutured in place using polypropylene sutures to maintain appropriate
alignment or misalignment (E). The wound was closed using double layer closure of the fascia
and skin utilizing absorbable sutures with interrupted stitches (F).

Figure 3: Electrophysiological data. Contraction of the TA was induced by stimulating the
peroneal nerve. Force was measured by securing the foot to the foot plate of a force transducer.
The average percent recovery (A) for the three treatment groups at the two time points along
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with the body weight normalized (N/kg) mean peak tetanic force produced (B) is shown for the
three treatment groups and control TA muscles at the two recovery time points. A representative
force profile for each treatment group is shown (C). n = 6/group at 2 weeks and n = 9/group at 12
weeks. Values are mean + SD.

Figure 4: Gross morphology. Representative samples of the autograft repaired muscles are
shown immediately after being secured into the VML defect (t = 0) and after being harvested at
either 2 or 12 weeks for each of the three treatment groups: Aligned, 45°, or 90° (A). TA muscles
were harvested, weighed, and the mass was normalized to body weight (g/kg) for each of the
treatment groups (B). n = 6/group at 2 weeks and n = 9/group at 12 weeks. Values are mean +
SD. * indicates significant difference from the body weight normalized control TA at the same
time point. (p < 0.05 with ANOVA with Tukey’s HSD)

Figure 5: Gene expression. RT-PCR was used to determine the relative expression of ECM
related structural proteins and regulatory factors Collagen I and III, TGFβ, MMP2, Timp1 and
myogenic markers MyoD and Pax7. n = 4/group at 2 weeks and n = 4/group at 12 weeks. Values
are mean + SE. * indicates significant difference from the relative expression of that gene for the
control TA at the same time point. (p < 0.05 with ANOVA with Tukey’s HSD)

Figure 6: Histology. Representative whole muscle sections of autograft repaired TA muscles at
2 weeks stained with Masson’s trichrome for aligned (A), 45° (B), 90° (C). Representative
samples stained with Masson’s trichrome showing relative alignment of autograft still present at
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2 weeks for aligned (D), 45° (E), 90° (F). * indicates myofibers still in their implanted
alignment. Black scale bar = 1mm. White scale bar = 100µm.
Figure 7: Long-term recovery. Representative transverse sections at the surface of the defect
site of muscle repaired with aligned (A), 45° unaligned (B), and 90° unaligned (C) autografts
stained with H&E. Representative transverse sections of muscle repaired with aligned (D), 45°
unaligned (E), and 90° unaligned (F) autografts immunostained for Collagen III. Average
myofiber area (G). Values are mean + SD. Black scale bar = 100µm. White scale bar = 100µm.
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Chapter 5

Conclusion

A. Evaluation of Muscle Regeneration

Skeletal muscle tissue engineering is still a relatively new field within biomedical
research, although evidence of initial explorations into the plasticity and “repairability” of
muscle date back more than a century.(Bursac et al., 2015; Thompson, 1971) The fact that
physicians still have few options when it comes to repairing VML necessitates further
innovation. The most successful strategies so far have combined scaffold and cell-based
approaches to deliver a construct that directs innate repair mechanisms towards a myogenic
response rather than fibrosis.(Aurora et al., 2015; Merritt et al., 2010; Page et al., 2011; Ward et
al., 2015) Moving forward, researchers should first start with a consensus of what constitutes
success in a strategy or technique to improve tissue regeneration after muscle trauma.
Contractile force measurements
The first and primary measure of success in skeletal muscle repair must be anchored in
the contractility of the repaired tissue. Skeletal muscle without contractility ceases to perform its
role within the human body and eventually develops into fibrotic tissue. Cosmetic appearances
are certainly important from a clinical perspective and improvements in patient satisfaction after
a traumatic injury are needed.(Mase et al., 2010) Likewise, other parameters used to evaluate
skeletal muscle repair and regeneration after traumatic injury, such as histological and
biomolecular measurements and observations, are very important from a research standpoint as
they allow investigators to elucidate mechanisms involved in the repair process and serve as
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snapshot of a certain aspect of regeneration. However, the priority needs to be placed on the
functional recovery from a traumatic injury that negatively impacts the patient’s freedom and
quality of life.
There are several methods for measuring contractile force in animal models and human
patients. In animal models there seems to be a consensus around the use of in vivo or in situ peak
tetanic contractile force as adequate measure of skeletal muscle function.(Corona, Ward, Baker,
Walters, & Christ, 2013; Grasman, Do, Page, & Pins, 2015; Han et al., 2016; M. T. A. Li,
Willett, Uhrig, Guldberg, & Warren, 2014b; Merritt et al., 2010; Mintz, Passipieri, Lovell, &
Christ, 2016; Page et al., 2011; Valentin, Turner, Gilbert, & Badylak, 2010) Peak tetanic
contractile force is obtained by immobilizing the joint proximal to the defected muscle and
electrodes are positioned to stimulate the nerve responsible for innervating the muscle of interest.
The appendage distal to the defected muscle is secured to a force transducer and when the
muscle is stimulated using parameters known to induce peak contraction, the force produced by
the muscle is measured. Peak tetanic contractile force is not the only in vivo measure of force
used, other studies have used twitch force(Han et al., 2016) and others have selected fatigue
testing.(Corona et al., 2013b; M. T. A. Li et al., 2014b) All protocols produce physiological
relevant data for evaluating the functional recovery of muscle from a VML injury.

Histology
Histological data provides researchers with data to elucidate spatial differences in VML
animal repair models. Direct measurements of morphological features and physiological
adaptations to the VML repair microenvironment are possible through thin sectioning of repaired
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skeletal muscle tissue. Appropriate staining protocols and visualization techniques allow
researchers to investigate the following broad categories: myogenesis, fibrosis, vascularization,
and innervation. Protocols for the histological analysis of in vivo myogenesis include
immunofluorescent stains for transcription factors such as Pax7, MyoD, and Ki67, and for
sarcomeric features such as embryonic-myosin heavy chain. Another technique for determining
myogenic activity is to observe sections for centrally located nuclei and other morphological
features indicative of differentiating muscle progenitor cells. Fibrosis within histological samples
can be determined through any staining protocol that locates the deposition of collagen and other
ECM constituents. The presence of collagen can be observed with techniques for brightfield
microscopy such as Masson’s trichrome or immunohistochemical staining. Immunofluorescence
can also be used to locate collagen. If care is taken to ensure that thin muscle sections have exact
exposure times (i.e. batch processing), quantitative data can be obtained from these histological
techniques.

Biomolecular Response
Another area of methods for gathering quantitative and qualitative data in the field of
skeletal muscle tissue engineering and regenerative medicine is to use protocols that provide data
on the biomolecular response of skeletal muscle tissue. The techniques could broadly include:
Western blotting, ELISA, biomolecular assays, RT-PCR, and gel electrophoresis. While Western
blots, gel electrophoresis, and ELISA techniques are not typically found in studies concerned
with investigating VML repair, RT-PCR is used in many studies to give researchers evidence of
cellular responses to regenerative therapies. Most published papers in the field generally examine
genes related to fibrosis (Collagen I & III, TGF-β, MMP1 & 2 & 9, Timp-1, CTGF) and
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myogenesis (MyoD, myogenin, Myf5, Pax3, Pax7). RT-PCR is an excellent tool to facilitate
investigations into the mechanisms of repair in skeletal muscle since it provides researchers with
snapshots of cellular activity at the prescribed timepoint.

Effect of Age
Almost all studies investigating skeletal muscle after VML in a rat model have been
performed on young (< 6 months old) rats. There has only been one study involving VML in an
aged rat model.(J. T. Kim, Kasukonis, Brown, Washington, & Wolchok, 2016) Regeneration
after VML was markedly decreased for all aged animals and preliminary results have shown that
DSM +MM repaired muscles had no significant improvements in contractile force recovery
compared to VML controls. Studies have suggested the decrease in the regenerative capacity of
satellite cells in aged muscle is due to age-related changes in the microenvironment of the
muscle and not necessarily due to age-related changes intrinsic to the cell.(Conboy, Conboy,
Smythe, & Rando, 2003; Conboy et al., 2005) Further studies should be performed in aged
animal VML models to validate techniques that have demonstrated success in younger animal
models.

B. Further Characterization

A study presented previously in this dissertation used DSM and MM together as a
construct for skeletal muscle regeneration after VML. Previous studies have shown that a DSM
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scaffold alone and a MM autograft made up of 25% of the defect volume with enough collagen
gel to completely fill the defect were not effective treatments for inducing muscle regeneration in
animal VML models.(Kasukonis et al., 2016; Sicari et al., 2014; Ward et al., 2015) In addition to
determining the optimal ratio of DSM:MM to repair VML, further work should be done to
investigate each constituent for more complete characterization and to ensure future clinical
studies have maximum regenerative potential.

Advantages of DSM
Although it has been established that DSM or any other acellular scaffold alone is not
sufficient to regenerate skeletal muscle after VML, DSM can be a component in an effective
strategy for repairing VML.(Kasukonis et al., 2016; Merritt et al., 2010) DSM maintains an
advantage over other acellular ECM scaffolds in that DSM is composed of aligned ECM,
contains skeletal muscle specific ECM-bound growth factors, and cadaveric skeletal muscle is
plentiful. With techniques similar to the one outlined previously in this dissertation, production
of DSM scaffolds for large VML injuries would be possible.(Kasukonis, Kim, Washington, &
Wolchok, 2016) There are still several studies that should be performed to further characterize
DSM, not only as a scaffold but as a template for engineered ECM constructs that by using ECM
harvested from cell cultures, would eliminate the need for donor tissue.(Hurd, Bhatti, Walker,
Kasukonis, & Wolchok, 2015)
These future avenues of research include determining if the source of the ECM has any
effect on the regenerative response of the host tissue. Previous studies have shown that there are
differences in the starting composition of ECM derived from different muscles, but the challenge
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is to discover if those differences correspond to increased or decreased regenerative potential.
Another question that needs to be answered is, does the degradation of ECM scaffolds before
they are implanted have any effect on their regenerative potential in the context of VML repair.
Decellularization protocols have been developed to lessen the degradation of ECM during the
process of lysing and stripping cells, but does that matter in the VML wound niche?(Gillies et
al., 2010) During the initial inflammatory response, macrophages will dismantle the donor ECM
as remodeling begins within the wound site. If the scaffold has been preconditioned with various
levels of degradation, will the remodeling response follow more myogenic or more fibrotic
pathways? Conversely, can the ECM scaffold be “functionalized” with growth factors in order to
affect the regenerative response of the host tissue? Continued exploration along these lines could
help push scaffold based therapies from 80-85% force recovery to 90-95% recovery. In
summary, even though in isolation DSM scaffolds will not generate an effective myogenic
response, further improvements to the scaffold should be investigated.

Advantages of MM
The use of MM as a constituent in a repair strategy appears to be the most promising
method of delivering cells and physiological cues to the site of VML.(Corona et al., 2013b;
Kasukonis et al., 2016) Autologous MM has an advantage over any allogeneic cell transplant in
that it does not require immunosuppressant drugs. It has an advantage over any isolated
autologous stem cell line because it is as close to off-the-shelf as cells can be with current
technologies. Most surgical suites do not contain the necessary apparatus for cell culture. In
addition, and more importantly, isolation and proliferation of a stem cell line would require a
preliminary procedure to harvest cells and several days or weeks to isolate the stem cells and
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expand them to a therapeutic level. This additional procedure to harvest cells could lead to
increased chance of infection and patient discomfort. Conversely, harvesting and mincing tissue
is certainly within the current skillset of surgeons and nurses within an operating room and could
be a procedure that is performed with concurrent to VML repair.(Ward et al., 2016) MM should
also be preferred to isolated stem cells or other muscle progenitor cells because it also delivers
pro-inflammatory and pro-myogenic factors to the defect site at the time of implantation. The
studies completed by the US Army Institute of Surgical Research team have shown the response
of surviving tissue to MM autografts is favorable for de novo formation of myofibers in the
defect area.(Corona et al., 2013b; Ward et al., 2015) Several questions remain regarding the
characterization of the initial MM but also the spatiotemporal response of the surviving muscle
and immune system to the MM autograft. Much as the innate regenerative processes of muscle
can be broken down into timelines of minutes and hours, then days and weeks, the response of
the initial immune and long-term fibrotic vs. myogenic remodeling that follows implantation
should be further studied. Evidence presented earlier in this dissertation indicates that even
though MM appears to induce myogenesis there appears to be long-term upregulation of genes
associated with fibrosis.(Kasukonis et al., 2016) MM has already shown potential as an autograft
and further characterization could potentially lead to a reduced donor volume being necessary if
scaffolds could be preconditioned with growth factors or cytokines after their relative importance
to muscle regeneration in a VML injury niche is determined.
Other studies should explore the effect the location of source muscle has on the
regenerative capacity of MM. Related studies must be done to determine the most effective
harvesting technique. One possibility is maximize the amount of donor tissue while minimizing
donor site morbidity or fibrosis could be to “mesh” biopsy a donor muscle similar to methods
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used to prepare autologous skin grafts.(Tanner, Vandeput, & Olley, 1964) Instead of taking a
smaller surface of skin and meshing it to stretch to the desired surface area, donor muscle would
be left in place and several small volume biopsies could be taken to give the desired quantity.
This leads to the next avenue of inquiry: What is the smallest biopsy that can be taken
from a muscle such that it suffers no long-term negative effects? A recent study to investigate the
regenerative potential of isolated MSC delivered with a fibrin glue inadvertently found that a
5mm biopsy from the TA of a rat was insufficient to produce an irrecoverable defect.(Pereira et
al., 2014) When force measurements were obtained 35 days after the creation of a defect, there
was no significant difference between the peak tetanic force produced by the defected muscle
and uninjured muscle.(Pereira et al., 2014) Of course further studies should be performed to
determine if multiple biopsies from a donor muscle will afford researchers enough donor MM
without any deleterious effects on the donor tissue.

Effects of Alignment
Although micropatterning and aligned engineered scaffolds induce myoblast and
myofiber alignment under in vitro conditions, (Aviss et al., 2010; Choi et al., 2008b; Hinds,
Bian, Dennis, & Bursac, 2011; Huang et al., 2010b; Lam et al., 2009) it has been demonstrated
that mechanical and electrical stimuli also produce aligned myofibers under the same
conditions.(Boonen et al., 2010b; Donnelly et al., 2010; Langelaan et al., 2011; Pennisi, Olesen,
de Zee, Rasmussen, & Zachar, 2011; Tatsumi, 2010; Vandenburgh & Karlisch, 1989)
One aspect about the effect of fiber alignment on skeletal muscle repair that needs to be
determined is whether the location of the defect has any bearing on how much alignment matters.
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Many of the studies that used porcine SIS and other scaffolds with no alignment seem to have
success repairing abdominal wall defects.(Prevel et al., 1995; Valentin et al., 2010) While this
could be due to the “functional fibrosis” described by a different group, it could also be due to
the location of the injury.(Corona et al., 2013a) If abdominal wall injuries and extremity muscle
injuries respond differently to fiber alignment, more specific strategies could be developed to suit
each injury niche.

C. Future Directions for VML
Rehabilitation
When human patients suffer musculoskeletal trauma, the standard of care in almost all
cases involves physical rehabilitation. However, post-implantation protocols in small animal
models do not consistently include exercise such as voluntary running wheels. Some studies have
included physical rehabilitation in both VML model and in stem cell based interventions for
myopathies such as DMD.(Ambrosio et al., 2009; Bouchentouf, Benabdallah, Mills, &
Tremblay, 2006; Corona et al., 2013b) Rehabilitation was shown to improve outcomes in the
cases of stem cell transplants and there were mixed results with the exercise treatment group in
the VML animal model.
A different study indirectly highlights the effect rehabilitation can have on muscle that
suffers traumatic injury. A murine model in which myotoxin-induced direct muscle damage and
hind limb ischemia were used for skeletal muscle trauma.(Cezar et al., 2016) Cyclic mechanical
compression was applied through a pressure cuff or a biphasic ferrogel scaffold which was
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implanted at the injection site of myotoxin and actuated with an external permanent magnet.
Decreased fibrosis and increased oxygen perfusion was reported in the muscle treated with the
biphasic ferrogel scaffold.(Cezar et al., 2016) Although the study did not make comparisons to
normal muscle, the authors did report a two fold increase in contractile force when compared to
injured muscle that did not receive any therapeutic interventions.(Cezar et al., 2016) This study
was not performed in a VML model, however, cyclic mechanical compression through a
biphasic ferrogel scaffold could potentially be used to decrease fibrosis and improve regeneration
in animal models for VML

Whole muscle replacement and scaling up
Currently, most animal models used for VML repair investigations are rodents. While
animal models are a necessary tool for preclinical investigations, in certain instances size
differences can outweigh any physiological similarities when studying a small animal model.
VML is typically presented as an injury where 20% of the muscles volume is absent after
trauma. A 20% reduction in the TA of a rat will result in a loss of mass of ~100mg and a volume
less than 0.5 cm3. Large defects in the skeletal muscle of humans could be >200cm3 depending
on the affected muscle. This difference in scale matters as the diffusion of oxygen into a scaffold
immediately after implantation can sustain a greater proportion of the cells in a rodent model
than in a human patient.
A very recent study by Ward et al. demonstrated that autologous MM could provide
significant functional recovery in a porcine VML model.(Ward et al., 2016) By creating a 3cm x
3cm x 1.5cm defect in the peroneous tertius, they reduced the maximum tetanic force by 43%. In
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muscles repaired with autologous MM, the PT only suffered a 27% reduction in peak tetanic
contractile force, which represents a 35% increase over the nonrepaired muscles. The recovery in
the larger porcine model was diminished from the recovery observed in rat VML models, where
force recovery is generally around 80-85%.(Corona et al., 2013b; Merritt et al., 2010) Ward et al.
attributed this difference to the size discrepancy between the defect size in the two animal
models. They also observed an increased inflammatory and fibrotic response in the porcine
model which hindered revascularization and axonal regeneration. Further studies using larger
animal models and more specifically, larger defect sizes will accelerate the development of
effective therapies and strategies for treating VML.
The two clinical studies currently published do provide evidence for use of porcine SIS or
UBM in VML repair, but there needs to be a more systemic approach when there are multiple
injury sites and various comorbidities that complicate results observed in these initial studies.(J.
Dziki et al., 2016; Sicari et al., 2014) Skeletal muscle tissue engineering still has several specific
challenges that will have to be addressed before a new standard of care emerges for the treatment
of VML.

F. Remaining Challenges
Vascularization
One of the biggest challenges for any translational tissue engineering application to
overcome, especially scaffold-based therapies, is the challenge of vascularization. Scaffolds by
their nature have material that separates one portion of damaged tissue from another portion.
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Scaffolds used to repair VML and regenerate skeletal muscle have seemingly opposing design
requirements in that one requirement the scaffold should occupy the space left by the volumetric
defect and the other is that it allow for in the infiltration of host inflammatory and myogenic cells
into all points within the defect void.
Engineered skeletal muscle constructs offer an alternative approach to the use of
scaffolds, but the scale of the current generation of engineered muscle constructs is too small to
have an application in VML repair.(Juhas, Ye, & Bursac, 2016; Juhas, Engelmayr, Fontanella,
Palmer, & Bursac, 2014; VanDusen, Syverud, Williams, Lee, & Larkin, 2014b; Williams,
Kostrominova, Arruda, & Larkin, 2013) Although the Larkin group has used engineered
constructs to repair VML in animal models, the defect sizes are thus far not clinically
relevant.(VanDusen et al., 2014b; Williams et al., 2013) In order to serve as a new standard for
the treatment of VML, engineered constructs would have to have sufficient vasculature with
functional capillary beds before implantation and would need to have relatively large arteries and
veins to connect to systemic circulation of the host. This is in addition to scaling engineered
constructs up to a volume sufficient to repair or even replace whole muscle which has suffered a
VML injury. However, engineered skeletal muscle has other important applications in
biomedical research, including as in vitro models for pharmacological investigations and
diseased tissue surrogates.(Juhas et al., 2016)
Fibrosis vs. Myogenesis
The final challenge to be discussed in this dissertation is specific to skeletal muscle tissue
engineering. The advancement of the field should be focused on: (1) understanding the response
of the host immune and muscle tissue to direct cellular activity to myogenesis or fibrosis and (2)
how to manipulate scaffold based therapies to maximize the myogenic and regenerative response
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of the host tissue. As discussed previously, further characterization of DSM and MM along with
characterization of the in vivo response to a combined construct in a VML injury niche will be
key to developing an effective therapy that is ready for clinical study. Although fibrotic repair
can provide some functional benefit, therapeutic success should be defined as maximizing
myogenesis for permanent 100% contractile force recovery. In order to successfully repair and
regenerate skeletal muscle after a VML injury, researchers should have a clear understanding of
the differences between innate muscle repair for minor injuries and attempts at self-repair by
muscle after it has suffered a VML injury. The cellular, biochemical, and mechanical cues that
are unique to VML injuries should be elucidated to direct researcher toward developing therapies
that induce a robust myogenic response.
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